PT J
AU Gonzalo-Marin, J
   Vila, JJ
   Perez-Miranda, M
AF Gonzalo-Marin, Juana
   Jose Vila, Juan
   Perez-Miranda, Manuel
TI Role of endoscopic ultrasound in the diagnosis of pancreatic cancer
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Endosonography; Pancreatic neoplasms; Endoscopy; Diagnosis; Neoplasm Staging; Therapeutics
AB Endoscopic ultrasonography (EUS) with or without fine needle aspiration has become the main technique for evaluating pancreatobiliary disorders and has proved to have a higher diagnostic yield than positron emission tomography, computed tomography (CT) and transabdominal ultrasound for recognising early pancreatic tumors. As a diagnostic modality for pancreatic cancer, EUS has proved rates higher than 90%, especially for lesions less than 2-3 cm in size in which it reaches a sensitivity rate of 99% vs 55% for CT. Besides, EUS has a very high negative predictive value and thus EUS can reliably exclude pancreatic cancer. The complication rate of EUS is as low as 1.1%-3.0%. New technical developments such as elastography and the use of contrast agents have recently been applied to EUS, improving its diagnostic capability. EUS has been found to be superior to the recent multidetector CT for T staging with less risk of overstaying in comparison to both CT and magnetic resonance imaging, so that patients are not being ruled out of a potentially beneficial resection. The accuracy for N staging with EUS is 64%-82%. In unresectable cancers, EUS also plays a therapeutic role by means of treating oncological pain through celiac plexus block, biliary drainage in obstructive jaundice in patients where endoscopic retrograde cholangiopancreatography is not affordable and aiding radiotherapy and chemotherapy. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
C1 [Gonzalo-Marin, Juana] Quiron Hosp, Dept Gastroenterol, Unit Endoscopy, Marbella 29603, Spain.
   [Jose Vila, Juan] Complejo Hosp Navarra, Unit Endoscopy, Dept Gastroenterol, Pamplona 31008, Spain.
   [Perez-Miranda, Manuel] Hosp Univ Rio Hortega, Dept Gastroenterol, Dulzaina St, Valladolid 47012, Spain.
C3 Servicio Navarro de Salud - Osasunbidea; Hospital del Rio Hortega
RP Perez-Miranda, M (corresponding author), Hosp Univ Rio Hortega, Dept Gastroenterol, Dulzaina St, Valladolid 47012, Spain.
EM mperezmiranda@saludcastillayleon.es
CR Alsohaibani F, 2009, CAN J GASTROENTEROL, V23, P26, DOI 10.1155/2009/194351
   Unknown -, 1900, DOI 10.1016/J.JACI.2012.05.050 DOI 10.1016/J.JACI.2012.05.050, V0, P0
   Arabul M, 2012, HEPATO-GASTROENTEROL, V59, P1599, DOI 10.5754/hge11608
   Arcidiacono PG, 2011, COCHRANE DB SYST REV, V16, P0
   Ardengh JC, 2007, J PANCREAS, V8, P413
   Aslanian H, 2005, AM J GASTROENTEROL, V100, P1381, DOI 10.1111/j.1572-0241.2005.41675.x
   Barthet M, 1996, ENDOSCOPY, V28, P487, DOI 10.1055/s-2007-1005528
   Becker D, 2001, GASTROINTEST ENDOSC, V53, P784, DOI 10.1067/mge.2001.115007
   Berberat P, 1999, WORLD J SURG, V23, P882, DOI 10.1007/s002689900593
   Bhutani MS, 2004, ENDOSCOPY, V36, P385, DOI 10.1055/s-2004-814320
   Bipat S, 2005, J COMPUT ASSIST TOMO, V29, P438, DOI 10.1097/01.rct.0000164513.23407.b3
   Bories E, 2007, ENDOSCOPY, V39, P287, DOI 10.1055/s-2007-966212
   Burmester E, 2003, GASTROINTEST ENDOSC, V57, P246, DOI 10.1067/mge.2003.85
   Byrne MF, 2002, GASTROENTEROLOGY, V122, P1631, DOI 10.1053/gast.2002.33576
   Canto MI, 2004, CLIN GASTROENTEROL H, V2, P606, DOI 10.1016/S1542-3565(04)00244-7
   Chang KJ, 2000, CANCER-AM CANCER SOC, V88, P1325, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1325::AID-CNCR8>3.0.CO;2-T
   Chen VK, 2004, AM J GASTROENTEROL, V99, P2223, DOI 10.1111/j.1572-0241.2004.40042.x
   Chong A, 2011, GASTROINTEST ENDOSC, V74, P933, DOI 10.1016/j.gie.2010.10.020
   Collins D, 2006, ENDOSCOPY, V38, P935, DOI 10.1055/s-2006-944734
   DOnofrio M, 2007, ABDOM IMAGING, V32, P171, DOI 10.1007/s00261-006-9010-6
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DeWitt J, 2004, ANN INTERN MED, V141, P753, DOI 10.7326/0003-4819-141-10-200411160-00006
   Dietrich CF, 2009, ENDOSCOPIC ULTRASOUN, V0, P196
   Dietrich CF, 2008, CLIN GASTROENTEROL H, V6, P590, DOI 10.1016/j.cgh.2008.02.030
   EISENBERG E, 1995, ANESTH ANALG, V80, P290, DOI 10.1097/00000539-199502000-00015
   Eloubeidi MA, 2003, CANCER CYTOPATHOL, V99, P285, DOI 10.1002/cncr.11643
   Eloubeidi MA, 2008, DIGEST DIS, V26, P356, DOI 10.1159/000177022
   Erickson RA, 2000, GASTROINTEST ENDOSC, V51, P184, DOI 10.1016/S0016-5107(00)70416-0
   Fritscher-Ravens A, 2002, AM J GASTROENTEROL, V97, P2768
   Frulloni L, 2010, DIGEST LIVER DIS, V42, PS381, DOI 10.1016/S1590-8658(10)60682-2
   Fukasawa M, 2012, GASTROINTEST ENDOSC, V75, P132
   Fusari M, 2010, RADIOL MED, V115, P453, DOI 10.1007/s11547-010-0490-7
   Fusaroli P, 2010, CLIN GASTROENTEROL H, V8, P629, DOI 10.1016/j.cgh.2010.04.012
   GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4
   Giovannini M, 2010, GASTROEN CLIN BIOL, V34, P436, DOI 10.1016/j.gcb.2010.05.004
   Gong TT, 2012, GASTROINTEST ENDOSC, V76, P301, DOI 10.1016/j.gie.2012.02.051
   Gress F, 1997, GASTROINTEST ENDOSC, V45, P138, DOI 10.1016/S0016-5107(97)70236-0
   Gress FG, 1999, GASTROINTEST ENDOSC, V50, P786, DOI 10.1016/S0016-5107(99)70159-8
   Hakimé A, 2007, J RADIOL, V88, P11, DOI 10.1016/S0221-0363(07)89785-X
   Harewood GC, 2002, AM J GASTROENTEROL, V97, P1386, DOI 10.1016/S0002-9270(02)04133-3
   Hartwig W, 2009, BRIT J SURG, V96, P5, DOI 10.1002/bjs.6407
   Hirooka Y, 2003, J GASTROEN HEPATOL, V18, P1323, DOI 10.1046/j.1440-1746.2003.03040.x
   Hocke M, 2006, WORLD J GASTROENTERO, V12, P246, DOI 10.3748/wjg.v12.i2.246
   Howard TJ, 1997, AM J SURG, V174, P237, DOI 10.1016/S0002-9610(97)00132-3
   Hunt GC, 2002, GASTROINTEST ENDOSC, V55, P232, DOI 10.1067/mge.2002.121342
   Iglesias-Garcia J, 2012, GASTROINTEST ENDOSC, V75, P147
   Iglesias-Garcia J, 2011, AM J GASTROENTEROL, V106, P1705, DOI 10.1038/ajg.2011.119
   Iglesias-Garcia J, 2011, GASTROINTEST ENDOSC, V73, P1189, DOI 10.1016/j.gie.2011.01.053
   Iglesias-Garcia J, 2010, GASTROENTEROLOGY, V139, P1172, DOI 10.1053/j.gastro.2010.06.059
   Iglesias-Garcia J, 2009, GASTROINTEST ENDOSC, V70, P1101, DOI 10.1016/j.gie.2009.05.011
   Itoi T, 2005, ENDOSCOPY, V37, P362, DOI 10.1055/s-2004-826156
   Jacobson BC, 2005, GASTROINTEST ENDOSC, V61, P8, DOI 10.1016/S0016-5107(04)02393-4
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kahaleh M, 2004, GASTROINTEST ENDOSC, V60, P138, DOI 10.1016/S0016-5107(04)01528-7
   Kahaleh M, 2012, GASTROINTEST ENDOSC, V75, P193
   Kala Z, 2007, EUR J RADIOL, V62, P166, DOI 10.1016/j.ejrad.2007.01.039
   Katanuma A, 2012, ENDOSCOPY, V44, PE160, DOI 10.1055/s-0031-1291716
   KAUFMAN AR, 1989, GASTROINTEST ENDOSC, V35, P214, DOI 10.1016/S0016-5107(89)72761-9
   Kinney T, 2010, SURG CLIN N AM, V90, P235, DOI 10.1016/j.suc.2009.12.003
   Klapman JB, 2005, AM J GASTROENTEROL, V100, P2658, DOI 10.1111/j.1572-0241.2005.00315.x
   Krishna NB, 2009, GASTROINTEST ENDOSC, V70, P70, DOI 10.1016/j.gie.2008.10.030
   Kulig J, 2005, SURG ENDOSC, V19, P361, DOI 10.1007/s00464-004-9056-x
   LeBlanc JK, 2004, GASTROINTEST ENDOSC, V59, P475, DOI 10.1016/S0016-5107(03)02863-3
   Magno P, 2008, GASTROINTEST ENDOSC, V67, P1147, DOI 10.1016/j.gie.2008.02.053
   Mallery S, 2004, GASTROINTEST ENDOSC, V59, P100, DOI 10.1016/S0016-5107(03)02300-9
   Manabu Matsumura, 2007, FOLIA PHARMACOLOGICA JAPONICA, V130, P413
   MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719
   Mertz HR, 2000, GASTROINTEST ENDOSC, V52, P367, DOI 10.1067/mge.2000.107727
   Michaels AJ, 2007, WORLD J GASTROENTERO, V13, P3575, DOI 10.3748/wjg.v13.i26.3575
   Millikan KW, 1999, AM SURGEON, V65, P618
   NAKAIZUMI A, 1995, DIGEST DIS SCI, V40, P696, DOI 10.1007/BF02064392
   Napoleon B, 2010, ENDOSCOPY, V42, P564, DOI 10.1055/s-0030-1255537
   Oh HC, 2011, GASTROENTEROLOGY, V140, P172, DOI 10.1053/j.gastro.2010.10.001
   Owens DJ, 2010, SURG ONCOL CLIN N AM, V19, P255, DOI 10.1016/j.soc.2009.11.009
   Ozawa Y, 2002, J ULTRAS MED, V21, P983, DOI 10.7863/jum.2002.21.9.983
   Paquin SC, 2005, GASTROINTEST ENDOSC, V61, P610, DOI 10.1016/S0016-5107(05)00082-9
   Perez-Miranda M, 2010, WORLD J GASTRO ENDOS, V2, P212, DOI 10.4253/wjge.v2.i6.212
   Puli SR, 2007, GASTROINTEST ENDOSC, V65, P788, DOI 10.1016/j.gie.2006.08.028
   Ramsay Duncan, 2004, AUSTRALAS RADIOL, V48, P154, DOI 10.1111/j.1440-1673.2004.01277.x
   Recaldini Chiara, 2008, INT J MED SCI, V5, P203
   Reicher S, 2011, PANCREAS, V40, P1057, DOI 10.1097/MPA.0b013e3182200201
   Rickes S, 2002, SCAND J GASTROENTERO, V37, P1313, DOI 10.1080/003655202761020605
   ROSCH T, 1991, GASTROINTEST ENDOSC, V37, P347, DOI 10.1016/S0016-5107(91)70729-3
   Rulyak SJ, 2003, GASTROINTEST ENDOSC, V57, P23, DOI 10.1067/mge.2003.28
   Saftoiu A, 2009, J CLIN ULTRASOUND, V37, P1, DOI 10.1002/jcu.20534
   Sakamoto H, 2008, ULTRASOUND MED BIOL, V34, P525, DOI 10.1016/j.ultrasmedbio.2007.09.018
   Sakamoto H, 2009, J GASTROEN HEPATOL, V24, P384, DOI 10.1111/j.1440-1746.2008.05636.x
   Sanders MK, 2010, GASTROINTEST ENDOSC, V71, P1178, DOI 10.1016/j.gie.2009.12.020
   Sandrasegaran K, 2010, AM J ROENTGENOL, V195, P42, DOI 10.2214/AJR.10.4421
   Schmulewitz N, 2003, ENDOSCOPY, V35, P0
   Seicean A, 2010, ULTRASCHALL MED, V31, P571, DOI 10.1055/s-0029-1245833
   Seicean A, 2010, WORLD J GASTROENTERO, V16, P4253, DOI 10.3748/wjg.v16.i34.4253
   Sethi A, 2012, GASTROINTEST ENDOSC, V75, P147
   Shah JN, 2004, GASTROINTEST ENDOSC, V59, P923, DOI 10.1016/S0016-5107(04)00340-2
   Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5
   Soriano A, 2004, AM J GASTROENTEROL, V99, P492, DOI 10.1111/j.1572-0241.2004.04087.x
   Takahashi K, 2005, GASTROINTEST ENDOSC, V61, P76, DOI 10.1016/S0016-5107(04)02224-2
   Taylor B, 2003, WORLD J SURG, V27, P1249, DOI 10.1007/s00268-003-7245-8
   Tellez-Avila FI, 2012, PANCREAS, V41, P636, DOI 10.1097/MPA.0b013e31823e3632
   Toft KG, 2006, ULTRASOUND MED BIOL, V32, P107, DOI 10.1016/j.ultrasmedbio.2005.09.008
   Varadarajulu S, 2005, GASTROINTEST ENDOSC, V62, P728, DOI 10.1016/j.gie.2005.06.051
   Varadarajulu S, 2010, SURG CLIN N AM, V90, P251, DOI 10.1016/j.suc.2010.01.002
   Vila JJ, 2012, GASTROINTEST ENDOSC, V76, P1133, DOI 10.1016/j.gie.2012.08.001
   Wallace MB, 2001, GASTROINTEST ENDOSC, V53, P294, DOI 10.1067/mge.2001.112191
   Wiersema MJ, 1996, GASTROINTEST ENDOSC, V43, P102, DOI 10.1016/S0016-5107(06)80108-2
   Wyse JM, 2011, J CLIN ONCOL, V29, P3541, DOI 10.1200/JCO.2010.32.2750
   Yan BM, 2007, AM J GASTROENTEROL, V102, P430, DOI 10.1111/j.1572-0241.2006.00967.x
   YASUDA K, 1993, ENDOSCOPY, V25, P151, DOI 10.1055/s-2007-1010274
   Yeo Theresa Pluth, 2002, CURR PROBL CANCER, V26, P176, DOI 10.1067/mcn.2002.129579
NR 109
TC 58
Z9 69
U1 0
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1948-5204
EI 
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD SEP 15
PY 2014
VL 6
IS 9
BP 360
EP 368
DI 10.4251/wjgo.v6.i9.360
PG 9
WC Oncology; Gastroenterology & Hepatology
SC Oncology; Gastroenterology & Hepatology
GA V9A4O
UT WOS:000422133300006
PM 25232461
DA 2026-01-16
ER

PT J
AU Hansen, L
   Leo, MC
   Chang, MF
   Zucker, BL
   Sasaki, A
AF Hansen, Lissi
   Leo, Michael C.
   Chang, Michael F.
   Zucker, Betsy L.
   Sasaki, Anna
TI Pain and Self-Care Behaviours in Adult Patients with End-Stage Liver Disease: A longitudinal description
SO JOURNAL OF PALLIATIVE CARE
LA English
DT Article
DE palliative care; survival time; simple prognostic scores
ID quality-of-life; integrating palliative care; psychological distress; cancer pain; transplant; model; acupuncture; medications; cirrhosis; severity
AB This prospective descriptive study investigated pain characteristics in 20 outpatients with end-stage liver disease (ESLD) who were approaching the end of life, described variability in pain between and within patients, and described the pharmacological and nonpharmacological pain management strategies used. The instruments we utilized were the Brief Pain Inventory (BPI) and the self-care behaviour (SCB) log for pain. Data were collected once a month over a six-month period. BPI severity of, and interference from pain mean scores ranged from 5.52 to 6.03 and 5.36 to 6.64, respectively. The top three pain-relieving behaviours reported by patients were "taking pain medication," "taking a nap," and "asking for help." Pain medication intake differed between patients who were pursuing a liver transplant and those who were not eligible for one. If we are to effectively improve care for ESLD patients, it is essential that we understand the ways in which these patients experience pain and the pain management strategies they employ.
C1 [Hansen, Lissi] Oregon Hlth & Sci Univ, Sch Nursing, SN ORD, Portland, OR 97239 USA.
   [Leo, Michael C.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA.
   [Chang, Michael F.; Zucker, Betsy L.; Sasaki, Anna] Portland VA Med Ctr, Portland, OR USA.
   [Sasaki, Anna] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Kaiser Permanente; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University
RP Hansen, L (corresponding author), Oregon Hlth & Sci Univ, Sch Nursing, SN ORD, 3455 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM hansenli@ohsu.edu
FU National Institute of Nursing Research, National Institutes of Health (NIH) [R03 NR010614]
CR Pérez-San-Gregorio MA, 2013, J CLIN PSYCHOL MED S, V20, P97, DOI 10.1007/s10880-012-9309-0
   Unknown -, 2012, NATL VITAL STAT REPO, V0, P0
   Unknown -, 2012, NHPCO FACTS AND FIGURES: HOSPICE CARE IN AMERICA, V0, P0
   Antaki F, 2007, J CLIN GASTROENTEROL, V41, P412, DOI 10.1097/01.mcg.0000225594.01201.9b
   Boyd K, 2012, HEPATOLOGY, V55, P1650, DOI 10.1002/hep.25621
   Casarett DJ, 2003, J PAIN SYMPTOM MANAG, V25, PS6, DOI 10.1016/S0885-3924(03)00097-6
   Chandok N, 2010, MAYO CLIN PROC, V85, P451, DOI 10.4065/mcp.2009.0534
   Chang VT, 2002, J PAIN SYMPTOM MANAG, V24, P494, DOI 10.1016/S0885-3924(02)00516-X
   Cowan DT, 2005, PAIN MED, V6, P113, DOI 10.1111/j.1526-4637.2005.05020.x
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Davis H, 1998, J PSYCHOSOM RES, V44, P547, DOI 10.1016/S0022-3999(97)00288-2
   De Bona M, 2000, J HEPATOL, V33, P609, DOI 10.1034/j.1600-0641.2000.033004609.x
   Desbiens NA, 2000, J AM GERIATR SOC, V48, PS183, DOI 10.1111/j.1532-5415.2000.tb03130.x
   Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005
   El-Jawahri Areej, 2011, J SUPPORT ONCOL, V9, P87
   Ersek M, 1999, CANCER PRACT, V7, P226, DOI 10.1046/j.1523-5394.1999.75007.x
   Hansen L, 2010, NURS CLIN N AM, V45, P411, DOI 10.1016/j.cnur.2010.03.005
   Health Resources and Services Administration, 2012, OPTN SRTR 2011 ANN D, V0, P0
   Higginson IJ, 2010, CANCER J, V16, P423, DOI 10.1097/PPO.0b013e3181f684e5
   Hope AA, 2011, J PALLIAT CARE, V27, P20, DOI 10.1177/082585971102700105
   Kamath PS, 2003, LIVER TRANSPLANT, V9, P19, DOI 10.1053/jlts.2003.50031
   Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172
   Kaplan R, 2000, J PAIN SYMPTOM MANAG, V19, P265, DOI 10.1016/S0885-3924(00)00117-2
   KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032
   Larson AM, 2006, JAMA-J AM MED ASSOC, V295, P2168, DOI 10.1001/jama.295.18.2168
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001
   Madan A, 2012, PROG TRANSPLANT, V22, P379, DOI 10.7182/pit2012535
   McMillan SC, 2011, CANCER NURS, V34, P89, DOI 10.1097/NCC.0b013e3181f70aee
   Medici V, 2008, LIVER TRANSPLANT, V14, P1100, DOI 10.1002/lt.21398
   National Institutes of Health (NIH) US Department of Health and Human Services, 2012, HUM SUBJ PROT INCL W, V0, P0
   Office of Integrity Oregon Health and Science University (OHSU), 2007, GUID HUM SUBJ RES DE, V0, P0
   Ratcliffe J, 2002, LIVER TRANSPLANT, V8, P263, DOI 10.1053/jlts.2002.31345
   Rhee C, 2007, J PALLIAT MED, V10, P677, DOI 10.1089/jpm.2006.0246
   Riley TR III, 2003, DIGEST DIS SCI, V48, P1914, DOI 10.1023/A:1026149732756
   Roth K, 2000, J AM GERIATR SOC, V48, P0
   Schieffer BM, 2005, J PAIN, V6, P620, DOI 10.1016/j.jpain.2005.04.004
   Simone Charles B 2nd, 2012, J OPIOID MANAG, V8, P9
   Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wang XS, 1999, CANCER, V86, P1848, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1848::AID-CNCR29>3.3.CO;2-D
   Younossi ZM, 2001, AM J GASTROENTEROL, V96, P2199, DOI 10.1016/S0002-9270(01)02519-9
NR 44
TC 18
Z9 22
U1 0
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0825-8597
EI 2369-5293
J9 J PALLIAT CARE
JI J. Palliative Care
PD SPR 15
PY 2014
VL 30
IS 1
BP 32
EP 40
DI 10.1177/082585971403000105
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational Health
GA AE2HW
UT WOS:000333794900005
PM 24826441
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Farrar, JT
   Bruner, D
   Zee, J
   Bowman, M
   Seluzicki, C
   DeMichele, A
   Xie, SX
AF Mao, Jun J
   Farrar, John T
   Bruner, Deborah
   Zee, Jarcy
   Bowman, Marjorie
   Seluzicki, Christina
   DeMichele, Angela
   Xie, Sharon X
TI Electroacupuncture for fatigue, sleep, and psychological distress in breast
SO Cancer
LA English
DT Journal Article
DE acupuncture; aromatase inhibitors; breast neoplasm; fatigue; psychological distress; sleep
AB BACKGROUND: Although fatigue, sleep disturbance, depression, and anxiety are  associated with pain in breast cancer patients, it is unknown whether acupuncture  can decrease these comorbid symptoms in cancer patients with pain. The objective  of this study was to evaluate the effect of electroacupuncture (EA) on fatigue,  sleep, and psychological distress in breast cancer survivors who experience joint  pain related to aromatase inhibitors (AIs). METHODS: The authors performed a  randomized controlled trial of an 8-week course of EA compared with a waitlist  control (WLC) group and a sham acupuncture (SA) group in postmenopausal women  with breast cancer who self-reported joint pain attributable to AIs. Fatigue,  sleep disturbance, anxiety, and depression were measured using the Brief Fatigue  Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), and the Hospital  Anxiety and Depression Scale (HADS). The effects of EA and SA versus WLC on these  outcomes were evaluated using mixed-effects models. RESULTS: Of the 67 randomly  assigned patients, baseline pain interference was associated with fatigue  (Pearson correlation coefficient [r]=0.75; P < .001), sleep disturbance (r=0.38;  P=.0026), and depression (r=0.58; P < .001). Compared with the WLC condition, EA  produced significant improvements in fatigue (P=.0095), anxiety (P=.044), and  depression (P=.015) and a nonsignificant improvement in sleep disturbance  (P=.058) during the 12-week intervention and follow-up period. In contrast, SA  did not produce significant reductions in fatigue or anxiety symptoms but did  produce a significant improvement in depression compared with the WLC condition  (P=.0088). CONCLUSIONS: Compared with usual care, EA produced significant  improvements in fatigue, anxiety, and depression; whereas SA improved only  depression in women experiencing AI-related arthralgia.
C1 Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
   Department of Biostatistics and Epidemiology, Center for ClinicalEpidemiology and Biostatistics, University of Pennsylvania, Philadelphia,Pennsylvania
   Department of Family Medicine and Community Health, Perelman Schoolof Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
NR 0
TC 0
SN 1097-014
EI 0008-543
J9 Cancer
PD AUG 1
PY 2014
VL 120
IS 23
BP 3744
EP 51
DI 10.1002/cncr.28917
PG -3693
WC Aged; Anastrozole; Androstadienes; adverse effects; Anxiety; psychology; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; complications; Depression; psychology; Electroacupuncture; methods; Fatigue; complications; Female; Humans; Letrozole; Middle Aged; Nitriles; adverse effects; Quality of Life; Sleep Wake Disorders; complications; Stress, Psychological; psychology; Treatment Outcome; Triazoles; adverse effects
UT PubMed:25077452
PM 25077452
DA 2014-08-01
ER

PT J
AU Lee, JH
   Li, DX
   Yoon, H
   Go, D
   Quan, FS
   Min, BI
   Kim, SK
AF Lee, Ji-Hye
   Li, Dong Xing
   Yoon, Heera
   Go, Donghyun
   Quan, Fu Shi
   Min, Byung-Il
   Kim, Sun Kwang
TI Serotonergic mechanism of the relieving effect of bee venom acupuncture on
SO BMC complementary and alternative medicine
LA English
DT Journal Article
AB BACKGROUND: Oxaliplatin, an important chemotherapy drug for advanced colorectal  cancer, often induces peripheral neuropathy, especially cold allodynia. Our  previous study showed that bee venom acupuncture (BVA), which has been  traditionally used in Korea to treat various pain symptoms, potently relieves  oxaliplatin-induced cold allodynia in rats. However, the mechanism for this  anti-allodynic effect of BVA remains poorly understood. We investigated whether  and how the central serotonergic system, a well-known pathway for acupuncture  analgesia, mediates the relieving effect of BVA on cold allodynia in  oxaliplatin-injected rats. METHODS: The behavioral signs of cold allodynia in  Sprague-Dawley (SD) rats were induced by a single injection of oxaliplatin (6  mg/kg, i.p.). Before and after BVA treatment, the cold allodynia signs were  evaluated by immersing the rat's tail into cold water (4°C) and measuring the  withdrawal latency. For BVA treatment, a diluted BV (0.25 mg/kg) was  subcutaneously administered into Yaoyangguan (GV3) acupoint, which is located  between the spinous processes of the fourth and the fifth lumbar vertebra.  Serotonin was depleted by a daily injection of DL-p-chlorophenylalanine (PCPA,  150 mg/kg, i.p.) for 3 days. The amount of serotonin in the spinal cord was  measured by ELISA. Serotonergic receptor antagonists were administered  intraperitoneally or intrathecally before BVA treatment. RESULTS: The serotonin  levels in the spinal cord were significantly increased by BVA treatment and such  increase was significantly reduced by PCPA. This PCPA pretreatment abolished the  relieving effect of BVA on oxaliplatin-induced cold allodynia. Either of  methysergide (mixed 5-HT1/5-HT2 receptor antagonist, 1 mg/kg, i.p.) or MDL-72222  (5-HT3 receptor antagonist, 1 mg/kg, i.p) blocked the anti-allodynic effect of  BVA. Further, an intrathecal injection of MDL-72222 (12 μg) completely blocked  the BVA-induced anti-allodynic action, whereas NAN-190 (5-HT1A receptor  antagonist, 15 μg, i.t.) or ketanserin (5-HT2A receptor antagonist, 30 μg, i.t.)  did not. CONCLUSIONS: These results suggest that BVA treatment alleviates  oxaliplatin-induced acute cold allodynia in rats via activation of the  serotonergic system, especially spinal 5-HT3 receptors. Thus, our findings may  provide a clinically useful evidence for the application of BVA as an alternative  therapeutic option for the management of peripheral neuropathy, a dose-limiting  side effect that occurs after an administration of oxaliplatin.
C1 Department of East-west Medicine, Graduate School, Kyung Hee University, Seoul 130-701, Republic of Korea. skkim77@khu.ac.kr.
NR 0
TC 0
SN 1472-688
EI 
J9 BMC Complement Altern Med
PD DEC 8
PY 2014
VL 14
IS 
BP 471
EP 471
DI 10.1186/1472-6882-14-471
PG 0
WC Acupuncture Analgesia; Acupuncture Points; Animals; Apitherapy; Bee Venoms; pharmacology; Cold Temperature; Fenclonine; pharmacology; Hyperalgesia; chemically induced; Ketanserin; pharmacology; Male; Neuralgia; drug therapy; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; drug therapy; Piperazines; pharmacology; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; metabolism; Serotonin; metabolism; Serotonin 5-HT3 Receptor Agonists; pharmacology; Serotonin Antagonists; pharmacology; Spinal Cord; drug effects; Tropanes; pharmacology
UT PubMed:25481535
PM 25481535
DA 2014-12-08
ER

PT J
AU Axelsson, CK
   Ballegaard, S
   Karpatschof, B
   Schousen, P
AF Axelsson, Christen K.
   Ballegaard, Soren
   Karpatschof, Benny
   Schousen, Peer
TI Pressure pain sensitivity as a marker for stress and pressure pain sensitivity-guided stress management in women with primary breast cancer
SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
LA English
DT Article
DE Acupuncture; acupressure; clinical stress score; EORTC questionnaire; HADS questionnaire; patient education; self-evaluated stress; SF 36 questionnaire
ID angina-pectoris; integrated rehabilitation; acupuncture-point; mental stress; depression; health; risk; intervention; allostasis; disease
AB Objectives. To validate (1) Pressure Pain Sensitivity (PPS) as a marker for stress and (2) a PPS-guided intervention in women with primary Breast Cancer (BC). Methods. (1) A total of 58 women with BC were examined before and after 6 months of intervention. A control group of 165 women office employees was divided in a High Stress Group (HSG, n = 37) and a Low Stress Group (LSG, n = 128) to evaluate the association between PPS, questionnaire-related Quality of Life (QOL) and self-evaluated stress. (2) A PPS-guided stress management program (n = 40) was compared to a Psychosocial Group Intervention (PGI, n = 91) and no treatment (n = 86) with respect to a European Organization for Research and Treatment of Cancer (EORTC) questionnaire measured QOL. Results. (1) Resting PPS and changes in PPS during the intervention period correlated significantly to EORTC and Short Form 36 (SF 36) main scores: (all p < 0.05). Between BC, HSG and LSG there was a significant and positive correlation with respect to PPS, SF 36 main scores, depression, and clinical stress scores (all p < 0.05). However, the BC group scored significantly lower than both HSG and LSG (both p < 0.05) with respect to self-evaluated stress. (2) The PPS-guided intervention group improved EORTC main score, pain and nausea, when compared to the control groups (all p < 0.05). Conclusions. PPS was positively associated with QOL, which was in contrast to self-evaluated stress. PPS-guided intervention improved QOL in women with breast cancer.
C1 [Axelsson, Christen K.] Univ Copenhagen, Herlev Hosp, Dept Breast Surg, DK-2730 Herlev, Denmark.
   [Ballegaard, Soren] UllCare, Hellerup, Denmark.
   [Karpatschof, Benny] Univ Copenhagen, Inst Psychol, Copenhagen K, Denmark.
   [Schousen, Peer] Horsholm Hosp, Surg Ctr, Horsholm, Denmark.
C3 University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen
RP Axelsson, CK (corresponding author), Bakkevej 14B, DK-2830 Virum, Denmark.
EM cax@dadlnet.dk
FU Danish Cancer Society; KID Foundation, Copenhagen, Denmark
CR Andersen BL, 2008, CANCER-AM CANCER SOC, V113, P3450, DOI 10.1002/cncr.23969
   Andersen BL, 2004, J CLIN ONCOL, V22, P3570, DOI 10.1200/JCO.2004.06.030
   Andersen SR, 2013, ACTA ONCOL, V52, P336, DOI 10.3109/0284186X.2012.745948
   Unknown -, 2006, AM J MED, V0, P0
   BALLEGAARD S, 1991, J INTERN MED, V229, P357, DOI 10.1111/j.1365-2796.1991.tb00359.x
   Ballegaard S, 2004, J ALTERN COMPLEM MED, V10, P777
   BALLEGAARD S, 1995, ACUPUNCTURE ELECTRO, V20, P101, DOI 10.3727/036012995816357113
   BALLEGAARD S, 1993, ACUPUNCTURE ELECTRO, V18, P103, DOI 10.3727/036012993816357548
   Ballegaard S, 2009, SCAND J CLIN LAB INV, V69, P713, DOI 10.1080/00365510903042734
   Ballegaard S, 2014, SCAND J CLIN LAB INV, V74, P116, DOI 10.3109/00365513.2013.862847
   Ballegaard S, 2012, SCAND J CLIN LAB INV, V72, P459, DOI 10.3109/00365513.2012.695023
   BCoTC M, 1980, ESS CHIN AC, V0, P0
   Bergmann N, 2013, SCAND J CLIN LAB INV, V73, P373, DOI 10.3109/00365513.2013.785588
   BJORNER JB, 1997, DANISH MANUAL SF 36, V0, P0
   Boesen EH, 2011, EUR J CANCER, V47, P1363, DOI 10.1016/j.ejca.2011.01.002
   Boles M, 2004, J OCCUP ENVIRON MED, V46, P737, DOI 10.1097/01.jom.0000131830.45744.97
   Bredal IS, 2013, CANC NURS, V2013, P0
   Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968
   Christensen S, 2009, BREAST CANCER RES TR, V113, P339, DOI 10.1007/s10549-008-9920-9
   DUNDEE JW, 1991, J ROY SOC MED, V84, P210, DOI 10.1177/014107689108400409
   Ekman R, 2002, STRESS, V0, P69
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Folkow B, 2001, SCAND CARDIOVASC J, V35, P163, DOI 10.1080/140174301750305036
   Goetzel RZ, 2009, J OCCUP ENVIRON MED, V51, P487, DOI 10.1097/JOM.0b013e31819eb902
   Holmes SD, 2006, PROG CARDIOVASC DIS, V49, P106, DOI 10.1016/j.pcad.2006.08.013
   Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE
   Karasek R, 2006, MED LAV, V97, P258
   Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243
   Korte SM, 2005, NEUROSCI BIOBEHAV R, V29, P3, DOI 10.1016/j.neubiorev.2004.08.009
   Loeppke R, 2009, J OCCUP ENVIRON MED, V51, P411, DOI 10.1097/JOM.0b013e3181a39180
   Magnusson G, 2010, J ALTERN COMPLEM MED, V16, P369, DOI 10.1089/acm.2009.0097
   Matsubara T, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/543291
   McEwen Bruce S, 2006, DIALOGUES CLIN NEUROSCI, V8, P367
   McEwen BS, 2004, ANN NY ACAD SCI, V1032, P1, DOI 10.1196/annals.1314.001
   McEwen BS, 1998, ANN NY ACAD SCI, V840, P33, DOI 10.1111/j.1749-6632.1998.tb09546.x
   Montazeri Ali, 2004, ASIAN PAC J CANCER PREV, V5, P316
   Montazeri A, 2008, BMC CANCER, V8, P0, DOI 10.1186/1471-2407-8-330
   Moraska A, 2010, EVID-BASED COMPL ALT, V7, P409, DOI 10.1093/ecam/nen029
   Nielsen NR, 2005, BRIT MED J, V331, P548, DOI 10.1136/bmj.38547.638183.06
   Noble RE, 2002, METABOLISM, V51, P37, DOI 10.1053/meta.2002.33190
   Oosterhuis WP, 2004, CLIN CHEM, V50, P806, DOI 10.1373/clinchem.2003.025528
   Penninx BWJH, 2013, BMC MED, V11, P0, DOI 10.1186/1741-7015-11-129
   Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456
   Rosmond R, 2005, PSYCHONEUROENDOCRINO, V30, P1, DOI 10.1016/j.psyneuen.2004.05.007
   SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344
   Stansfeld SA, 1998, PSYCHOSOM MED, V60, P247, DOI 10.1097/00006842-199805000-00004
   Wannamethee SG, 2005, ARCH INTERN MED, V165, P2644, DOI 10.1001/archinte.165.22.2644
   Würtzen H, 2013, EUR J CANCER, V49, P1365, DOI 10.1016/j.ejca.2012.10.030
NR 48
TC 5
Z9 6
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0036-5513
EI 1502-7686
J9 SCAND J CLIN LAB INV
JI Scand. J. Clin. Lab. Invest.
PD AUG 15
PY 2014
VL 74
IS 5
BP 399
EP 407
DI 10.3109/00365513.2014.900187
PG 9
WC Medical Laboratory Technology; Medicine, Research & Experimental
SC Medical Laboratory Technology; Research & Experimental Medicine
GA AN2QA
UT WOS:000340429200005
PM 24697620
DA 2026-01-16
ER

PT J
AU Cheon, S
   Zhang, X
   Lee, IS
   Cho, SH
   Chae, Y
   Lee, H
AF Cheon, Soyeon
   Zhang, Xiuyu
   Lee, In-Seon
   Cho, Seung-Hun
   Chae, Younbyoung
   Lee, Hyangsook
TI Pharmacopuncture for Cancer Care: A Systematic Review
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID alternative medicine; complementary; acupuncture; management; injection
AB Background. Pharmacopuncture, injection to acupoints with pharmacological medication or herbal medicine, is a new acupuncture therapy widely available in Korea and China for cancer-related symptoms. However, the evidence is yet to be clear. Objective. To determine pharmacopuncture's effectiveness on cancer-related symptoms. Methods. Eleven databases were searched for randomized controlled trials of pharmacopuncture in cancer patients. The Cochrane risk of bias (ROB) assessment tool was used for quality assessment. Results. Twenty-two studies involving 2,459 patients were included. Five trials of chemotherapy-induced nausea and vomiting (CINV) underwent meta-analysis. Pharmacopuncture significantly relieved severity of CINV compared with control group (3 trials, risk ratio (RR) 1.28, 95% confidence interval (CI) -1.14-1.44). The frequency of CINV was also significantly reduced with pharmacopuncture (2 trials, RR 2.47, 95% CI = 2.12-2.89). Seventeen trials studied various symptoms, and in most studies, pharmacopuncture significantly relieved pain, ileus, hiccup, fever, and gastrointestinal symptoms and improved quality of life in various cancer patients. ROB was generally high. Conclusion. It may be suggested with caution that pharmacopuncture may help various symptom relief in cancer patients, but it is hard to draw a firm conclusion due to clinical heterogeneity and high ROB of the included studies, hence warranting further investigation.
C1 [Cheon, Soyeon; Zhang, Xiuyu; Lee, In-Seon; Chae, Younbyoung] Kyung Hee Univ, Grad Sch, Dept Korean Med Sci, Seoul 130701, South Korea.
   [Cheon, Soyeon; Zhang, Xiuyu; Lee, In-Seon; Chae, Younbyoung; Lee, Hyangsook] Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Seoul 130701, South Korea.
   [Cho, Seung-Hun] Kyung Hee Univ, Med Ctr, Hosp Korean Med, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University Hospital
RP Lee, H (corresponding author), Kyung Hee Univ, Coll Korean Med, Acupuncture & Meridian Sci Res Ctr, Kyung Hee Dae Ro 26, Seoul 130701, South Korea.
EM erc633@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government (Ministry of Science, ICT & Future Planning) [2013R1A6A6029251]; National R & D Program for Cancer Control, Ministry for Health& Welfare, Republic of Korea [1020330]
CR Anderson JG, 2012, J ALTERN COMPLEM MED, V18, P235, DOI 10.1089/acm.2011.0022
   刘增慧, 2011, 广东医学 GUANGDONG MEDICAL JOURNAL, V32, P1769
   Unknown -, 1979, WHO HDB REP RES CANC, V0, P0
   Arthur K, 2012, INTEGR CANCER THER, V11, P232, DOI 10.1177/1534735411433832
   Bao YJ, 2014, SUPPORT CARE CANCER, V22, P825, DOI 10.1007/s00520-013-2063-5
   Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI 10.1200/JCO.2010.34.4614
   Chen J, 2010, BRIT J SURG, V97, P1798, DOI 10.1002/bjs.7227
   Dou Z, 2004, ZHEJIANG J INTEGRATE, V14, P538
   Gansler T, 2010, CA-CANCER J CLIN, V60, P345, DOI 10.3322/caac.20088
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   [胡定政 Hu Dingzheng], 2003, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V23, P587
   Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009
   Jemal Ahmedin, 2011, CA CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim JD, 2010, J ACUPUNCT MERIDIAN, V3, P141, DOI 10.1016/S2005-2901(10)60029-5
   유상민, 2006, JOURNAL OF ACUPUNCTURE RESEARCH, V23, P39
   Loke YK, 2011, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 510, V0, P0
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Ripamonti CI, 2011, ANN ONCOL, V22, Pvi69, DOI 10.1093/annonc/mdr390
   Schulz KF, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-18
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Song HG, 2009, J PHARMACOPUNCT, V12, P111, DOI 10.3831/KPI.2009.12.4.111
   Spadacio C, 2008, REV SAUDE PUBL, V42, P158, DOI 10.1590/S0034-89102008000100023
   Stewart B, 2015, WORLD CANCER REPORT 2014, V0, P0
   Strudwick Mark W, 2007, ACUPUNCT MED, V25, P166
   Weitzel JN, 2011, CA-CANCER J CLIN, V61, P327, DOI 10.3322/caac.20128
   Yan ZM, 2012, QUINTESSENCE INT, V43, P695
   최주영, 2009, JOURNAL OF ACUPUNCTURE RESEARCH, V26, P95
   You Q, 2009, INT J GYNECOL CANCER, V19, P567, DOI 10.1111/IGC.0b013e31819d8b48
NR 57
TC 22
Z9 25
U1 0
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/804746
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AH7BC
UT WOS:000336286300001
PM 24899911
DA 2026-01-16
ER

PT J
AU Bao, Y
   Kong, X
   Yang, L
   Liu, R
   Shi, Z
   Li, W
   Hua, B
   Hou, W
AF Bao, Yanju
   Kong, Xiangying
   Yang, Liping
   Liu, Rui
   Shi, Zhan
   Li, Weidong
   Hua, Baojin
   Hou, Wei
TI Complementary and alternative medicine for cancer pain: an overview of systematic
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB Background and Objective. Now with more and more published systematic reviews of  Complementary and Alternative Medicine (CAM) on adult cancer pain, it is  necessary to use the methods of overview of systematic review to summarize  available evidence, appraise the evidence level, and give suggestions to future  research and practice. Methods. A comprehensive search (the Cochrane Library,  PubMed, Embase, and ISI Web of Knowledge) was conducted to identify all  systematic reviews or meta-analyses of CAM on adult cancer pain. And the evidence  levels were evaluated using GRADE approach. Results. 27 systematic reviews were  included. Based on available evidence, we could find that psychoeducational  interventions, music interventions, acupuncture plus drug therapy, Chinese herbal  medicine plus cancer therapy, compound kushen injection, reflexology, lycopene,  TENS, qigong, cupping, cannabis, Reiki, homeopathy (Traumeel), and creative arts  therapies might have beneficial effects on adult cancer pain. No benefits were  found for acupuncture (versus drug therapy or shame acupuncture), and the results  were inconsistent for massage therapy, transcutaneous electric nerve stimulation  (TENS), and Viscum album L plus cancer treatment. However, the evidence levels  for these interventions were low or moderate due to high risk of bias and/or  small sample size of primary studies. Conclusion. CAM may be beneficial for  alleviating cancer pain, but the evidence levels were found to be low or  moderate. Future large and rigor randomized controlled studies are needed to  confirm the benefits of CAM on adult cancer pain.
C1 Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Nanxiaojie, Dongzhimennei Avenue, Beijing 100700, China.
   Department of Nephrology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD MAY 13
PY 2014
VL 2014
IS 
BP 170396
EP 170396
DI 10.1155/2014/170396
PG 0
UT PubMed:24817897
PM 24817897
DA 2014-05-13
ER

PT J
AU Lin, MN
   Li, XH
   Liang, WN
   Liu, JH
   Guo, JH
   Zheng, JX
   Liu, XX
AF Lin, Munan
   Li, Xihai
   Liang, Wenna
   Liu, Jianhua
   Guo, Jianhong
   Zheng, Jingxiong
   Liu, Xianxiang
TI Needle-knife therapy improves the clinical symptoms of knee osteoarthritis by inhibiting the expression of inflammatory cytokines
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE needle-knife therapy; acupuncture; knee joint; osteoarthritis
ID collagen gene-expression; cartilage degradation; chondrocytes; disease; acupuncture; suppression; chinese; alpha; fluid; risk
AB Knee osteoarthritis (KOA) is a degenerative joint disease that occurs mainly in the elderly population. However, there are currently no effective treatments for treating this condition. In this study, the efficacy of needle-knife therapy, a technique of traditional Chinese medicine that has been widely used to treat KOA was investigated. Patients (n=170) with KOA were randomly divided for needle-knife therapy (treatment group) and acupuncture therapy (control group). Outcome evaluation included stiffness, pain, physiological function, overall changes, total symptom score, clinical curative effects and the concentrations of interleukin (IL)-1 beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha) in the synovial fluid. The trial was completed in 151 patients (233 knees) from a total of 170 patients (264 knees); the treatment group comprised 76 patients (117 knees) who completed the trial and 9 patients (14 knees) who were removed from the study, and the control group comprised 75 patients (116 knees) who completed the trial and 10 patients (17 knees) who were removed from the study. The symptom scores of KOA in stages I-IV were reduced significantly in the treatment group and those of stages I-III were decreased significantly in the control group. The effective rate of the KOA therapy in the patients of stages III and IV in the treatment group was significantly higher than that in the control group. After treatment, the decrements of IL-1 beta, IL-6 and TNF-alpha in the treatment group were greater than those in the control group. These results showed that the use of needle-knife therapy to treat KOA effectively improved the clinical symptoms by inhibiting the expression of inflammatory cytokines.
C1 [Lin, Munan; Liu, Jianhua; Guo, Jianhong; Zheng, Jingxiong] Nanjing Mil Command, Dept Tradit Chinese Med, Fuzhou Gen Hosp, Fuzhou 350025, Fujian, Peoples R China.
   [Li, Xihai; Liu, Xianxiang] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou 350108, Fujian, Peoples R China.
   [Liang, Wenna] Fujian Univ Tradit Chinese Med, Res Base Tradit Chinese Med Syndrome, Fuzhou 350122, Fujian, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine
RP Liu, JH (corresponding author), Nanjing Mil Command, Dept Tradit Chinese Med, Fuzhou Gen Hosp, Outpatient Bldg,156 Xierhuanbei Rd, Fuzhou 350025, Fujian, Peoples R China.
EM lmnan_fzzyy@126.com
FU National Natural Science Foundation of China [81102609]; Natural Science Foundation of Fujian Province [2011J05074]
CR Ahsin S, 2009, PAIN, V147, P60, DOI 10.1016/j.pain.2009.08.004
   Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
   Blower AL, 1997, ALIMENT PHARM THERAP, V11, P283, DOI 10.1046/j.1365-2036.1997.d01-604.x
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016
   Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Fu Mu-Yong, 2011, ZHONGGUO ZHEN JIU, V31, P1062
   Goldring MB, 2007, J CELL PHYSIOL, V213, P626, DOI 10.1002/jcp.21258
   Goldring MB, 2004, CLIN ORTHOP RELAT R, V0, PPS37, DOI 10.1097/01.blo.0000144484.69656.e4
   GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110
   Guo Chang-qing, 2011, ZHONGGUO GU SHANG, V24, P656
   Hamburger MI, 2003, SEMIN ARTHRITIS RHEU, V32, P296, DOI 10.1053/sarh.2002.50008
   Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Lechner M, 2011, J ALTERN COMPLEM MED, V17, P539, DOI 10.1089/acm.2010.0602
   Li HY, 2010, ALTERN THER HEALTH M, V16, P38
   Li XH, 2011, CHIN J INTEGR MED, V17, P436, DOI 10.1007/s11655-011-0751-x
   Li XH, 2010, J TRADIT CHIN MED, V30, P108, DOI 10.1016/S0254-6272(10)60024-6
   Li XH, 2013, INT J MOL MED, V31, P1349, DOI 10.3892/ijmm.2013.1341
   Li XH, 2011, J MED PLANTS RES, V5, P3896
   Lu Di, 2013, ZHONGGUO GU SHANG, V26, P214
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   McGettigan P, 2006, JAMA-J AM MED ASSOC, V296, P1633, DOI 10.1001/jama.296.13.jrv60011
   OLIVERIA SA, 1995, ARTHRITIS RHEUM, V38, P1134, DOI 10.1002/art.1780380817
   Porée B, 2008, J BIOL CHEM, V283, P4850, DOI 10.1074/jbc.M706387200
   SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0
   Sarzi-Puttini P, 2005, SEMIN ARTHRITIS RHEU, V35, P1, DOI 10.1016/j.semarthrit.2005.01.013
   SHARIF M, 1995, ARTHRITIS RHEUM, V38, P78, DOI 10.1002/art.1780380112
   SMITH RL, 1989, CONNECT TISSUE RES, V18, P307, DOI 10.3109/03008208909019079
   Stöve J, 2000, PATHOBIOLOGY, V68, P144, DOI 10.1159/000055915
   Tan C, 2010, J ACUPUNCT MERIDIAN, V3, P173, DOI 10.1016/S2005-2901(10)60033-7
   Tsentralfarband fun die bundistishe organisatsyonen in Amerika, 1905, ONT HLTH TECHNOL A 5, V1, P1
   Wang HM, 2010, CHIN J INTEGR MED, V16, P378, DOI 10.1007/s11655-010-0512-2
   Wu MX, 2010, CHIN J INTEGR MED, V16, P291, DOI 10.1007/s11655-010-0513-1
   Yuan PW, 2010, J TRADIT CHIN MED, V30, P254, DOI 10.1016/S0254-6272(10)60052-0
   Zeng Gui-Gang, 2008, ZHONGGUO ZHEN JIU, V28, P244
NR 36
TC 28
Z9 37
U1 4
U2 46
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD APR 15
PY 2014
VL 7
IS 4
BP 835
EP 842
DI 10.3892/etm.2014.1516
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AE9BP
UT WOS:000334299200013
PM 24669238
DA 2026-01-16
ER

PT J
AU Lee, J
   Yoon, SW
AF Lee, Jinsoo
   Yoon, Seong Woo
TI Efficacy and Safety of Moxibustion for Relieving Pain in Patients With Metastatic Cancer: A Pilot, Randomized, Single-Blind, Sham-Controlled Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE moxibustion; cancer pain; true moxibustion; sham moxibustion; metastatic cancer
ID quality-of-life; functional assessment; acupuncture; validation; prevalence; management; scale; care
AB Background. Moxibustion has been traditionally used to manage pain related to chronic diseases, including cancer. This study aims to investigate the efficacy and safety of moxibustion for relieving cancer pain in patients with metastatic cancer. Methods. A total of 16 patients were randomly divided into a true moxibustion (TM) group or a sham moxibustion (SM) group. In both groups, moxibustion was applied for 10 minutes, once daily for 7 consecutive days. In the SM group, the moxa cone was removed earlier than in the TM group, so as not to deliver heat stimulation completely into the skin. The changes of pain severity using the Brief Pain Inventory (BPI) and quality of life measured by the Functional Assessment of Cancer Therapy-General (FACT-G) were observed. A blinding credibility test was done to validate the sham moxibustion procedure. Results. The total BPI score significantly decreased in the TM group compared with the SM group (TM vs SM: -0.97 +/- 1.05 vs 0.35 +/- 0.60, P = .025). The 2 subsets of BPI, pain intensity score and pain interference score, also significantly decreased in the TM group (TM vs SM: intensity, -0.82 +/- 0.93 vs 0.46 +/- 0.87, P = .020; interference, -1.12 +/- 1.31 vs 0.24 +/- 0.61, P = .047). Even after adjusting for the values of opioid consumption, these results remained significant. FACT-G did not significantly improve in the TM group. The blinding to sham moxibustion was credible and no serious adverse events occurred. Conclusion. We suggest that moxibustion could be a safe and potential modality for cancer-related pain in patients with metastatic cancer. With the limitation of small sample size, a larger and long-term follow-up study is necessary to determine more definitely the efficacy of moxibustion.
C1 [Lee, Jinsoo; Yoon, Seong Woo] Kyung Hee Univ, Korean Med Hosp Gangdong, Seoul 130090, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital
RP Yoon, SW (corresponding author), Kyung Hee Univ, Korean Med Hosp Gangdong, Dept Korean Internal Med, 149 Sangil Dong, Seoul 130090, South Korea.
EM stepano212@hanmail.net
FU Clinical Research Institute, Kyung Hee University Hospital at Gangdong [KHNMCCRI-2010-03]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2008, MOX PLANT (ORDER NO 6), V0, P0
   [卞镝 Bian Di], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P641
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S
   Cleeland C S, 1988, J PAIN SYMPTOM MANAGE, V3, P23, DOI 10.1016/0885-3924(88)90134-0
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   de Valois BA, 2012, EUR J ONCOL NURS, V16, P301, DOI 10.1016/j.ejon.2011.07.005
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fukuda F, 2005, NEUROCHEM RES, V30, P1607, DOI 10.1007/s11064-005-8839-3
   Han Chnaghyun, 2008, KOREAN JOURNAL OF ACUPUNCTURE, V25, P85
   Harris JD, 2008, CLIN J PAIN, V24, PS8, DOI 10.1097/AJP.0b013e31816b58eb
   Kuai Le, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P197
   Lee EH, 2004, JPN J CLIN ONCOL, V34, P393, DOI 10.1093/jjco/hyh070
   Lee MS, 2010, AM J CHINESE MED, V38, P829, DOI 10.1142/S0192415X10008275
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   McGrath PA, 1996, J PAIN SYMPTOM MANAG, V12, P87, DOI 10.1016/0885-3924(96)00099-1
   Murase K, 2000, JPN J PHYSIOL, V50, P133, DOI 10.2170/jjphysiol.50.133
   Noguchi E, 2009, J PHYSIOL SCI, V59, P421, DOI 10.1007/s12576-009-0052-8
   Okada K, 2009, EVID-BASED COMPL ALT, V6, P11, DOI 10.1093/ecam/nem090
   Park JE, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-124
   Park JE, 2010, COMPLEMENT THER MED, V18, P215, DOI 10.1016/j.ctim.2010.07.001
   Plante GE, 2010, METABOLISM, V59, PS47, DOI 10.1016/j.metabol.2010.07.010
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Raphael J, 2010, PAIN MED, V11, P742, DOI 10.1111/j.1526-4637.2010.00840.x
   Valeberg BT, 2008, EUR J PAIN, V12, P582, DOI 10.1016/j.ejpain.2007.09.004
   Wang XM, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/704584
   Yun YH, 2004, ONCOLOGY-BASEL, V66, P439, DOI 10.1159/000079497
   Zhao BX, 2006, COMPLEMENT THER MED, V14, P53, DOI 10.1016/j.ctim.2005.06.003
NR 31
TC 19
Z9 26
U1 0
U2 26
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAY 15
PY 2014
VL 13
IS 3
BP 211
EP 216
DI 10.1177/1534735413510025
PG 6
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA AH6UE
UT WOS:000336265900008
PM 24282101
DA 2026-01-16
ER

PT J
AU Dymáčková, R
   Sláma, O
AF Dymáčková, R
   Sláma, O
TI [Acupuncture in the treatment of symptoms of oncological diseases in the Western
SO Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
LA cze
DT Journal Article
AB Acupuncture is one of the methods of traditional Chinese Medicine (TCM). In Asia,  methods of TCM are quite often used in oncological patients in combination with  classical medicine. In Europe and North America, the position of the TCM is not  so clear. In the last few years, some studies were done which were supposed to  verify scientifically the effectiveness of acupuncture in the treatment of some  symptoms in oncological patients and adverse effects of oncological treatment.  Results of these studies indicate that acupuncture is effective in the treatment  of pain, nausea, vomiting and xerostomia. The International Society of  Integrative Oncology formulated some recommendations for using methods of TCM in  oncological patients. In this field, there is still a lot of possibilities for  further studies which could help acupuncture to become an important therapeutic  method even in our region.
NR 0
TC 0
SN 
EI 0862-495
J9 Klin Onkol
PD AUG 15
PY 2014
VL 27
IS 4
BP 291
EP 3
DI 
PG -288
WC Acupuncture Therapy; Europe; Humans; Medicine, Chinese Traditional; Nausea; etiology; Neoplasms; complications; North America; Pain; etiology; Vomiting; etiology; Xerostomia; etiology
UT PubMed:25115720
PM 25115720
DA 2014-08-15
ER

PT J
AU Frankel, E
   Garland, S
   Meghani, SH
   Vapiwala, N
   Mao, JJ
AF Frankel, Eitan
   Garland, Sheila
   Meghani, Salimah H.
   Vapiwala, Neha
   Mao, Jun J.
TI Patients' perspectives on integrating acupuncture into the radiation oncology setting
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Acupuncture; Radiotherapy; Pain; Health disparity; Knowledge; CAM
ID randomized controlled-trial; cancer-related fatigue; alternative medicine; oral complications; induced xerostomia; breast-cancer; radiotherapy; complementary; care; pain
AB Introduction: Acupuncture has potential as a supportive care service for cancer symptom management. However, little is known about patients' willingness to use acupuncture in the context of conventional cancer care. Methodology: We conducted a cross-sectional survey study among patients with cancer during their last week of fractionated/external beam radiotherapy (RT). The main outcome variable was self-reported likelihood of using acupuncture during RT. Knowledge about acupuncture and pain severity was measured along with socio-demographic and clinical variables. Multivariate logistic regression was performed to identify factors associated with willingness to use acupuncture. Results: Among the 305 participants, 79 (26.4%) were likely to use acupuncture during RT if such services were offered at a reasonable price, 143 (46.9%) had no knowledge of acupuncture, and 206 (67.6%) reported having pain. In multivariate analyses, non-Whites (adjusted odds ratio [AOR] 1.94, 95% confidence interval [CI] 1.06-3.56), and those with pain (AOR 2.52, CI 1.25-5.10) were more interested in using acupuncture. In addition, patients with preexisting knowledge about acupuncture were also more likely to use acupuncture than those without this knowledge (AOR 2.23, CI 1.28-3.88). Conclusions: Patients of non-White race, those with pain or those with prior knowledge about acupuncture were more willing to utilize acupuncture during RT. Since half of the patients had no knowledge about acupuncture, interventions to improve patients' knowledge are needed to facilitate the successful integration of acupuncture into cancer care. (C) 2014 Elsevier GmbH. All rights reserved.
C1 [Frankel, Eitan; Garland, Sheila; Mao, Jun J.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Garland, Sheila; Meghani, Salimah H.; Vapiwala, Neha; Mao, Jun J.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Mao, Jun J.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Meghani, Salimah H.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
   [Vapiwala, Neha] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Mao, JJ (corresponding author), Univ Penn, Dept Family Med & Community Hlth, 3400 Spruce St 2 Gates, Philadelphia, PA 19104 USA.
EM frankel4@uic.edu; sheila.garland@uphs.upenn.edu; meghanis@nursing.upenn.edu; vapiwala@uphs.upenn.edu; jun.mao@uphs.upenn.edu
FU National Center for Complementary and Alternative Medicine grant [1K23 AT004112-05]
CR Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Bedard PL, 2007, J CLIN ONCOL, V25, P3482, DOI 10.1200/JCO.2007.11.3670
   Chambers MS, 2007, HEAD NECK-J SCI SPEC, V29, P58, DOI 10.1002/hed.20456
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   DREIZEN S, 1977, POSTGRAD MED, V61, P85, DOI 10.1080/00325481.1977.11712115
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Hickok JT, 2005, CANCER, V104, P1772, DOI 10.1002/cncr.21364
   Kumar P, 2012, J PALLIAT MED, V15, P923, DOI 10.1089/jpm.2011.0217
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Mao Jun J, 2008, J CANCER SURVIV, V2, P116, DOI 10.1007/s11764-008-0052-3
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Maranzano E, 2010, RADIOTHER ONCOL, V94, P36, DOI 10.1016/j.radonc.2009.11.001
   Matthews EE, 2012, CANCER NURS, V35, PE1, DOI 10.1097/NCC.0b013e3182277222
   Meghani SH, 2012, PAIN MED, V13, P5, DOI 10.1111/j.1526-4637.2011.01289.x
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Sciubba JJ, 2006, LANCET ONCOL, V7, P175, DOI 10.1016/S1470-2045(06)70580-0
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stone PC, 2008, EUR J CANCER, V44, P1097, DOI 10.1016/j.ejca.2008.02.037
   Swarup AB, 2006, AM J CLIN ONCOL-CANC, V29, P468, DOI 10.1097/01.coc.0000221326.64636.b2
   Vallerand AH, 2005, PAIN MED, V6, P242, DOI 10.1111/j.1526-4637.2005.05038.x
NR 28
TC 4
Z9 4
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD OCT 15
PY 2014
VL 6
IS 5
BP 532
EP 537
DI 10.1016/j.eujim.2014.06.007
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AR9UM
UT WOS:000343923800004
PM 25386224
DA 2026-01-16
ER

PT J
AU Ryu, HK
   Baek, YH
   Park, YC
   Seo, BK
AF Ryu, Hee Kyoung
   Baek, Yong-Hyeon
   Park, Yeon-Cheol
   Seo, Byung-Kwan
TI Current Studies of Acupuncture in Cancer-Induced Bone Pain Animal Models
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID rat model; management; mechanisms; expression; hyperalgesia
AB Acupuncture is generally accepted as a safe and harmless treatment option for alleviating pain. To explore the pain mechanism, numerous animal models have been developed to simulate specific human pain conditions, including cancer-induced bone pain (CIBP). In this study, we analyzed the current research methodology of acupuncture for the treatment of CIBP. We electronically searched the PubMed database for animal studies published from 2000 onward using these search terms: (bone cancer OR cancer) AND (pain OR analgesia) AND (acupuncture OR pharmacopuncture OR bee venom). We selected articles that described cancer pain in animal models. We analyzed the methods used to induce cancer pain and the outcome measures used to assess the effects of acupuncture on CIBP in animal models. We reviewed articles that met our inclusion criteria. Injection of mammary cancer cells into the cavity of the tibia was the most frequently used method for inducing CIBP in the animal models. Among the eight selected studies, five studies demonstrated the effects of electroacupuncture on CIBP. The effects of acupuncture were assessed by measuring pain-related behavior. Future researches will be needed to ascertain the effectiveness of acupuncture for treating CIBP and to explore the specific mechanism of CIBP in animal models.
C1 [Ryu, Hee Kyoung; Baek, Yong-Hyeon; Park, Yeon-Cheol; Seo, Byung-Kwan] Kyung Hee Univ Hosp Gangdong, Dept Acupuncture & Moxibust, Seoul 134727, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital
RP Seo, BK (corresponding author), Kyung Hee Univ Hosp Gangdong, Dept Acupuncture & Moxibust, 149 Sangil Dong, Seoul 134727, South Korea.
EM seohbk@hanmail.net
FU Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI13C0379]
CR Buga S, 2012, CANCER CONTROL, V19, P154, DOI 10.1177/107327481201900210
   Camacho DF, 2014, CANCER METAST REV, V33, P545, DOI 10.1007/s10555-013-9476-y
   Clezardin Philippe, 2013, BONEKEY REP, V2, P267, DOI 10.1038/bonekey.2013.1
   Coleman RE, 2006, CLIN CANCER RES, V12, P6243S, DOI 10.1158/1078-0432.CCR-06-0931
   Delaney A, 2008, BRIT J ANAESTH, V101, P87, DOI 10.1093/bja/aen100
   Diel IJ, 2006, EJC SUPPL, V4, P1, DOI 10.1016/j.ejcsup.2006.07.001
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Hampson G, 2012, INT J WOMENS HEALTH, V4, P455, DOI 10.2147/IJWH.S24783
   Hu S, 2012, J NEUROINFLAMM, V9, P0, DOI 10.1186/1742-2094-9-278
   Jimenez-Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749-6632.2009.05429.x
   Kuai Le, 2012, ZHONGGUO ZHEN JIU, V32, P331
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Ma C, 2007, INT ANESTHESIOL CLIN, V45, P121, DOI 10.1097/AIA.0b013e31803419b1
   Mao-Ying QL, 2012, MOL BRAIN, V5, P0, DOI 10.1186/1756-6606-5-16
   Mao-Ying Qi-liang, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P830, DOI 10.3736/jcim20080812
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Muralidharan A, 2013, INFLAMMOPHARMACOLOGY, V21, P339, DOI 10.1007/s10787-013-0183-7
   Pacharinsak C, 2008, COMPARATIVE MED, V58, P220
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P0
   Paley CA, 2011, ACUPUNCT MED, V29, P0, DOI 10.1136/aim.2010.003087
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Ripamonti C, 2000, CURR REV PAIN, V4, P187
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sabino MAC, 2003, INT J CANCER, V104, P550, DOI 10.1002/ijc.10999
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19-24-10886.1999
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   Wacnik PW, 2003, PAIN, V101, P175, DOI 10.1016/S0304-3959(02)00312-3
   Wong MH, 2011, BREAST CANCER-TARGET, V3, P35, DOI 10.2147/BCTT.S6655
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
NR 36
TC 7
Z9 11
U1 1
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/191347
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AS4SO
UT WOS:000344267200001
PM 25383081
DA 2026-01-16
ER

PT J
AU Balneaves, LG
   Lee, RT
   Guns, EST
   Zick, SM
   Bauer-Wu, S
   Greenlee, H
AF Balneaves, Lynda G.
   Lee, Richard T.
   Guns, Emma S. Tomlinson
   Zick, Suzanna M.
   Bauer-Wu, Susan
   Greenlee, Heather
TI Tenth International Conference of the Society for Integrative Oncology Translational Science in Integrative Oncology: From Bedside to Bench to Best Practices
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
AB 107: The Effect of Two Types of Self-Administered Acupressure Compared to Standard of Care on Depression and Anxiety in Fatigued Breast Cancer SurvivorsBackground: There are nearly 3 million breast cancer survivors (BCS) in the United States. Mood disorders in BCS are common, with 38% of women having moderate to high anxiety, and 22% having moderate to high depression. Depression may interfere with survivors' quality of life, decreased adherence to adjuvant therapy and be associated with lower rates of survival. Current treatments for mood disorders can be difficult to implement and/or have unacceptable side effects; thus, there is a need for new treatments in this area. Methods: We compared the effect of 6 weeks of 2 types of self-administered acupressure (stimulating [SA] and relaxing [RA]) versus standard of care (SC) in 32 women for depression, and in 57 women with anxiety who reported 8 at baseline on the Hospital Anxiety Depression Scale (HADS) depression or anxiety subscales, as appropriate, and who were from an ongoing randomized clinical trial on acupressure for persistent cancer-related fatigue in BCS. Analyses of variance (ANOVA) were performed on mean differences of changes (baseline to week 6) in anxiety and depression subscales by group. Results: There was a significant decrease in depression (P = .02 vs SA; P = .06 vs SC) but not in anxiety (P = .36 vs SA; P = .46 vs SC) in the RA group compared with either SA or SC. This represents a -47% mean decrease from baseline in depression in the RA group versus -16% in the SA group and 22% in the SC group, and on average a movement from being borderline abnormal on the HADS depression subscale at baseline (9.2 0.98, 0-21 point scale) to normal (4.9 2.7) at 6 weeks. Conclusion: In this preliminary analysis, self-administered RA engenders a greater antidepressive response as compared with either SA or SC in fatigued BCS. These findings should be interpreted with caution given our small sample size. More rigorous studies are recommended. Abstract 67: Electro-Acupuncture for Aromatase Inhibitor-Related Arthralgia and Comorbid Symptoms in Breast Cancer Survivors: A Randomized Placebo-Controlled TrialBackground: Arthralgia and comorbid symptoms (e.g., fatigue, insomnia) are common among breast cancer patients receiving aromatase inhibitors (AIs). Methods: We conducted a randomized, placebo-controlled trial of electro-acupuncture compared with wait-list control (WLC) and sham acupuncture in postmenopausal women with breast cancer who self-attributed their arthralgia to taking AIs. Acupuncturists delivered 10 treatments of tailored acupuncture with 2-Hz electrostimulation via a TENS (transcutaneous electrical nerve stimulation) unit. Sham acupuncture was conducted using nonpenetrating Streitberger needles at nontraditional acupuncture points and lacked electrostimulation. The primary endpoint was pain severity measured by Brief Pain Inventory (BPI) between electro-acupuncture and WLC at week 8; durability of response at week 12; and comparison of electro-acupuncture to sham acupuncture were secondary aims. Results: Sixty-seven patients were randomized to the 3 arms. At week 8, the electro-acupuncture group had clinically important and significant reduction in joint pain severity (-2.2 vs -0.2, P = .0004) and pain-related interference (-2.0 vs 0.2, P = .0006) compared with the WLC. The electro-acupuncture group also had significant improvement in fatigue as measured by the Brief Fatigue Inventory (-2.1 vs 0.4, P = .0016) and sleep as measured by the Pittsburg Sleep Quality Index (-2.2 vs 0.3, P = .021) compared with the WLC. The improvement in pain, fatigue, and sleep appeared to be maintained at 4 weeks following the last acupuncture treatment. The magnitude of effects on these symptoms was similar in the electro-acupuncture and sham acupuncture groups. Discussion: Electro-acupuncture significantly improved AI-related arthralgia and comorbid fatigue and sleep problems over usual care with clinically important and durable changes. Our preliminary findings suggest that electro-acupuncture may have the potential to address a cluster of symptoms in breast cancer survivors receiving AIs. The similar treatment effects between the electro and sham groups suggest that a large component of acupuncture effect is mediated through the process of acupuncture delivery rather than the specificity of needling techniques. Abstract 53: Association of Physical Activity and Telomere Length in Breast Cancer SurvivorsBackground: Cellular telomere length (TL) is a biomarker of accumulated cellular damage and human aging. Evidence suggests that TL may be affected by a host of psychosocial and lifestyle factors, including physical activity (PA). This is the first study to evaluate the relationship between PA and TL in breast cancer survivors. Methods: A cross-sectional sample of 392 postmenopausal women with stage 0-III breast cancer at an outpatient breast oncology clinic of a large university hospital completed questionnaires and provided a blood sample. TL was determined using mean terminal restriction fragment length and isolated from peripheral blood mononuclear cells. PA was dichotomized into 2 groups (none vs moderate to vigorous) using the International Physical Activity Questionnaire. Multivariate logistic and linear regression analyses were performed to identify factors associated with TL and PA. Results: Among participants, 66 (17%) did not participate in any PA. In the adjusted model, older women (>65 years) has significantly shorter TL (coefficient = -0.27; P = .02), while women who participated in moderate to vigorous PA has significantly longer TL (coefficient = 0.22; P = .03). Obese women (body mass index 30 kg/m(2)) were 64% less likely to engage in PA (adjusted odds ratio [AOR] = 0.44; P = .05), and women experiencing higher levels of fatigue were 15% less likely (AOR = 0.85; P = .05). Women with a college (AOR = 2.37; P = .03) or graduate education (AOR = 2.37; P = .001) were both significantly more likely to engage in PA. Conclusion: Lack of PA is associated with shortened TL, warranting prospective investigation of the potential role of PA on cellular aging in breast cancer survivors. Future research is needed to address the barriers to PA in women with breast cancer, especially for those who are obese and with lower education. Abstract 20: Tumor Resistance, Immuno-Enhancement and Life Span Increase Mediated by an Extract of North American GinsengBackground: Cells belonging to the innate immune system, that is, natural killer (NK) cells, act as the first line of defense against developing neoplasms. We previously showed both tumor reduction and immune-enhancement in leukemia cell-injected DBA/2 mice given a proprietary extract of North American ginseng (CVT-E002) daily, via the diet. The extract is in the marketplace as Cold FX. Methods: Elderly, female C3H/HeN mice were used because they are prone to the development of assorted cancers, predominant among which are breast cancers. A homogenized mixture of powdered standard mouse chow containing CVT-E002 (80 mg/6 g chow/day/mouse), was fed for 11 months, from age 22 months, after which half the mice were euthanized (age 33 months). The chow of parallel control mice contained no CVT-E002. The spleens (SPL) and bone marrow (BM) were removed and assayed for their content of NK cells and lymphocytes. The remaining half of the CVT-E002-fed mice were placed on the control diet at 11 months and left to assess life span. Results: In mice consuming CVT-E002 from 22 to 33 months, the absolute numbers of NK cells in their SPL and BM were elevated over control (P < .0004 and P < .0001, respectively) as were the absolute numbers of lymphocytes (non-NK) in both organs (P < .0001 and P < .0001, respectively). No CVT-E002-consuming mouse had any tumors at whole-body autopsy when euthanized (age 33 months) versus 100% bearing tumors (47% breast cancers) in control-diet mice. The remaining half (above) of the CVT-E002-consuming mice lived on until they were intentionally euthanized just over 4 years of ageall still tumor free. Conclusion: The results indicate (1) a profound effect of CVT-E002 in tumor resistance, (2) a significant increase in the numbers of immune cells, and (3) a strikingly long life (>4 years) in these inbred mice, equivalent to 126 human years. Abstract 30: Pomegranate Extracts Impact Androgen Biosynthesis Pathways In Vitro and In VivoBackground: Residual tissue androgens are consistently detected within prostate tumors from chemically castrated patients and are thought to facilitate androgen receptor (AR)-mediated disease progression to castration-resistant prostate cancer (CRPC). The source of these steroids has been attributed to the conversion of adrenally sourced precursor substrates. Testosterone and dihydrotestosterone (DHT) can be produced through 3 biosynthesis pathways: (4), (5), and backdoor pathways. Pomegranate extracts have been demonstrated to have anticancer activity, particularly in CRPC. This study examines the effects of pomegranate extracts (POMELLA) on steroid biosynthesis using PCa cell lines (22RV1 and LNCaP) in vitro as well as the conditional PTEN knockout prostate cancer model in vivo. Methods: Steroids produced by 22RV1 and LNCaP cells (treated by POMELLA) for 48 hours at 2, 4, 5, 8, 12 mu g/mL, respectively, as well as mouse serum taken after treatment with PFEs in drinking water (0.17 g/L of POMELLA in 1% sucrose solution for 20 weeks) or control (1% sucrose water) were analyzed via UPLC/MS/MS. Results: In vitro experiments showed that POMELLA extracts significantly reduced testosterone, DHT, dehydroepiandrosterone (DHEA), androstenedione, androsterone, and pregnenolone production. Testosterone and DHT were significantly lower in cells treated with pomegranate extracts compared with controls, at 5 to 12 mu g/mL concentrations (n = 6, P < .05). Our in vivo study also confirmed that testosterone and DHEA in the serum of the POMELLA-treated mice were significantly lower than control mice (n = 7, P < .05). Conclusion: Pomegranate extracts attenuate testosterone and DHT in vitro and lower serum androgen levels in vivo, in a conditional PTEN knockout prostate cancer model. Abstract 109: Drug-Micronutrient Interactions in Cancer: The Case of Vitamin DBackground: The chemopreventive and therapeutic effects of vitamin D3 are exerted through 1,25-(OH)(2)D3, the dihydroxy metabolite of vitamin D3. Inactivation of 1,25-(OH)(2)D3 by cytochrome P450 3A (CYP3A) enzymes can be an important determinant of its serum and tissue levels. The purpose of the present study was to assess the potential of various medications, which are commonly used in the treatment regimens of patients with cancer (eg, abiraterone, ketoconazole, tamoxifen, taxanes) and as premedications (eg, dexamethasone, prednisone) to chemotherapy, on biotransformation of 1,25-(OH)(2)D3 in human and mouse liver microsomes. Methods: Adult CD-1 mice were treated with vehicle (50% ethanol), dexamethasone (80 mg/kg/day) or prednisone (80 mg/kg/d) for 3 consecutive days by intraperitoneal injection. Mouse livers were used to prepare microsomes by differential ultracentrifugation. In vitro reaction mixtures contained potassium phosphate buffer, mouse or human hepatic microsomal protein (XenoTech LLC) or human recombinant CYP3A4 supersomes, NADPH, and a fixed concentration of 20 mu M 1,25-(OH)(2)D3. Reactions were initiated with NADPH after initial preincubation of microsomes with 1,25-(OH)(2)D3 and various concentrations of abiraterone (0.2-100 mu M), ketoconazole (0.05-10 mu M), tamoxifen (1-100 mu M), and docetaxel (0.1-1.24 mu M) at 37 degrees C. Formation of hydroxylated metabolites of 1,25-(OH)(2)D3 were analyzed by liquid chromatography-mass spectrometry method. Results: The formation of hydroxy metabolites was significantly stimulated in hepatic microsomes from mice treated with dexamethasone compared with vehicle- and prednisone-treated group. Co-incubation of 1,25-(OH)(2)D3 with various drugs led to up to similar to 85% to 99% inhibition of formation of hydroxylated metabolites of 1,25-(OH)(2)D3 and therefore reduced inactivation of active vitamin D3. The IC50 values (GraphPad PrismTM v4.0 software) for individual metabolites of 1,25-(OH)(2)D3 ranged from 0.012 to 2.20 mu M in human liver microsomes. Conclusions: In summary, our results suggest that premedications and co-medications administered in cancer patients can either exacerbate or inhibit the CYP3A-mediated inactivation of active vitamin D3 leading to altered vitamin D homeostasis. Abstract 71: Disturbed Sleep in Cancer Survivors: Is There a Place for Mindfulness-Based Interventions?Background: After completing treatment, cancer survivors often suffer from a multitude of physical and mental health impairments, resulting in compromised quality of life. This exploratory study investigated whether 2 mind-body interventions, Mind-Body Bridging (MBB) and Mindfulness Meditation (MM), could improve posttreatment cancer survivors' self-reported sleep disturbance and comorbid symptoms, as compared to Sleep Hygiene Education (SHE) as an active control. Methods: This randomized controlled trial examined 57 cancer survivors with clinically significant self-reported sleep disturbance, randomly assigned to receive MBB, MM, or SHE. All interventions were conducted in three sessions, once per week. Patient-reported outcomes were assessed via the Medical Outcomes Study Sleep Scale and other indicators of psychosocial functioning relevant to quality of life, stress, depression, mindfulness, self-compassion, and well-being. Results: Mixed effects model analysis revealed that mean sleep disturbance symptoms in the MBB and MM groups were lower than in the SHE group, indicating that both mind-body interventions improved sleep. Also, compared with the SHE group, the MBB group showed reductions in self-reported depression symptoms and improvements in overall levels of mindfulness, self- compassion, and well-being at postintervention. Conclusions: This study provides preliminary evidence that brief sleep-focused MBB and MM are promising interventions for sleep disturbance in cancer survivors. Integrating MBB or MM into posttreatment supportive plans should enhance care of cancer survivors with sleep disturbance. Because MBB produced additional secondary benefits, MBB may serve as a promising multipurpose intervention for posttreatment cancer survivors suffering from sleep disturbance and other comorbid symptoms. Management of sleep problems in survivors is a high priority issue that demands more attention in cancer survivorship. Abstract 133: EEG Imaging and Neuromodulation of Acute Pain in Head and Neck Cancer Patients Undergoing RadiotherapyBackground: We investigated the effectiveness of a brain-computer interface (LORETA neurofeedback) to manage acute onset pain and examine the neurophysiological mechanisms and localization of pain as a result of head and neck radiation. Methods: Patients undergoing head and neck radiation (n = 4 of 10 to date; male; right-handed; mean age = 53.5 years) completed baseline questionnaires and underwent a baseline electroencephalography (EEG). A second EEG was done on the first written prescription for pain medications, but before the medications were started, and a final EEG was performed at the conclusion of radiotherapy. Patients had a total of 6 LORETA neurofeedback sessions after their pain became at least a 4 on a 0 to 10 scale for 3 consecutive days. Patients were asked to rate their pain on a scale of 0 to 10 before and after each neurofeedback session. The Brief Pain Inventory (BPI), the Multidimensional Pain Inventory (MPI), and the MD Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) were completed at baseline and end of radiotherapy. Results: LORETA results demonstrated that (1) regions of the pain network increase in beta (13-21 Hz) activity relative to baseline (primary somatosensory cortex, dorsolateral prefrontal cortex), and other regions not associated with the pain network also increased in activity (precuneus). During LORETA neurofeedback sessions, patients could reduce activity in the pain network relative to their painful EEG map activity. Pain ratings also decreased from pre- to post-session (mean decrease = 2.14). Self-report data and the association between self-report and brain activity will be presented with the complete data set (n = 10). Conclusions: We were able to capture brain activity during acute pain onset and show that patients can change that brain activity to a less painful state with LORETA neurofeedback. Identification of these regions and successful EEG neurofeedback training will allow a targeted approach to acute pain management that is independent of medications. Abstract 136: Baseline Depression Levels Moderate the Effectiveness of Expressive Writing for Patients With Renal Cell CarcinomaBackground: Expressive writing (EW) has been demonstrated to be an effective approach to improve quality of life in cancer patients. We previously reported that EW reduced intrusive thoughts and improved cancer-related symptoms (MD Anderson Symptom Inventory [MDASI]) in renal cell carcinoma (RCC) patients. Here we examined if depressive symptoms at study entry moderated the effectiveness of the EW program. Methods: Patients (n = 277) with RCC scheduled to receive surgical or systemic treatment were randomly assigned to write about either their deepest thoughts and feelings about their cancer (EW) or neutral topics (NW) on 4 separate occasions over 10 days. Patients completed measures of depressive symptoms (Center for Epidemiologic Studies-Depression [CES-D]), MDASI, fatigue (Brief Fatigue Inventory [BFI]), and sleep disturbances (Pittsburgh Sleep Quality Index [PSQI]) at baseline, and 1, 4, and 10 months after the writing sessions. Results: The mean age of participants was 58 years, and 41% were female. Participants had been diagnosed with stage I (38%), stage II (14%), stage III (18%), or stage IV (28%). After controlling for baseline levels of the outcome variables, multilevel modeling analyses revealed that participants in the EW group who had elevated depressive symptoms at baseline had worse outcomes than those in the NW group with elevated depressive symptoms at baseline. Specifically, at 1 month postintervention, participants in the EW group reported more cancer-related symptoms (MADSI; P < .01), sleep disturbances (PSQI; P < .01), and fatigue (BFI; P < .01) compared with those in the NW group. There were no group differences for those low in baseline depressive scores. Conclusions: These findings suggest that patient baseline characteristics may moderate the effectiveness of an EW program. Those with elevated depressive symptoms at study entry do not appear to benefit from an EW program and, in fact, EW may result in worse outcomes. Clinician-facilitated treatments providing more intense supportive care may be need to improve quality of life outcomes in patients with depressive symptoms. Abstract 127: Acupuncture for Dysphagia After Chemoradiation Therapy in Head And Neck Cancer: A Pilot Randomized Sham-Controlled TrialBackground: Dysphagia is a common side effect following chemoradiation therapy (CRT) in patients with head and neck cancer (HNC). The purpose of this pilot trial was to assess the feasibility of recruiting HNC patients and to collect preliminary data on the efficacy and safety of acupuncture on dysphagia-related quality-of-life (QOL). Methods: Patients were eligible if diagnosed with stage III-IV HNC, without evidence of distance metastasis, receiving curative-intent CRT. Patients were randomized to 12 sessions of either active or sham acupuncture, once every 2 weeks, over 24 weeks from during CRT to 20-week post-CRT. All study personnel and the patients were blinded; the treating acupuncturists were not. MD Anderson Dysphagia Inventory (MDADI) and other questionnaires were measured at baseline (end of CRT), end of acupuncture, and at 6 months follow-up (12-month post-CRT). Data were analyzed by repeated-measures analysis of variance (ANOVA) adjusting for baseline. Results: Accrual was completed in December 2011. Among 42 patients enrolled, 35 (83%) received at least 8 sessions of acupuncture, and 28 (67%) received all 12. Six patients withdrew because of time constraints. No serious side effects were observed. The mean MDADI total scores improved from baseline in both treatment arms (64.5 [SE +/- 2.4] vs 71.4 [SE +/- 3.1], P = .048; 64.5 [SE +/- 2.4] vs 77.8 [SE +/- 3.0], P < .001); the difference in improvement was not significant (P = .12). The median feeding tube duration did not differ between active and sham treatments (n = 39, median 125 days vs 147 days, P = .93). Conclusions: Acupuncture is a safe and feasible treatment for HNC patients. In the pilot trial, improvements in QOL parameters from end of CRT to the time points examined were observed but they did not differ between the 2 arms. Efficacy of acupuncture to improve swallowing-related QOL in HNC patients may require more frequent or longer duration of treatment.
C1 [Balneaves, Lynda G.] Univ British Columbia, Sch Nursing, Vancouver, BC V6T 2B5, Canada.
   [Lee, Richard T.] Univ Texas MD Anderson Canc Ctr, Dept Gen Med, Houston, TX 77030 USA.
   [Guns, Emma S. Tomlinson] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V6T 2B5, Canada.
   [Zick, Suzanna M.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA.
   [Zick, Suzanna M.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
   [Bauer-Wu, Susan] Univ Virginia, Sch Nursing, Charlottesville, VA 22903 USA.
   [Greenlee, Heather] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
   [Greenlee, Heather] Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 University of British Columbia; University of Texas System; UTMD Anderson Cancer Center; University of British Columbia; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Virginia; Columbia University
RP Balneaves, LG (corresponding author), Univ British Columbia, Sch Nursing, T201-2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.
EM lynda.balneaves@nursing.ubc.ca
FU National Institutes of Health's National Cancer Institute; National Institutes of Health's National Center for Complementary and Alternative Medicine [R13CA183288]; Canadian Institutes for Health Research; Lotte and John Hecht Memorial Foundation; Weil Foundation
CR Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
NR 1
TC 3
Z9 4
U1 7
U2 327
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JAN 15
PY 2014
VL 13
IS 1
BP 5
EP 11
DI 10.1177/1534735413517743
PG 7
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA AA0GQ
UT WOS:000330774000001
PM 24420529
DA 2026-01-16
ER

PT J
AU Weilert, F
AF Weilert, Frank
TI Prospective evaluation of simplified algorithm for EUS-guided intra-hepatic
SO Surgical endoscopy
LA English
DT Journal Article
AB BACKGROUND: EUS-guided biliary drainage (EUS-BD) is technically challenging but  alternative method of therapeutic intervention when ERCP fails. OBJECTIVE: Assess  the feasibility, safety and risks of EUS-BD with intra-hepatic biliary access and  anterograde interventions using an algorithm to increase flexibility of  interventions, limit adverse events and improve procedural time. DESIGN:  Prospective observational cohort study. PATIENTS: 21 consecutive patients  underwent EUS-BD drainage for failed ERCP. MAIN OUTCOME MEASURES: Technical and  clinical success rates with adverse event rate using simplified algorithm.  RESULTS: Patient recruitment from June 2011-October 2013; mean age of 67.4 years,  predominantly male (70.5 %) with pancreatic cancer (52.4 %), cholangiocarcinoma  (14.3 %), other malignant biliary obstruction (9.5 %) and benign biliary  obstruction (23.8 %). Prior interventions included failed ERCP in 18/21 (85.7 %)  while 3/21 (14.3 %) had primary EUS-BD. Anterograde cholangiogram was achieved in  all patients. Technical success was achieved in 20/21 (95.2 %) with clinical  success was achieved in 19/21 (90.4 %). Placement of access wire was across the  ampulla in 10/20 (50 %) and into CBD or contra-lateral IHD in 10/20 (50 %). Tract  dilatation was accomplished in 17/20 (85 %) but required completion using  intra-hepatic needle knife in 3/20 (15 %). Anterograde interventions were  performed in 16/20 (80 %) but crossover to rendezvous in 3/20 (15 %) or  choledochoduodenostomy 1/20 (5 %). Three patients 3/21 (14.3 %) also had  endoscopic duodenal SEMS placement to relieve duodenal obstruction. Two patients  (9.5 %) had post-procedural bile leak and pain. CONCLUSION: EUS-guided  anterograde biliary drainage using the intra-hepatic access route has high  technical and clinical success with low adverse rate. We would promote a  simplified standardized algorithm, which gives flexibility of direct anterograde  interventions.
C1 Department of Gastroenterology, Waikato Hospital, Pembroke Street, Hamilton, 3200, New Zealand, frank.weilert@waikatodhb.health.nz.
NR 0
TC 0
SN 1432-221
EI 
J9 Surg Endosc
PD JUN 1
PY 2014
VL 28
IS 11
BP 3193
EP 9
DI 10.1007/s00464-014-3588-5
PG -3184
WC Aged; Aged, 80 and over; Algorithms; Bile Duct Neoplasms; diagnosis; Bile Ducts, Intrahepatic; surgery; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; diagnosis; Drainage; methods; Endosonography; methods; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; diagnosis; Prospective Studies; Reoperation; Surgery, Computer-Assisted; methods; Treatment Failure
UT PubMed:24879144
PM 24879144
DA 2014-06-01
ER

PT J
AU Mandıroğlu, S
   Cevik, C
   Aylı, M
AF Mandıroğlu, Sibel
   Cevik, Cemal
   Aylı, Meltem
TI Acupuncture for neuropathic pain due to bortezomib in a patient with multiple
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE Acupuncture
AB Multiple myeloma (MM) is characterised by an increase in plasma cells,  particularly in the bone marrow but also in other organs and systems, and with  the abnormal production of immunoglobulin. Bortezomib, a current treatment  option, inhibits angiogenesis by proteasome inhibition and is known to be  effective in the treatment of MM. Peripheral neuropathy (PN) is a common  dose-related side effect of bortezomib in patients with MM. We describe a case of  PN due to bortezomib treatment which responded dramatically to acupuncture  treatment, enabling his bortezomib treatment to continue. The patient was a  74-year-old man with pain, numbness, tingling and weakness in his hands and feet  after 22 days of bortezomib treatment given by the haematology clinic. His  neuropathic pain score was 8/10. There were no autonomic symptoms.  Electroneurophysiological testing confirmed sensorimotor PN. Acupuncture  treatment was planned as his neuropathic pain continued. Acupuncture was  administered bilaterally to ST36, SP6 and LI4 15 times (every other day in the  first five sessions and then twice a week). The numbness, tingling and pain  symptoms substantially decreased after the first two treatments. After the 15th  session acupuncture treatment was continued once a month. At the end of the sixth  month the neuropathic pain assessment score was 0/10. There was no side effect of  acupuncture treatment. Acupuncture seems promising as a complementary medical  treatment for neuropathic pain from bortezomib-induced PN. Clinical studies  involving more cases and electrophysiological studies are necessary to  investigate the effectiveness of acupuncture.
C1 Department of Physical Medicine and Rehabilitation, Ankara Physical Medicine and Rehabilitation Training and Research Hospital, , Ankara, Turkey.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD JAN 7
PY 2014
VL 32
IS 2
BP 194
EP 6
DI 10.1136/acupmed-2013-010491
PG -188
WC Acupuncture Therapy; Aged; Boronic Acids; adverse effects; Bortezomib; Humans; Male; Multiple Myeloma; drug therapy; Neuralgia; chemically induced; Pyrazines; adverse effects
UT PubMed:24389811
PM 24389811
DA 2014-01-07
ER

PT J
AU Lian, WL
   Pan, MQ
   Zhou, DH
   Zhang, ZJ
AF Lian Wei-Ling
   Pan Min-qi
   Zhou Dai-han
   Zhang Zhang-jin
TI Effectiveness of Acupuncture for Palliative Care in Cancer Patients: A Systematic Review
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Review
DE acupuncture; palliative care; cancer; tumor
ID prolonged postoperative ileus
AB Objective: To critically evaluate the currently available randomized clinical trials regarding the effectiveness of acupuncture in palliative care for cancer patients, hence, to provide sufficient evidences for the widespread use of acupuncture in cancer treatment. Methods: Two independent reviewers extracted data from all of the randomized clinical trials (RCTs) that assessed the efficacy of acupuncture in palliative care for cancer patients. Seven databases were searched from their respective inception to December 2010. All eligible trials identified were evaluated by two independent reviewers using the Jadad scale, and data from the articles were validated and extracted. Results: In total, 33 RCTs met the inclusion criteria. The effects of acupuncture on different cancer-related aspects were shown, including chemotherapy or radiotherapy-induced side effects (13/33, 39.4%), cancer pain (6/33, 18.2%), post-operative urinary retention (4/33, 12.1%), quality of life (2/33, 6.1%), vasomotor syndrome (2/33, 6.1%), post-operative gastrointestinal dysfunction (2/33, 6.1%), prevention of prolonged postoperative ileus (2/33, 6.1%), joint symptoms (1/33, 3.0%), and immunomodulation (1/33, 3.0%). Conclusions: The result of our systematic review suggested that the effectiveness of acupuncture in palliative care for cancer patients is promising, especially in reducing chemotherapy or radiotherapy-induced side effects and cancer pain. Acupuncture may be an appropriate adjunctive treatment for palliative care.
C1 [Lian Wei-Ling; Pan Min-qi; Zhang Zhang-jin] Univ Hong Kong, Sch Chinese Med, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Lian Wei-Ling; Zhou Dai-han] Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou 510006, Guangdong, Peoples R China.
C3 University of Hong Kong; Guangzhou University of Chinese Medicine
RP Zhou, DH (corresponding author), Guangzhou Univ Chinese Med, Sch Clin Med 1, Guangzhou 510006, Guangdong, Peoples R China.
EM 13902206571@139.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   施钰岚, 2008, 中国中西医结合杂志 CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, V28, P158
   牛春风, 2008, 中国老年学杂志 CHINESE JOURNAL OF GERONTOLOGY, V28, P924
   张青, 2006, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V47, P209
   Unknown -, 2008, JIANGSU TRADITIONAL, V0, P0
   Unknown -, 2009, STUDY TERRAIN CORREC, V0, P0
   Bausewein C, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005623.pub2
   Beinfield H, 2003, ALTERN THER HEALTH M, V9, P38
   Chen C, 2004, NEW J TRADIT CHIN ME, V36, P46
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Fu Jie, 2006, ZHONGGUO ZHEN JIU, V26, P250
   Garcia MK, 2008, MED ACUPUNCT, V20, P83, DOI 10.1089/acu.2008.0607
   He Bi-mei, 2007, ZHONGGUO ZHEN JIU, V27, P369
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang ZF, 2008, LIAONING J TRAD CHIN, V35, P917
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Liu B, 2009, HEBEI J TRADIT CHIN, V31, P1040
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Mai ZF, 2008, MODERN PREVENTIVE MEDICINE, V35, P122
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Qiao DP, 2008, J PRACT ONCOL, V22, P446
   Sagar SM, 2008, CURR TREAT OPTION ON, V9, P117, DOI 10.1007/s11864-008-0063-3
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   World Health Organization (WHO), 2010, DEFINITION OF PALLIATIVE CARE, V0, P0
   Wu B, 1996, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V16, P139
   XIA Y, 1986, JOURNAL OF TRADITIONAL CHINESE MEDICINE, V6, P23
   Yang Yan, 2009, ZHONGGUO ZHEN JIU, V29, P955
NR 48
TC 39
Z9 47
U1 0
U2 36
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD FEB 15
PY 2014
VL 20
IS 2
BP 136
EP 147
DI 10.1007/s11655-013-1439-1
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AC9ND
UT WOS:000332860400009
PM 24338183
DA 2026-01-16
ER

PT J
AU Tas, D
   Uncu, D
   Sendur, MA
   Koca, N
   Zengin, N
AF Tas, Demet
   Uncu, Dogan
   Sendur, Mehmet Ali
   Koca, Nuran
   Zengin, Nurullah
TI Acupuncture as a Complementary Treatment for Cancer Patients Receiving Chemotherapy
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Acupuncture; cancer; chemotherapy; nausea; insomnia; anxiety; vomiting; pain; Turkey
ID insomnia severity index; breast-cancer; anxiety; nausea; pain; electroacupuncture; stimulation; moxibustion; fatigue; women
AB Background: Medical treatment for eliminating the side effects of cancer therapy may not always be efficacious. Acupuncture is one of the most widely accepted alternative and complementary therapies in use today. In this study, we investigated the efficacy of acupuncture in patients experiencing cancer treatment side effects, including nausea, vomiting, pain, poor sleep quality and anxiety. Materials and Methods: A total of 45 inpatients who underwent chemotherapy between February and April 2013 in the Oncology Department of Numune Hospital were included in our study. Acupuncture was administered to the patients one day prior to chemotherapy, on the day of chemotherapy and one day after chemotherapy. The patients were evaluated on nausea, vomiting, pain, sleep quality and anxiety before the chemotherapy and on the 4th day of chemotherapy. Results: Of the 45 patients included in the study, 18 (40%) were female and 27 (60%) were male. A total of 25 (55.6%) had an elementary school education; 32 patients (71%) had stage 4 cancer and were treated with palliative chemotherapy (the patient characteristics are shown in Table 1). Statistically significant decreases (p<0.001) in pain, nausea, vomiting, insomnia and anxiety scores were observed after the acupuncture treatment compared to baseline. There were no differences in the age, gender, education level, stage or metastasis levels between the patient groups whose symptoms improved or were unchanged. Conclusions: Our study showed that acupuncture has positive effects in cancer treatment patients who experience nausea, vomiting, pain, poor sleep quality and anxiety as side effects of chemotherapy. Chemotherapy-related side effects in cancer patients could be decreased by the concurrent use of acupuncture.
C1 [Tas, Demet] Minist Hlth, Tradit Complementary & Alternat Med Dept, Ankara, Turkey.
   [Uncu, Dogan; Sendur, Mehmet Ali; Koca, Nuran; Zengin, Nurullah] Ankara Numune Training & Res Hosp, Med Oncol Clin, Ankara, Turkey.
C3 Ministry of Health - Turkey; Ankara Numune Training & Research Hospital
RP Tas, D (corresponding author), Minist Hlth, Tradit Complementary & Alternat Med Dept, Ankara, Turkey.
EM demettas19691@hotmail.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bai LJ, 2010, J MAGN RESON IMAGING, V31, P71, DOI 10.1002/jmri.22006
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893
   Boysan M, 2010, ANADOLU PSIKIYATR DE, V11, P248
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Cheng CH, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1093/ecam/nep132
   Cheuk DKL, 2012, COCHRANE DATABASE SY, V12, P0
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cohen Andrea J, 2005, INTEGR CANCER THER, V4, P131, DOI 10.1177/1534735405276419
   Eich H, 2000, FORTSCHR NEUROL PSYC, V68, P137, DOI 10.1055/s-2000-11624
   Erkmen H, 1996, JOURNAL OF COGNITIVE PSYCHOTHERAPY, V0, P0
   Ezzo J, 2006, J ALTERN COMPLEM MED, V12, P489, DOI 10.1089/acm.2006.12.489
   Guo R, 1995, J TRADIT CHIN MED, V15, P262
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Josefson A, 2003, RHEUMATOLOGY, V42, P1149, DOI 10.1093/rheumatology/keg312
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Pilkington K, 1900, V25, V0, P1
   Roscoe JA, 2000, J PAIN SYMPTOM MANAG, V20, P113, DOI 10.1016/S0885-3924(00)00159-7
   Sok SR, 2003, J ADV NURS, V44, P375, DOI 10.1046/j.0309-2402.2003.02816.x
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vinjamury SP, 2013, CHIN MED, V30, P8
   Yano T, 2004, NEUROCHEM RES, V29, P283, DOI 10.1023/B:NERE.0000010457.00855.8c
   Zhang Hong, 2003, J TRADIT CHIN MED, V23, P55
NR 35
TC 21
Z9 23
U1 0
U2 42
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
EI 
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PD JUN 15
PY 2014
VL 15
IS 7
BP 3139
EP 3144
DI 10.7314/APJCP.2014.15.7.3139
PG 6
WC Oncology
SC Oncology
GA AI4KQ
UT WOS:000336834500033
PM 24815460
DA 2026-01-16
ER

PT J
AU Ryu, HK
   Baek, YH
   Park, YC
   Seo, BK
AF Ryu, Hee Kyoung
   Baek, Yong-Hyeon
   Park, Yeon-Cheol
   Seo, Byung-Kwan
TI Current studies of acupuncture in cancer-induced bone pain animal models.
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB Acupuncture is generally accepted as a safe and harmless treatment option for  alleviating pain. To explore the pain mechanism, numerous animal models have been  developed to simulate specific human pain conditions, including cancer-induced  bone pain (CIBP). In this study, we analyzed the current research methodology of  acupuncture for the treatment of CIBP. We electronically searched the PubMed  database for animal studies published from 2000 onward using these search terms:  (bone cancer OR cancer) AND (pain OR analgesia) AND (acupuncture OR  pharmacopuncture OR bee venom). We selected articles that described cancer pain  in animal models. We analyzed the methods used to induce cancer pain and the  outcome measures used to assess the effects of acupuncture on CIBP in animal  models. We reviewed articles that met our inclusion criteria. Injection of  mammary cancer cells into the cavity of the tibia was the most frequently used  method for inducing CIBP in the animal models. Among the eight selected studies,  five studies demonstrated the effects of electroacupuncture on CIBP. The effects  of acupuncture were assessed by measuring pain-related behavior. Future  researches will be needed to ascertain the effectiveness of acupuncture for  treating CIBP and to explore the specific mechanism of CIBP in animal models.
C1 Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.
   Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.
   Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.
   Department of Acupuncture & Moxibustion, Kyung Hee University Hospital at Gangdong, 149 Sangil-dong, Gangdong-gu, Seoul 134-727, Republic of Korea.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD NOV 11
PY 2014
VL 2014
IS 
BP 191347
EP 191347
DI 10.1155/2014/191347
PG 0
UT PubMed:25383081
PM 25383081
DA 2014-11-11
ER

PT J
AU Tas, D
   Uncu, D
   Sendur, MA
   Koca, N
   Zengin, N
AF Tas, Demet
   Uncu, Dogan
   Sendur, Mehmet Ali
   Koca, Nuran
   Zengin, Nurullah
TI Acupuncture as a complementary treatment for cancer patients receiving
SO Asian Pacific journal of cancer prevention : APJCP
LA English
DT Journal Article
AB BACKGROUND: Medical treatment for eliminating the side effects of cancer therapy  may not always be efficacious. Acupuncture is one of the most widely accepted  alternative and complementary therapies in use today. In this study, we  investigated the efficacy of acupuncture in patients experiencing cancer  treatment side effects, including nausea, vomiting, pain, poor sleep quality and  anxiety. MATERIALS AND METHODS: A total of 45 inpatients who underwent  chemotherapy between February and April 2013 in the Oncology Department of Numune  Hospital were included in our study. Acupuncture was administered to the patients  one day prior to chemotherapy, on the day of chemotherapy and one day after  chemotherapy. The patients were evaluated on nausea, vomiting, pain, sleep  quality and anxiety before the chemotherapy and on the 4th day of chemotherapy.  RESULTS: Of the 45 patients included in the study, 18 (40%) were female and 27  (60%) were male. A total of 25 (55.6%) had an elementary school education; 32  patients (71%) had stage 4 cancer and were treated with palliative chemotherapy  (the patient characteristics are shown in Table 1). Statistically significant  decreases (p<0.001) in pain, nausea, vomiting, insomnia and anxiety scores were  observed after the acupuncture treatment compared to baseline. There were no  differences in the age, gender, education level, stage or metastasis levels  between the patient groups whose symptoms improved or were unchanged.  CONCLUSIONS: Our study showed that acupuncture has positive effects in cancer  treatment patients who experience nausea, vomiting, pain, poor sleep quality and  anxiety as side effects of chemotherapy. Chemotherapy-related side effects in  cancer patients could be decreased by the concurrent use of acupuncture.
C1 Traditional, Complementary and Alternative Medicine Department, Ministry of Health, Ankara, Turkey E-mail : demettas19691@hotmail.com.
NR 0
TC 0
SN 2476-762
EI 
J9 Asian Pac J Cancer Prev
PD MAY 13
PY 2014
VL 15
IS 7
BP 3139
EP 44
DI 10.7314/apjcp.2014.15.7.3139
PG -3095
WC Acupuncture Therapy; Adult; Aged; Antineoplastic Agents; adverse effects; Anxiety; therapy; Female; Humans; Male; Middle Aged; Nausea; therapy; Neoplasms; drug therapy; Pain Management; methods; Sleep Initiation and Maintenance Disorders; therapy; Turkey; Vomiting; therapy; Young Adult
UT PubMed:24815460
PM 24815460
DA 2014-05-13
ER

PT J
AU Silva, JG
   Santana, CG
   Inocêncio, KR
   Orsini, M
   Machado, S
   Bergmann, A
AF Silva, Julio Guilherme
   Santana, Camila Gonçalves
   Inocêncio, Kelly Rosane
   Orsini, Marco
   Machado, Sergio
   Bergmann, Anke
TI Electrocortical Analysis of Patients with Intercostobrachial Pain Treated with
SO Journal of physical therapy science
LA English
DT Journal Article
DE Electroencephalography; Mastectomy; Transcutaneous electric nerve stimulation
AB [Purpose] Among the physical therapeutic procedures to decrease pain, there is  transcutaneous electrical neural stimulation (TENS). There is no consensus about  its efficacy for oncological patients, especially for post-mastectomy pain and  eletrocortical changes in somatosensory areas. The aim of this study was to  analyze acute electrocortical changes after TENS treatment of patients with  intercostobrachial post mastectomy pain. [Subjects] Eighteen patients were  divided into acupuncture (A) and burst (B) group. [Methods] In this pre and  post-intervention study each group was measured for EEG analysis in absulte power  in alpha band (8-14 Hz). Outcomes variables were the alpha waveband in the  sensorymotor cortex and pain pre-and-post TENS intervention. Data were analyzed  using ANOVA to compare times (rest, 10 and 15 min), group and electrodes. Pain  was analyzed using percentual pain evaluation (PPE) in both groups. [Results]  Outcomes indicate main effects of time and electrodes because of slow (8-10 Hz)  and fast alpha (10-12 Hz) wavebands decreased. PPE reduced 88.4% in A and 66.3%  in G. [Conclusion] TENS promoted electrical modification in the parietal region  and a decrease in pain. Future studies should investigate other wave must be  proposed for other bands and use different methods of EEG analysis to elucidate  the actual mechanisms behind the efficacy of TENS treatment.
C1 Department of Physical Therapy, Federal University of Rio de Janeiro (UFRJ), Brazil 
   Rehabilitation Science Masters Program, Augusto Motta University Center(UNISUAM), Brazil.
   Rehabilitation Science Masters Program, Augusto Motta University Center (UNISUAM), Brazil.
   Municipal Rehabilitation Center (CMR), Department of Physical Therapy in Oncology, Brazil.
   Department of Physical Therapy, Federal University of Rio de Janeiro (UFRJ), Brazil.
   Panic and Respiration Laboratory, Institute of Psychiatry, Federal University of Rio de Janeiro (UFRJ), Brazil 
   Quiropraxia Program, Central University, Chile.
   Rehabilitation Science Masters Program, Augusto Motta University Center (UNISUAM), Brazil 
   National Cancer Institute (INCA), Brazil.
NR 0
TC 0
SN 2187-562
EI 0915-528
J9 J Phys Ther Sci
PD APR 8
PY 2014
VL 26
IS 3
BP 349
EP 53
DI 10.1589/jpts.26.349
PG -296
UT PubMed:24707082
PM 24707082
DA 2014-04-08
ER

PT J
AU Pachman, DR
   Watson, JC
   Loprinzi, CL
AF Pachman, Deirdre R.
   Watson, James C.
   Loprinzi, Charles L.
TI Therapeutic Strategies for Cancer Treatment Related Peripheral Neuropathies
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Chemotherapy-induced peripheral neuropathy
ID acetyl-l-carnitine; quality-of-life; double-blind; topical amitriptyline; adjuvant breast; pain syndrm; neurosensory toxicity; induced neurotoxicity; scrambler therapy; oxaliplatin
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with multiple chemotherapeutic agents. CIPN may have a detrimental impact on patients' quality of life and functional ability, as well as result in chemotherapy dose reductions. Although symptoms of CIPN can improve with treatment completion, symptoms may persist. Currently, the treatment options for CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, has the most evidence supporting its use in the treatment of CIPN. Other agents with potential benefit for the treatment of established CIPN include gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel consisting of the combination of amitriptyline, ketamine, and baclofen; none of these, however, has been proven to be helpful and ongoing/future studies may well show that they are not beneficial. The use of these agents is often based on their efficacy in the treatment of non-CIPN neuropathic pain, but this does not necessarily mean that they will be helpful for CIPN-related symptoms. Other nonpharmacologic interventions including acupuncture and Scrambler therapy are supported by positive preliminary data; however, further larger, placebo-controlled trial data are needed to confirm or refute their effectiveness.
C1 [Pachman, Deirdre R.; Watson, James C.; Loprinzi, Charles L.] Mayo Clin Rochester, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Pachman, DR (corresponding author), Mayo Clin Rochester, 200 First St SW, Rochester, MN 55905 USA.
EM pachman.deirdre@mayo.edu
CR Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Bianchi G, 2005, EUR J CANCER, V41, P1746, DOI 10.1016/j.ejca.2005.04.028
   Bley KR, 2004, EXPERT OPIN INV DRUG, V13, P1445, DOI 10.1517/13543784.13.11.1445
   Campbell TC, 2013, J CLIN ONCOL, V31, P0
   Colvin LA, 2008, J CLIN ONCOL, V26, P4519, DOI 10.1200/JCO.2008.18.5017
   Coyne Patrick J, 2013, J PAIN PALLIAT CARE PHARMACOTHER, V27, P359, DOI 10.3109/15360288.2013.847519
   Derry Sheena, 2013, COCHRANE DATABASE SYST REV, V0, PPCD007393, DOI 10.1002/14651858.CD007393.pub3
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Durand JP, 2012, ANN ONCOL, V23, P200, DOI 10.1093/annonc/mdr045
   Durand JP, 2003, ANTI-CANCER DRUG, V14, P423, DOI 10.1097/00001813-200307000-00006
   Durand JP, 2005, ANTI-CANCER DRUG, V16, P587, DOI 10.1097/00001813-200506000-00015
   Durand JP, 2002, ANTI-CANCER DRUG, V13, P777, DOI 10.1097/00001813-200208000-00013
   Dworkin RH, 2010, MAYO CLIN PROC, V85, PS3, DOI 10.4065/mcp.2009.0649
   Evans JD, 2008, ANN PHARMACOTHER, V42, P1686, DOI 10.1345/aph.1L201
   Gedlicka C, 2002, J CLIN ONCOL, V20, P3359, DOI 10.1200/JCO.2002.99.502
   Gedlicka C, 2003, ANN ONCOL, V14, P339, DOI 10.1093/annonc/mdg051
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Guo Y, 2011, J CLIN ONCOLOGY S, V29, P9010
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549-010-1278-0
   Jiang Hequn, 2006, J TRADIT CHIN MED, V26, P8
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kidwell KM, 2012, CANCER-AM CANCER SOC, V118, P5614, DOI 10.1002/cncr.27593
   Kluding PM, 2012, J DIABETES COMPLICAT, V26, P424, DOI 10.1016/j.jdiacomp.2012.05.007
   Kohrman M, 2012, J CLIN ONCOL, V30, P0
   Liu YC, 2012, CANCER-AM CANCER SOC, V118, P1718, DOI 10.1002/cncr.26430
   Loprinzi CL, 2011, J CLIN ONCOL, V29, P1472, DOI 10.1200/JCO.2010.33.0308
   Lynch ME, 2005, ANESTHESIOLOGY, V103, P140, DOI 10.1097/00000542-200507000-00021
   Lynch ME, 2005, J PAIN, V6, P644, DOI 10.1016/j.jpain.2005.04.008
   Lynch ME, 2003, CLIN J PAIN, V19, P323, DOI 10.1097/00002508-200309000-00007
   Maestri A, 2005, TUMORI J, V91, P135, DOI 10.1177/030089160509100206
   Mariani G, 2000, P AM SOC CLIN ONCOL, V19, P0
   Marineo G, 2012, J PAIN SYMPTOM MANAG, V43, P87, DOI 10.1016/j.jpainsymman.2011.03.015
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   Moore R Andrew, 2009, COCHRANE DATABASE SYST REV, V0, PPCD007076, DOI 10.1002/14651858.CD007076.pub2
   Ozdoan M, 2004, TURKISH J CANC, V34, P110
   Pachman DR, 2014, J CLIN ONCOL, V32, P5
   Park SB, 2008, CURR MED CHEM, V15, P3081, DOI 10.2174/092986708786848569
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Podratz JL, 2011, NEUROBIOL DIS, V41, P661, DOI 10.1016/j.nbd.2010.11.017
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Reeves BN, 2012, CANCER-AM CANCER SOC, V118, P5171, DOI 10.1002/cncr.27489
   Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420
   Saarto T, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005454.pub2
   Saif MW, 2010, ANTICANCER RES, V30, P2927
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Speck R, 2012, SUPPORT CARE CANCER, V20, P2433, DOI 10.1007/s00520-011-1365-8
   Storey Dawn J, 2010, J PAIN SYMPTOM MANAGE, V39, Pe2, DOI 10.1016/j.jpainsymman.2010.02.004
   Storey DJ, 2010, J CLIN ONCOL S, V28, P0
   Stubblefield MD, 2012, CANCER-AM CANCER SOC, V118, P2250, DOI 10.1002/cncr.27463
   Sucheston LE, 2011, BREAST CANCER RES TR, V130, P993, DOI 10.1007/s10549-011-1671-3
   Ta LE, 2006, NEUROTOXICOLOGY, V27, P992, DOI 10.1016/j.neuro.2006.04.010
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   Tsavaris N, 2008, PAIN MED, V9, P1209, DOI 10.1111/j.1526-4637.2007.00325.x
   Weisbroad BL, 2014, J CLIN ONCOL S, V32, P0
   WHITE CM, 2004, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003904.PUB2
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Won HH, 2012, CANCER-AM CANCER SOC, V118, P2828, DOI 10.1002/cncr.26614
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yang YH, 2012, SUPPORT CARE CANCER, V20, P1491, DOI 10.1007/s00520-011-1237-2
   Ziegler D, 2004, DIABETIC MED, V21, P114, DOI 10.1111/j.1464-5491.2004.01109.x
NR 69
TC 24
Z9 29
U1 0
U2 35
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD DEC 15
PY 2014
VL 15
IS 4
BP 567
EP 580
DI 10.1007/s11864-014-0303-7
PG 14
WC Oncology
SC Oncology
GA AS8ZG
UT WOS:000344532800005
PM 25119581
DA 2026-01-16
ER

PT J
AU Garcia, MK
   Driver, L
   Haddad, R
   Lee, R
   Palmer, JL
   Wei, Q
   Frenkel, M
   Cohen, L
AF Garcia, M. Kay
   Driver, Larry
   Haddad, Robin
   Lee, Richard
   Palmer, J. Lynn
   Wei, Qi
   Frenkel, Moshe
   Cohen, Lorenzo
TI Acupuncture for Treatment of Uncontrolled Pain in Cancer Patients: A Pragmatic Pilot Study
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; pain; cancer; complementary medicine; integrative medicine; symptom management
ID auricular acupuncture
AB Purpose. Pain control is an ongoing challenge in the oncology setting. Prior to implementing a large randomized trial at our institution, we investigated the feasibility, safety, and initial efficacy of acupuncture for uncontrolled pain among cancer patients. Hypotheses. Our hypotheses were that the acupuncture treatments provided would be (a) feasible, (b) safe, and (c) a beneficial adjunct to pain management. Study Design. This was a single arm, nonrandomized pragmatic pilot study. Methods. Participants experiencing pain 4 on a 0 to 10 numeric rating scale received a maximum of 10 treatments on an individualized basis. Recruitment, attrition, compliance, and adverse events (AEs) were assessed. Pain (Brief Pain Inventory-Short Form), quality of life (MD Anderson Symptom Inventory [MDASI]), and patient satisfaction were assessed at baseline and at the end of treatment. Results. Of 115 patients screened, 52 (45%) were eligible and agreed to participate. Eleven (21%) were lost to follow-up, leaving 41 who completed all study procedures. No AEs were reported. Mean pain severity was 6.0 +/- 1.3 at baseline and 3.8 +/- 2.0 at follow-up (P < .0001). Pain interference was 6.2 +/- 2.3 at baseline and 4.3 +/- 2.8 at follow-up (P < .0011). On the MDASI, the mean symptom severity was 4.6 +/- 1.8 at baseline and 3.2 +/- 1.9 at follow-up (P < .0001), and mean symptom interference was 5.8 +/- 2.4 at baseline and 4.1 +/- 2.9 at follow-up (P < .002). Prescribed pain medications decreased across the course of the study. Patient satisfaction was high: 87% reported that their expectations were met very well or extremely well; 90% said they were likely to participate again; 95% said they were likely to recommend acupuncture to others; and 90% reported they found the service to be useful or very useful. Conclusions. Acupuncture was feasible, safe, and a helpful treatment adjunct for cancer patients experiencing uncontrolled pain in this study. Randomized placebo-controlled trials are needed to confirm these results.
C1 [Garcia, M. Kay; Driver, Larry; Haddad, Robin; Lee, Richard; Palmer, J. Lynn; Wei, Qi; Cohen, Lorenzo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Frenkel, Moshe] Meir Med Ctr, Integrat Oncol Serv, Inst Oncol, Kefar Sava, Israel.
C3 University of Texas System; UTMD Anderson Cancer Center; Tel Aviv University; Sackler Faculty of Medicine
RP Garcia, MK (corresponding author), Univ Texas MD Anderson Canc Ctr, Integrat Med Program, 1515 Holcombe Blvd,Unit 0462, Houston, TX 77030 USA.
EM kaygarcia@mdanderson.org
FU United States National Cancer Institute (NCI) [CA121503]; NCI Cancer Center [CA016672]; University of Texas MD Anderson Cancer Center; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER
CR Alimi D, 2000, J PAIN SYMPTOM MANAG, V19, P81, DOI 10.1016/S0885-3924(99)00140-2
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526-4637.2009.00774.x
   Burton Allen W, 2012, J SUPPORT ONCOL, V10, P89, DOI 10.1016/j.suponc.2011.08.004
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
   Dedman P, 1998, MANUAL ACUPUNCTURE, V0, P0
   Deng L, 1997, CHINESE ACUPUNCTURE, V0, P0
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   HAN JS, 1980, AM J CHINESE MED, V8, P331, DOI 10.1142/S0192415X80000311
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Huang LC, 1996, AURICULOTHERAPY, V0, P0
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385
   Lao Lixing, 2006, J SOC INTEGR ONCOL, V4, P13
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   MacPherson Hugh, 2005, ACUPUNCT MED, V23, P112
   Mittleman E, 2000, J AM VET MED ASSOC, V217, P1201, DOI 10.2460/javma.2000.217.1201
   Niemtzow RC, 2006, J ALTERN COMPLEM MED, V12, P597, DOI 10.1089/acm.2006.597
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Sherman Karen J, 2009, J CLIN OUTCOMES MANAG, V16, P224
   Ulett GA, 2003, AM J PUBLIC HEALTH, V93, P1037, DOI 10.2105/AJPH.93.7.1037
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 32
TC 23
Z9 26
U1 0
U2 29
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAR 15
PY 2014
VL 13
IS 2
BP 133
EP 140
DI 10.1177/1534735413510558
PG 8
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA AB1KF
UT WOS:000331549700005
PM 24282103
DA 2026-01-16
ER

PT J
AU Bell, A
   Helm, J
   Reid, J
AF Bell, A.
   Helm, J.
   Reid, J.
TI Veterinarians' attitudes to chronic pain in dogs
SO VETERINARY RECORD
LA English
DT Article
ID quality-of-life; appendicular osteosarcoma; antiinflammatory drugs; neuropathic pain; questionnaire; pharmacokinetics; acupuncture; validation; analgesia; morphine
AB Veterinary surgeons in the UK were invited to complete an internet survey concerning their attitudes to chronic pain in dogs. UK veterinary surgeons numbering 215 completed surveys in full along with 48 worldwide specialists in anaesthesia and 37 worldwide specialists in oncology. Osteoarthritis, dental and aural disease, vertebral and spinal cord conditions, neoplasia and skin conditions were considered important causes of chronic pain in dogs. UK practitioners used significantly fewer classes of analgesic drugs regularly than either category of specialist. The major barriers to adequate treatment of chronic pain were reported as difficulties with pain assessment, expense of drugs, and difficulties with owner compliance. Illustrations of six common neoplastic conditions were used and scored for pain according to prior experience by practitioners. All six conditions were consistently described as involving some degree of pain with primary bone tumour and oral tumour, causing severe pain and moderate to severe pain, respectively. Years since graduation and specialist status affected the pain scores attributed to the conditions. There was a significant correlation between the pain score attributed to the illustrated condition, and the tendency to administer analgesia.
C1 [Bell, A.; Helm, J.; Reid, J.] Univ Glasgow, Sch Vet Med, Glasgow G61 1QH, Lanark, Scotland.
C3 University of Glasgow
RP Bell, A (corresponding author), Univ Glasgow, Sch Vet Med, Glasgow G61 1QH, Lanark, Scotland.
EM Andrew.bell@glasgow.ac.uk
FU Boehringer Ingelheim
CR Adams VJ, 2005, JAVMA-J AM VET MED A, V226, P567, DOI 10.2460/javma.2005.226.567
   Beckman BW, 2006, J VET DENT, V23, P50, DOI 10.1177/089875640602300110
   Bound NJ, 2011, VET REC, V168, P0, DOI 10.1136/vr.d1021
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Brown DC, 2008, JAVMA-J AM VET MED A, V233, P1278, DOI 10.2460/javma.233.8.1278
   Brown DC, 2009, PAIN MED, V10, P133, DOI 10.1111/j.1526-4637.2008.00513.x
   Capner CA, 1999, VET REC, V145, P95
   Chen Lucy, 2011, J OPIOID MANAG, V7, P267
   Chew DJ, 1998, J AM VET MED ASSOC, V213, P1282
   Colvin LA, 2008, BRIT J ANAESTH, V101, P1, DOI 10.1093/bja/aen120
   Dobson JM, 2002, J SMALL ANIM PRACT, V43, P240, DOI 10.1111/j.1748-5827.2002.tb00066.x
   Fan TM, 2007, J VET INTERN MED, V21, P431, DOI 10.1892/0891-6640(2007)21[431:SPFPTO]2.0.CO;2
   Fleming JM, 2011, J VET INTERN MED, V25, P187, DOI 10.1111/j.1939-1676.2011.0695.x
   Flôr PB, 2013, VET ANAESTH ANALG, V40, P316, DOI 10.1111/vaa.12023
   Fox S M, 2010, CHRONIC PAIN IN SMALL ANIMAL MEDICINE, V0, P74
   Fox SM, 2012, VET CLIN N AM-SMALL, V42, P727, DOI 10.1016/j.cvsm.2012.04.010
   Giorgi M, 2009, VET RES COMMUN, V33, P875, DOI 10.1007/s11259-009-9236-1
   Habacher G, 2006, J VET INTERN MED, V20, P480, DOI 10.1892/0891-6640(2006)20[480:EOAIVM]2.0.CO;2
   Hielm-Björkman AK, 2009, AM J VET RES, V70, P727, DOI 10.2460/ajvr.70.6.727
   Hunter JEB, 2010, VET REC, V167, P947, DOI 10.1136/vr.c7045
   Innes JF, 2010, VET REC, V166, P226, DOI 10.1136/vr.c97
   Johnston SA, 1997, VET CLIN N AM-SMALL, V27, P699, DOI 10.1016/S0195-5616(97)50076-3
   Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316
   KuKanich B, 2005, J VET PHARMACOL THER, V28, P461, DOI 10.1111/j.1365-2885.2005.00681.x
   Kukanich B, 2005, J VET PHARMACOL THER, V28, P371, DOI 10.1111/j.1365-2885.2005.00661.x
   KuKanich B, 2004, J VET PHARMACOL THER, V27, P239, DOI 10.1111/j.1365-2885.2004.00578.x
   KuKanich B, 2010, J VET PHARMACOL THER, V33, P15, DOI 10.1111/j.1365-2885.2009.01098.x
   KuKanich B, 2012, VET ANAESTH ANALG, V39, P69, DOI 10.1111/j.1467-2995.2011.00675.x
   Lascelles BDX, 2008, J VET INTERN MED, V22, P53, DOI 10.1111/j.1939-1676.2007.0014.x
   LASCELLES BDX, 2012, WITHROW MACEWENS SMA, V0, P245
   Lascelles BDX, 1999, VET REC, V145, P601, DOI 10.1136/vr.145.21.601
   Lindley S, 2006, IN PRACTICE, V28, P544, DOI 10.1136/inpract.28.9.544
   Looney A, 2010, TOP COMPANION ANIM M, V25, P32, DOI 10.1053/j.tcam.2009.10.008
   Lund EM, 1999, J AM VET MED ASSOC, V214, P1336
   Malek S, 2012, BMC VET RES, V8, P0, DOI 10.1186/1746-6148-8-185
   Mathews KA, 2008, VET CLIN N AM-SMALL, V38, P1365, DOI 10.1016/j.cvsm.2008.09.001
   [Merskey HIASPIASP], 1994, IASP TASK FORCE ON TAXONOMY, VSecond, P0
   Mölsä SH, 2013, JAVMA-J AM VET MED A, V243, P689, DOI 10.2460/javma.243.5.689
   Platt S, 2013, BSAVA MANUAL OF CANINE AND FELINE NEUROLOGY, V4a, P252
   Raekallio M, 2003, VET J, V165, P131, DOI 10.1016/S1090-0233(02)00186-7
   Ramirez O III, 1999, VET RADIOL ULTRASOUN, V40, P517, DOI 10.1111/j.1740-8261.1999.tb00385.x
   Reid J, 2013, J SMALL ANIM PRACT, V54, P227, DOI 10.1111/jsap.12059
   Reid J, 2013, IN PRACTICE, V35, P51, DOI 10.1136/inp.f631
   Rusbridge C, 2008, VET J, V175, P164, DOI 10.1016/j.tvjl.2006.12.007
   Sasamura T, 2002, EUR J PHARMACOL, V441, P185, DOI 10.1016/S0014-2999(02)01450-4
   Sessler DI, 2008, CONTEMP CLIN TRIALS, V29, P517, DOI 10.1016/j.cct.2008.01.002
   Wiseman-Orr ML, 2006, AM J VET RES, V67, P1826, DOI 10.2460/ajvr.67.11.1826
   Wiseman-Orr ML, 2004, AM J VET RES, V65, P1077, DOI 10.2460/ajvr.2004.65.1077
   Xellyerw P, 2007, J AM ANIM HOSP ASSOC, V43, P235, DOI 10.5326/0430235
   Yazbek KVB, 2005, JAVMA-J AM VET MED A, V226, P1354, DOI 10.2460/javma.2005.226.1354
NR 50
TC 32
Z9 35
U1 1
U2 60
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0042-4900
EI 2042-7670
J9 VET REC
JI Vet. Rec.
PD NOV 1
PY 2014
VL 175
IS 17
BP 
EP 
DI 10.1136/vr.102352
PG 7
WC Veterinary Sciences
SC Veterinary Sciences
GA AS2DH
UT WOS:000344089100015
PM 25028465
DA 2026-01-16
ER

PT J
AU Bao, T
   Goloubeva, O
   Pelser, C
   Porter, N
   Primrose, J
   Hester, L
   Sadowska, M
   Lapidus, R
   Medeiros, M
   Lao, L
   Dorsey, SG
   Badros, AZ
AF Bao, Ting
   Goloubeva, Olga
   Pelser, Colleen
   Porter, Neil
   Primrose, James
   Hester, Lisa
   Sadowska, Mariola
   Lapidus, Rena
   Medeiros, Michelle
   Lao, Lixing
   Dorsey, Susan G
   Badros, Ashraf Z
TI A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; bortezomib; multiple myeloma; peripheral neuropathy
AB BACKGROUND: Peripheral neuropathy is the dose limiting toxicity of bortezomib in  patients with multiple myeloma (MM). OBJECTIVES: To examine the safety,  feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral  neuropathy (BIPN) symptoms. METHODS: Patients with MM experiencing persistent  BIPN ≥grade 2 despite adequate medical intervention and discontinuation of  bortezomib received 10 acupuncture treatments for 10 weeks (2×/week for 2 weeks,  1×/week for 4 weeks, and then biweekly for 4 weeks). Responses were assessed by  the Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer  Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire,  and the Neuropathy Pain Scale (NPS). Repeated-measures analysis of variance was  used to test for monotonic decline in scores on each of the measures. Serial  serum levels of proinflammatory and neurotrophic cytokines were obtained at  baseline and weeks 1, 2, 4, 8, and 14. RESULTS: Twenty-seven patients with MM  were enrolled in the trial. There were no adverse events associated with the  acupuncture treatments. TNSc data were deemed invalid and therefore were not  reported. At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction  suggesting decreased pain, and improved function (P values were <.0001 for both  FACT/GOG-Ntx and NPS at weeks 10 and 14). However, nerve conduction studies did  not significantly change between baseline assessment and end of study. There was  no correlation in serum cytokines for responders versus none responders.  CONCLUSIONS: Acupuncture is safe, feasible and produces subjective improvements  in patients' symptoms. A follow-up randomized controlled trial is warranted.
C1 The University of Maryland School of Medicine, Baltimore, MD, USA baot@mskcc.org.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
   The University of Maryland School of Medicine, Baltimore, MD, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAY 29
PY 2014
VL 13
IS 5
BP 396
EP 404
DI 10.1177/1534735414534729
PG 8
WC Acupuncture Therapy; adverse effects; Aged; Antineoplastic Agents; therapeutic use; Boronic Acids; adverse effects; Bortezomib; Cytokines; metabolism; Feasibility Studies; Humans; Middle Aged; Multiple Myeloma; drug therapy; Pain Measurement; Peripheral Nervous System Diseases; chemically induced; Pilot Projects; Pyrazines; adverse effects; Time Factors; Treatment Outcome
UT PubMed:24867959
PM 24867959
DA 2014-05-29
ER

PT J
AU Mao, JJ
   Farrar, JT
   Bruner, D
   Zee, J
   Bowman, M
   Seluzicki, C
   DeMichele, A
   Xie, SX
AF Mao, Jun J.
   Farrar, John T.
   Bruner, Deborah
   Zee, Jarcy
   Bowman, Marjorie
   Seluzicki, Christina
   DeMichele, Angela
   Xie, Sharon X.
TI Electroacupuncture for Fatigue, Sleep, and Psychological Distress in Breast Cancer Patients With Aromatase Inhibitor-Related Arthralgia: A Randomized Trial
SO CANCER
LA English
DT Article
DE acupuncture; breast neoplasm; aromatase inhibitors; fatigue; sleep; psychological distress
ID symptom cluster; hospital anxiety; acupuncture; depression; pain; discontinuation; management; severity; patterns; system
AB BACKGROUNDAlthough fatigue, sleep disturbance, depression, and anxiety are associated with pain in breast cancer patients, it is unknown whether acupuncture can decrease these comorbid symptoms in cancer patients with pain. The objective of this study was to evaluate the effect of electroacupuncture (EA) on fatigue, sleep, and psychological distress in breast cancer survivors who experience joint pain related to aromatase inhibitors (AIs). METHODSThe authors performed a randomized controlled trial of an 8-week course of EA compared with a waitlist control (WLC) group and a sham acupuncture (SA) group in postmenopausal women with breast cancer who self-reported joint pain attributable to AIs. Fatigue, sleep disturbance, anxiety, and depression were measured using the Brief Fatigue Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), and the Hospital Anxiety and Depression Scale (HADS). The effects of EA and SA versus WLC on these outcomes were evaluated using mixed-effects models. RESULTSOf the 67 randomly assigned patients, baseline pain interference was associated with fatigue (Pearson correlation coefficient [r]=0.75; P < .001), sleep disturbance (r=0.38; P=.0026), and depression (r=0.58; P < .001). Compared with the WLC condition, EA produced significant improvements in fatigue (P=.0095), anxiety (P=.044), and depression (P=.015) and a nonsignificant improvement in sleep disturbance (P=.058) during the 12-week intervention and follow-up period. In contrast, SA did not produce significant reductions in fatigue or anxiety symptoms but did produce a significant improvement in depression compared with the WLC condition (P=.0088). CONCLUSIONSCompared with usual care, EA produced significant improvements in fatigue, anxiety, and depression; whereas SA improved only depression in women experiencing AI-related arthralgia. Cancer 2014;120:3744-3751. (c) 2014 American Cancer Society. In this randomized controlled trial among breast cancer patients who experience arthralgia related to aromatase, electroacupuncture produces significant improvements in fatigue, anxiety, and depression, whereas sham acupuncture improves only depression compared with usual care.
C1 [Mao, Jun J.; Farrar, John T.; DeMichele, Angela] Hosp Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Farrar, John T.; Zee, Jarcy; Seluzicki, Christina; DeMichele, Angela; Xie, Sharon X.] Univ Penn, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Seluzicki, Christina] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Bruner, Deborah] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA.
   [Bowman, Marjorie] Wright State Univ, Sch Med, Dayton, OH USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Emory University; University System of Ohio; Wright State University Dayton
RP Mao, JJ (corresponding author), Univ Penn, Dept Family Med & Community Hlth, 227 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM jun.mao@uphs.upenn.edu
FU National Institutes of Health (National Center for Complementary and Alternative Medicine [NCCAM]) [R21 AT004695]; NCCAM [K23 AT004112]
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bower JE, 2013, J CLIN ONCOL, V31, P1656, DOI 10.1200/JCO.2012.46.2143
   Burstein HJ, 2007, J CLIN ONCOL, V25, P0, DOI 10.1200/JCO.2007.11.9529
   Buysse D J, 1989, PSYCHIATRY RES, V28, P193
   CAO XD, 1983, ACUPUNCTURE ELECTRO, V8, P25, DOI 10.3727/036012983816715028
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cohen J, 1988, STAT POWER ANAL BEHA, V0, P0, DOI DOI 10.4324/9780203771587
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Kim HJ, 2014, CANCER NURS, V37, P88, DOI 10.1097/NCC.0b013e31828293e0
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2013, PHARMACOEPIDEM DR S, V22, P256, DOI 10.1002/pds.3365
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Miller AH, 2008, J CLIN ONCOL, V26, P971, DOI 10.1200/JCO.2007.10.7805
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Park HJ, 2011, CELL MOL NEUROBIOL, V31, P1123, DOI 10.1007/s10571-011-9718-x
   Smith AB, 2002, PSYCHOL PSYCHOTHER-T, V75, P165, DOI 10.1348/147608302169625
   So WKW, 2009, ONCOL NURS FORUM, V36, P405, DOI 10.1188/09.ONF.E205-E214
   Thornton LM, 2010, HEALTH PSYCHOL, V29, P333, DOI 10.1037/a0018836
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 28
TC 124
Z9 142
U1 2
U2 67
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 1
PY 2014
VL 120
IS 23
BP 3744
EP 3751
DI 10.1002/cncr.28917
PG 8
WC Oncology
SC Oncology
GA AU0QU
UT WOS:000345329600024
PM 25077452
DA 2026-01-16
ER

PT J
AU Jacoby, VL
   Jacoby, A
   Learman, LA
   Schembri, M
   Gregorich, SE
   Jackson, R
   Kuppermann, M
AF Jacoby, Vanessa L
   Jacoby, Alison
   Learman, Lee A
   Schembri, Michael
   Gregorich, Steven E
   Jackson, Rebecca
   Kuppermann, Miriam
TI Use of medical, surgical and complementary treatments among women with fibroids.
SO European journal of obstetrics, gynecology, and reproductive biology
LA English
DT Journal Article
DE Complementary treatments; Myomectomy; Uterine artery embolization; Uterine fibroids
AB OBJECTIVE: To examine the use of medical management, uterus-preserving surgery  (UPS), and complementary treatments among women with uterine fibroids. STUDY  DESIGN: Prospective cohort study of 933 premenopausal women ages 31-54 years with  symptomatic fibroids who participated in the Study of Pelvic Problems,  Hysterectomy, and Intervention Alternatives (SOPHIA) for an average of 4.3 years  (SD 2.5 years). Incident use of fibroid treatments was determined through annual  interviews. Linear regression models were used to compare changes in  fibroid-related symptoms among women who underwent UPS versus those who did not  undergo surgery. RESULTS: Participants were racially and ethnically diverse, with  a mean age of 43 years. During study follow-up, 531 participants (57%) did not  undergo UPS or hysterectomy, 250 (27%) had at least one UPS, and 152 (16%)  underwent hysterectomy. Complementary and alternative treatments were commonly  used, including exercise (45%), diet (34%), herbs (37%), and acupuncture (16%):  participants reported significant symptom improvement and few side effects with  these interventions. In multivariable linear regression models, women who did not  undergo surgery during the study reported improvement in dyspareunia (p<.001),  pelvic pain (p<.001), and menstrual cramps (p<.001). However, women who underwent  UPS reported greater overall resolution of "pelvic problems" compared with women  who did not have surgical treatment (difference in change score 1.18 on a  four-point Likert scale, p<.001). CONCLUSION: UPS are effective treatments for  women with fibroids, but many women use hormonal or complementary treatments and  report significant symptom improvement without surgical intervention.
C1 Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 1635 Divisadero St, Suite 600, San Francisco, CA, USA. Electronicaddress: jacobyv@obgyn.ucsf.edu.
   Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 1635 Divisadero St, Suite 600, San Francisco, CA, USA.
   Department of Obstetrics and Gynecology, Indiana University School of Medicine, USA.
   Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 1635 Divisadero St, Suite 600, San Francisco, CA, USA.
   Medicine, University of California, San Francisco, CA, USA
   Medical Effectiveness Research Center for Diverse Populations, University of California, San Francisco,CA, USA.
   Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 1635 Divisadero St, Suite 600, San Francisco, CA, USA
   Epidemiology &Biostatistics, University of California, San Francisco, CA, USA.
   Department of Obstetrics, Gynecology & Reproductive Sciences, University of California, 1635 Divisadero St, Suite 600, San Francisco, CA, USA
   Epidemiology &Biostatistics, University of California, San Francisco, CA, USA
   MedicalEffectiveness Research Center for Diverse Populations, University of California,San Francisco, CA, USA.
NR 0
TC 0
SN 1872-765
EI 0301-211
J9 Eur J Obstet Gynecol Reprod Biol
PD DEC 3
PY 2014
VL 182
IS 
BP 220
EP 5
DI 10.1016/j.ejogrb.2014.09.004
PG -215
WC Acupuncture Therapy; Adult; Analgesics, Opioid; therapeutic use; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Contraceptives, Oral, Hormonal; therapeutic use; Diet; Dyspareunia; etiology; Endometrial Ablation Techniques; Exercise; Female; Follow-Up Studies; Humans; Hysterectomy; Leiomyoma; complications; Low Back Pain; etiology; Middle Aged; Organ Sparing Treatments; Pelvic Pain; etiology; Plant Preparations; therapeutic use; Prospective Studies; Treatment Outcome; Uterine Artery Embolization; Uterine Hemorrhage; etiology; Uterine Myomectomy; Uterine Neoplasms; complications
UT PubMed:25445104
PM 25445104
DA 2014-12-03
ER

PT J
AU Gatti, A
   Gentili, M
   Baciarello, M
   Lazzari, M
   Marzi, R
   Palombo, E
   Sabato, AF
   Fanelli, G
AF Gatti, Antonio
   Gentili, Marta
   Baciarello, Marco
   Lazzari, Marzia
   Marzi, Rossella
   Palombo, Elisa
   Sabato, Alessandro F.
   Fanelli, Guido
TI Breakthrough pain in patients with controlled or uncontrolled pain: An observational study
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Article
DE BTP; Oncological pain; Pain treatment
ID cancer-pain; prevalence; recommendations; association; definition; opioids; care
AB Background: Breakthrough pain (BTP) is traditionally defined as a pain exacerbation in patients with chronic controlled pain. However, this definition has recently been challenged. Objectives: To evaluate the prevalence of unsatisfactory control in patients with chronic cancer pain, and investigate the frequency and intensity of BTP episodes. Methods: A total of 665 patients with chronic cancer pain attending 21 pain therapy units in Italy were evaluated for baseline pain intensity and number of BTP episodes over a 30-day period. All patients started, continued or modified treatment for BTP at enrollment, according to medical judgment. Results: The number of BTP events was higher in patients with uncontrolled baseline pain, although the intensity and duration of episodes were similar. In patients with uncontrolled baseline pain, the number of events decreased with time and reached values comparable with those reported in patients with controlled pain. Both the intensity of the pain and the duration of the BTP events exhibited similar values in the two groups at all time points, following increased monitoring and the prescription of analgesic medication. Conclusion: Patients with uncontrolled baseline pain experienced BTP flares with higher frequency, but similar intensity and duration with respect to patients with controlled pain at baseline. Notably, a close follow-up and adequate management of the BTP episodes led to an improvement of BTP in the observed patients.
C1 [Gatti, Antonio; Lazzari, Marzia; Palombo, Elisa; Sabato, Alessandro F.] Univ Roma Tor Vergata, Tor Vergata Polyclin, Pain Med & Anesthesiol Dept, Rome, Italy.
   [Gentili, Marta] Patient Assoc Vivere Senza Dolore, I-20154 Milan, Italy.
   [Baciarello, Marco; Fanelli, Guido] Univ Parma, Dept Surg Sci, Crit Care & Pain Med Unit, I-43100 Parma, Italy.
   [Marzi, Rossella] Maggiore della Carita Hosp, Pain Therapy Dept, Novara, Italy.
C3 University of Rome Tor Vergata; University of Parma
RP Gentili, M (corresponding author), Patient Assoc Vivere Senza Dolore, Piazza EL Morselli 1, I-20154 Milan, Italy.
EM presidenza@viveresenzadolore.it
CR Abernethy Amy P, 2008, AM J MANAG CARE, V14, P0
   Burton B, 2011, BR J NURS, V20, P0
   Burton Beth, 2011, BR J NURS, V20, P0
   Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018
   Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009
   Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014
   Dickman Andrew, 2011, CURR OPIN SUPPORT PALLIAT CARE, V5, P8, DOI 10.1097/SPC.0b013e3283434515
   Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136
   Gatti A, 2013, ADV THER, V30, P298, DOI 10.1007/s12325-013-0013-8
   Gatti A, 2012, ADV THER, V29, P464, DOI 10.1007/s12325-012-0022-z
   Gómez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9
   Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250
   Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680
   Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035
   Margarit Cesar, 2012, J PAIN RES, V5, P559, DOI 10.2147/JPR.S36428
   McMillan C, 2001, BR J NURS, V10, P860
   Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249
   Mercadante S, 2013, CURR MED RES OPIN, V29, P667, DOI 10.1185/03007995.2013.792247
   Portenoy R K, 1989, ONCOLOGY (WILLISTON PARK), V3, P25
   PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W
   Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003
   Portenoy Russell K, 2010, J OPIOID MANAG, V6, P97
   Portenoy Russell K, 2010, J OPIOID MANAG, V6, P109
   Schug S A, 1990, J PAIN SYMPTOM MANAGE, V5, P27, DOI 10.1016/S0885-3924(05)80006-5
   Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000
   Smith HS, 2013, J PAIN RES, V6, P189, DOI 10.2147/JPR.S40745
   Webster Lynn R, 2008, AM J MANAG CARE, V14, P0
   Zeppetella Giovambattista, 2009, CURR OPIN SUPPORT PALLIAT CARE, V3, P1, DOI 10.1097/SPC.0b013e3283260658
NR 28
TC 7
Z9 9
U1 0
U2 5
PU PULSUS GROUP INC
PI OAKVILLE
PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD NOV-DEC 15
PY 2014
VL 19
IS 6
BP E168
EP E171
DI 10.1155/2014/646312
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA AW0TR
UT WOS:000346007000004
PM 24945289
DA 2026-01-16
ER

PT J
AU Rossi, E
   Vita, A
   Baccetti, S
   Di, Stefano M
   Voller, F
   Zanobini, A
AF Rossi, Elio
   Vita, Alessandra
   Baccetti, Sonia
   Di Stefano, Mariella
   Voller, Fabio
   Zanobini, Alberto
TI Complementary and alternative medicine for cancer patients: results of the EPAAC
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
AB BACKGROUND: The Region of Tuscany Health Department was included as an associated  member in WP7 "Healthcare" of the European Partnership for Action Against Cancer  (EPAAC), initiated by the EU Commission in 2009. AIMS: The principal aim was to  map centres across Europe prioritizing those that provide public health services  and operating within the national health system in integrative oncology (IO).  METHODS: A cross-sectional descriptive survey design was used to collect data. A  questionnaire was elaborated concerning integrative oncology therapies to be  administered to all the national health system oncology centres or hospitals in  each European country. These institutes were identified by convenience sampling,  searching on oncology websites and forums. The official websites of these  structures were analysed to obtain more information about their activities and  contacts. RESULTS: Information was received from 123 (52.1 %) out of the 236  centres contacted until 31 December 2013. Forty-seven out of 99 responding  centres meeting inclusion criteria (47.5 %) provided integrative oncology  treatments, 24 from Italy and 23 from other European countries. The number of  patients seen per year was on average 301.2 ± 337. Among the centres providing  these kinds of therapies, 33 (70.2 %) use fixed protocols and 35 (74.5 %) use  systems for the evaluation of results. Thirty-two centres (68.1 %) had research  in progress or carried out until the deadline of the survey. The complementary  and alternative medicines (CAMs) more frequently provided to cancer patients were  acupuncture 26 (55.3 %), homeopathy 19 (40.4 %), herbal medicine 18 (38.3 %) and  traditional Chinese medicine 17 (36.2 %); anthroposophic medicine 10 (21.3 %);  homotoxicology 6 (12.8 %); and other therapies 30 (63.8 %). Treatments are mainly  directed to reduce adverse reactions to chemo-radiotherapy (23.9 %), in  particular nausea and vomiting (13.4 %) and leucopenia (5 %). The CAMs were also  used to reduce pain and fatigue (10.9 %), to reduce side effects of iatrogenic  menopause (8.8 %) and to improve anxiety and depression (5.9 %), gastrointestinal  disorders (5 %), sleep disturbances and neuropathy (3.8 %). CONCLUSIONS: Mapping  of the centres across Europe is an essential step in the process of creating a  European network of centres, experts and professionals constantly engaged in the  field of integrative oncology, in order to increase, share and disseminate the  knowledge in this field and provide evidence-based practice.
C1 Department of Research, Innovation and Human Resources, Regional Health Ministry of Region of Tuscany (Italy), Tuscan Network for Integrative Medicine, via T.Alderotti 26 N - 50100, Florence, Italy,retemedicinaintegrata@regione.toscana.it.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD DEC 5
PY 2014
VL 23
IS 6
BP 1795
EP 806
DI 10.1007/s00520-014-2517-4
PG -989
WC Acupuncture Therapy; statistics & numerical data; Anxiety; therapy; Complementary Therapies; statistics & numerical data; Cross-Sectional Studies; Delivery of Health Care; methods; Ethnicity; Europe; Female; Humans; Male; Medicine, Chinese Traditional; Neoplasms; therapy; Pain; Pain Management; Phytotherapy; statistics & numerical data; Surveys and Questionnaires; United States
UT PubMed:25471177
PM 25471177
DA 2014-12-05
ER

PT J
AU Zeng, YC
   Luo, TZ
   Finnegan-John, J
   Cheng, ASK
AF Zeng, Yingchun
   Luo, Taizhen
   Finnegan-John, Jennifer
   Cheng, Andy S. K.
TI Meta-Analysis of Randomized Controlled Trials of Acupuncture for Cancer-Related Fatigue
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; cancer-related fatigue; quality of life; randomized controlled trials (RCTs); meta-analysis
ID low-back-pain; breast-cancer; management; complementary; prevalence
AB Background. Fatigue is a distressing and pervasive problem for people with cancer. In recent years, acupuncture has gained increasing attention among researchers as an alternative management strategy for cancer-related fatigue (CRF). This review aimed to evaluate the effectiveness of acupuncture for CRF. Methods. Five databases (Medline, CINAHL, Scopus, the Cochrane Library, and CAJ Full-text Database) were searched up to May 2013. Randomized controlled trials (RCTs) of acupuncture for the treatment of CRF were considered for inclusion. Results. Seven RCTs were included for meta-analysis, involving a total of 689 subjects. Three studies compared acupuncture with sham acupuncture for CRF with follow-up at 10 weeks; the standardized mean difference (SMD) for general CRF change values was -0.82 (95% confidence interval [CI] = -1.90 to 0.26). When acupuncture plus education intervention was compared with usual care, there was a statistically significant difference for the change score of general CRF (SMD = -2.12; 95% CI = -3.21 to -1.03). The SMD for general CRF change scores between acupuncture with no treatment or wait-list control was -1.46 (95% CI = -3.56 to 0.63). Finally, the SMD for general CRF change scores between acupuncture with acupressure or self-acupuncture was -1.12 (95% CI = -3.03 to 0.78). Three trials reported data for general quality of life and functioning status, reporting enough data for statistical pooling but showing no statistically significant difference (Z score = 1.15, P = .25, SMD = 0.99, 95% CI = -0.70 to 2.68 and Z score = 1.13, P = .26, SMD = 1.38, 95% CI = -1.02 to 3.79, respectively). The I-2 statistics of all statistically pooled data were higher than 50%, indicating heterogeneity between the trials. Conclusions. There were 4 sets of comparison for the effectiveness of acupuncture for CRF; statistical pooling of the reduction in CRF from baseline to follow-up showed in favor of acupuncture. However, 3 sets of comparison for the pooled estimates of effect sizes had no statistical significance. Although one set of comparison (acupuncture plus education interventions vs usual care) had statistically significant differences, it is unclear whether this pooled positive outcome is attributable to the effects of acupuncture or to the education intervention. In addition, the duration of follow-up in these included trials was up to 10 weeks, and some RCTs had methodological flaws. Further rigorously designed RCTs adhering to acceptable standards of trial methodology are required to determine the effectiveness of acupuncture and its long-term effects on CRF.
C1 [Zeng, Yingchun; Luo, Taizhen] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou 510150, Guangdong, Peoples R China.
   [Finnegan-John, Jennifer] Kings Coll London, London WC2R 2LS, England.
   [Cheng, Andy S. K.] Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China.
C3 Guangzhou Medical University; University of London; King's College London; Hong Kong Polytechnic University
RP Zeng, YC (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Obstet, 63 DouBao Rd, Guangzhou 510150, Guangdong, Peoples R China.
EM chloezengyc@hotmail.co.uk
CR Azad A, 2013, J CLIN ONCOL, V31, P2057, DOI 10.1200/JCO.2012.47.8750
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Berger AM, 2009, ONCOL NURS FORUM, V36, P401, DOI 10.1188/09.ONF.E165-E177
   Bishop FL, 2008, J ACUPUNCT MERIDIAN, V1, P1, DOI 10.1016/S2005-2901(09)60001-7
   Borneman T, 2013, J HOSP PALLIAT NURS, V15, P77, DOI 10.1097/NJH.0b013e318286dc19
   Cherkin DC, 2009, TRIALS, V10, P0, DOI 10.1186/1745-6215-10-96
   Cheville AL, 2013, SUPPORT CARE CANCER, V21, P229, DOI 10.1007/s00520-012-1515-7
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Escalante CP, 2009, J GEN INTERN MED, V24, P412, DOI 10.1007/s11606-009-1056-z
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kirshbaum Marilyn, 2010, BR J COMMUNITY NURS, V15, P214
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Rosman S, 2009, EUR J CANCER CARE, V18, P28, DOI 10.1111/j.1365-2354.2007.00863.x
   Scott JA, 2011, ONCOL NURS FORUM, V38, P368, DOI 10.1188/11.ONF.E191-E203
   Servaes P, 2002, EUR J CANCER, V38, P27, DOI 10.1016/S0959-8049(01)00332-X
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Sood A, 2007, INTEGR CANCER THER, V6, P8, DOI 10.1177/1534735406298143
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Xu M, 2013, AM J CHINESE MED, V41, P1, DOI 10.1142/S0192415X13500018
   Zhang JH, 2010, B WORLD HEALTH ORGAN, V88, P915, DOI 10.2471/BLT.10.076737
NR 29
TC 47
Z9 59
U1 1
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAY 15
PY 2014
VL 13
IS 3
BP 193
EP 200
DI 10.1177/1534735413510024
PG 8
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA AH6UE
UT WOS:000336265900006
PM 24282102
DA 2026-01-16
ER

PT J
AU Weilert, F
AF Weilert, Frank
TI Prospective evaluation of simplified algorithm for EUS-guided intra-hepatic biliary access and anterograde interventions for failed ERCP
SO SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
LA English
DT Article
DE Pancreato Bilio; Cancer; Therapeutic; Palliation; Endoscopy; Endoscopic retrograde cholangiopancreatography (ERCP); Endoscopic ultrasound (EUS)
ID pancreatic-duct drainage; obstruction; cholangiopancreatography; experience; videos
AB EUS-guided biliary drainage (EUS-BD) is technically challenging but alternative method of therapeutic intervention when ERCP fails. Assess the feasibility, safety and risks of EUS-BD with intra-hepatic biliary access and anterograde interventions using an algorithm to increase flexibility of interventions, limit adverse events and improve procedural time. Prospective observational cohort study. 21 consecutive patients underwent EUS-BD drainage for failed ERCP. Technical and clinical success rates with adverse event rate using simplified algorithm. Patient recruitment from June 2011-October 2013; mean age of 67.4 years, predominantly male (70.5 %) with pancreatic cancer (52.4 %), cholangiocarcinoma (14.3 %), other malignant biliary obstruction (9.5 %) and benign biliary obstruction (23.8 %). Prior interventions included failed ERCP in 18/21 (85.7 %) while 3/21 (14.3 %) had primary EUS-BD. Anterograde cholangiogram was achieved in all patients. Technical success was achieved in 20/21 (95.2 %) with clinical success was achieved in 19/21 (90.4 %). Placement of access wire was across the ampulla in 10/20 (50 %) and into CBD or contra-lateral IHD in 10/20 (50 %). Tract dilatation was accomplished in 17/20 (85 %) but required completion using intra-hepatic needle knife in 3/20 (15 %). Anterograde interventions were performed in 16/20 (80 %) but crossover to rendezvous in 3/20 (15 %) or choledochoduodenostomy 1/20 (5 %). Three patients 3/21 (14.3 %) also had endoscopic duodenal SEMS placement to relieve duodenal obstruction. Two patients (9.5 %) had post-procedural bile leak and pain. EUS-guided anterograde biliary drainage using the intra-hepatic access route has high technical and clinical success with low adverse rate. We would promote a simplified standardized algorithm, which gives flexibility of direct anterograde interventions.
C1 Waikato Hosp, Dept Gastroenterol, Hamilton 3200, New Zealand.
C3 Waikato Hospital
RP Weilert, F (corresponding author), Waikato Hosp, Dept Gastroenterol, Pembroke St, Hamilton 3200, New Zealand.
EM frank.weilert@waikatodhb.health.nz
CR Burmester E, 2003, GASTROINTEST ENDOSC, V57, P246, DOI 10.1067/mge.2003.85
   Dhir V, 2012, GASTROINTEST ENDOSC, V75, P354, DOI 10.1016/j.gie.2011.07.075
   Giovannini M, 2003, ENDOSCOPY, V35, P1076, DOI 10.1055/s-2003-44596
   Khashab MA, 2013, GASTROINTEST ENDOSC, V78, P734, DOI 10.1016/j.gie.2013.05.013
   Maranki J, 2009, ENDOSCOPY, V41, P532, DOI 10.1055/s-0029-1214712
   Nguyen-Tang T, 2010, ENDOSCOPY, V42, P232, DOI 10.1055/s-0029-1243858
   Park DH, 2013, GASTROINTEST ENDOSC, V78, P91, DOI 10.1016/j.gie.2013.01.042
   Park DH, 2012, GASTROINTEST ENDOSC, V75, P692, DOI 10.1016/j.gie.2011.04.013
   Park DH, 2011, GASTROINTEST ENDOSC, V74, P1276, DOI 10.1016/j.gie.2011.07.054
   Püspök A, 2005, AM J GASTROENTEROL, V100, P1743, DOI 10.1111/j.1572-0241.2005.41806.x
   Shah Janak N, 2005, GASTROINTEST ENDOSC CLIN N AM, V15, P513, DOI 10.1016/j.giec.2005.03.003
   Shah JN, 2012, GASTROINTEST ENDOSC, V75, P56, DOI 10.1016/j.gie.2011.08.032
   SMITH AC, 1994, LANCET, V344, P1655, DOI 10.1016/S0140-6736(94)90455-3
   Stoker J, 1993, J VASC INTERV RADIOL, V4, P767, DOI 10.1016/S1051-0443(93)71970-3
   Tapping CR, 2011, EUR RADIOL, V21, P1948, DOI 10.1007/s00330-011-2121-7
   Vila JJ, 2012, GASTROINTEST ENDOSC, V76, P1133, DOI 10.1016/j.gie.2012.08.001
   Wiersema MJ, 1996, GASTROINTEST ENDOSC, V43, P102, DOI 10.1016/S0016-5107(06)80108-2
   Will U, 2005, ENDOSCOPY, V37, P171, DOI 10.1055/s-2004-826151
   Winick A B, 2001, TECH VASC INTERV RADIOL, V4, P200, DOI 10.1016/S1089-2516(01)90026-5
NR 19
TC 19
Z9 22
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-2794
EI 1432-2218
J9 SURG ENDOSC
JI Surg. Endosc.
PD NOV 15
PY 2014
VL 28
IS 11
BP 3193
EP 3199
DI 10.1007/s00464-014-3588-5
PG 7
WC Surgery
SC Surgery
GA AS3HL
UT WOS:000344168200022
PM 24879144
DA 2026-01-16
ER

PT J
AU Zeng, K
   Dong, HJ
   Chen, HY
   Chen, Z
   Li, B
   Zhou, QH
AF Zeng, Ke
   Dong, Hui-Juan
   Chen, Hong-Yun
   Chen, Zhe
   Li, Bai
   Zhou, Qing-Hui
TI Wrist-Ankle Acupuncture for Pain After Transcatheter Arterial Chemoembolization in Patients with Liver Cancer: A Randomized Controlled Trial
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Liver Cancer; Transcatheter Arterial Chemoembolization; Pain; Acupuncture; Wrist-Ankle Acupuncture; Randomized Controlled Trial
ID hepatocellular-carcinoma; back-pain
AB This study was designed to evaluate the analgesic effect of wrist-ankle acupuncture (WAA) for patients with primary liver cancer (PLC) after transcatheter arterial chemoembolization (TACE). Sixty PLC patients with post-TACE visual analog pain intensity scores greater than 3 were divided equally into two groups receiving either WAA or oral morphine sulphate (MOR) for post-TACE pain. Pain intensity scores were reassessed at 1, 2, 4, and 6 h after analgesic intervention. Patients were also monitored for adverse reactions to analgesic treatment. Pain scores recorded when the patients first felt pain after TACE showed no statistical difference between the two groups (p > 0.05). WAA and MOR had indistinguishable degrees of pain relief 1, 2, and 4 h after analgesic intervention (p > 0.05). At 6 h after intervention, the WAA group experienced significantly greater pain relief than the MOR group (p < 0.05). Incidence of abdominal distension was lower in the WAA group than in the MOR group (p < 0.05). The results suggest that WAA not only had an analgesic effect equal to or greater than MOR in PLC patients with moderate to severe post-TACE pain, but also reduced the incidence of postoperative abdominal distention.
C1 [Zeng, Ke; Dong, Hui-Juan; Chen, Hong-Yun; Chen, Zhe; Li, Bai; Zhou, Qing-Hui] Second Mil Med Univ, Sch Tradit Chinese Med, Changhai Hosp Tradit Chinese Med, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Zhou, QH (corresponding author), Second Mil Med Univ, Sch Tradit Chinese Med, Room 2203,800 Xiangyin Rd, Shanghai 200433, Peoples R China.
EM jcimzqh@163.com
CR ANDERSSON S A, 1975, AMERICAN JOURNAL OF CHINESE MEDICINE, V3, P311, DOI 10.1142/S0192415X75000396
   Unknown -, 2005, CHIN J INTEGRATED TR, V0, P0
   Barone M, 2003, HEPATO-GASTROENTEROL, V50, P183
   Chen XN, 2007, CHIN J PRACT NURS, V23, P26
   Chu Z, 1997, J TRADIT CHIN MED, V17, P280
   Han JS, 2006, MOD ONCOL, V14, P1274
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P361
   JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870
   Jamison RN, 1998, SPINE, V23, P2591, DOI 10.1097/00007632-199812010-00014
   Lao HH, 1999, WRIST ANKLE ACUPUNCT, V0, P1
   Lee HS, 1997, CANCER-AM CANCER SOC, V79, P2087, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M
   Lee SH, 2001, CARDIOVASC INTER RAD, V24, P368, DOI 10.1007/s00270-001-0073-z
   Li XZ, 2004, CLIN MED, V24, P22
   Li ZP, 2006, J PRACT DIAGN THER, V20, P613
   Liang JF, 2003, ZHEJIANG J PREV MED, V15, P14
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Lu DZ, 2004, J GUANGDONG MED COLL, V22, P183
   Lu XY, 2003, CHINESE J MODERN NUR, V20, P6
   Lu ZY, 2008, INTERNAL MED, V0, P371
   Ma HQ, 2011, CHIN FOREIGN MED RES, V9, P129
   Marra C, 2011, J ALTERN COMPLEM MED, V17, P239, DOI 10.1089/acm.2010.0256
   Meng Zhi-Qiang, 2003, ZHONG XI YI JIE HE XUE BAO, V1, P187, DOI 10.3736/jcim20030312
   Qin J, 2004, NURS J CHIN PLA, V21, P7
   Shu Shi, 2011, ZHONG XI YI JIE HE XUE BAO, V9, P605
   Su Jiang-tao, 2010, ZHONGGUO ZHEN JIU, V30, P617
   Tian Y, 2007, JIANGSU J TRADIT CHI, V39, P47
   Wang JY, 2010, J NANJING I PHYS ED, V9, P29
   Wang Q, 2012, AM J CHINESE MED, V40, P1157, DOI 10.1142/S0192415X12500851
   Xu M, 2013, AM J CHINESE MED, V41, P1, DOI 10.1142/S0192415X13500018
   Yang JY, 2005, THEORY PRACTICE INTE, V0, P236
   Zhai XF, 2013, J INTEGR MED-JIM, V11, P90, DOI 10.3736/jintegrmed2013021
   Zhang Huo-Jun, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P907, DOI 10.3736/jcim20080906
   Zhang XM, 2002, PROCEEDINGS FIFTEENTH INTERNATIONAL SYMPOSIUM ON MATHEMATICAL THEORY OF NETWORKS AND SYSTEMS, V0, P1
   Zhou QH, 2002, WRIST ANKLE ACUPUNCT, V0, P1
   Zhou QH, 2005, J ZHEJIANG COLL TRAD, V29, P53
   Zhou YL, 2005, ZHEJIANG CLIN MED J, V7, P397
   Zhu Z, 1998, J TRADIT CHIN MED, V18, P192
NR 39
TC 36
Z9 44
U1 1
U2 65
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2014
VL 42
IS 2
BP 289
EP 302
DI 10.1142/S0192415X14500190
PG 14
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA AD2UR
UT WOS:000333091500003
PM 24707863
DA 2026-01-16
ER

PT J
AU Bauml, J
   Basal, C
   Mao, JJ
AF Bauml, Joshua
   Basal, Coby
   Mao, Jun J.
TI Treatment of post-mastectomy pain syndrome with acupuncture: a case report
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
ID breast-cancer survivors; long-term; prevalence; surgery; care
AB Post-mastectomy pain syndrome (PMPS) is a common and severe neuropathic pain syndrome arising after breast surgery. Since few effective allopathic treatments exist for PMPS, many patients may seek assistance from complementary and alternative medicine. Here, we report a case of a woman with severe and persistent PMPS who was successfully treated with acupuncture.
C1 [Bauml, Joshua] Univ Penn, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
   [Basal, Coby] Univ Penn, Philadelphia, PA 19104 USA.
   [Mao, Jun J.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Mao, JJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
EM Jun.mao@uphs.upenn.edu
FU National Institutes of Health NCCAM [K23 AT004112]
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Blunt C, 2004, PAIN, V108, P294, DOI 10.1016/j.pain.2003.12.011
   Carpenter JS, 1998, J CLIN EPIDEMIOL, V51, P1285, DOI 10.1016/S0895-4356(98)00121-8
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gärtner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568
   Macdonald L, 2005, BRIT J CANCER, V92, P225, DOI 10.1038/sj.bjc.6602304
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Fabro EAN, 2012, BREAST, V21, P321, DOI 10.1016/j.breast.2012.01.019
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Smith WCS, 1999, PAIN, V83, P91, DOI 10.1016/S0304-3959(99)00076-7
   Vilholm OJ, 2008, BRIT J CANCER, V99, P604, DOI 10.1038/sj.bjc.6604534
NR 15
TC 6
Z9 9
U1 0
U2 23
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD APR 15
PY 2014
VL 32
IS 2
BP 183
EP 185
DI 10.1136/acupmed-2013-010459
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AE2WS
UT WOS:000333834600015
PM 24240772
DA 2026-01-16
ER

PT J
AU Kong, S
   Zhang, YH
   Liu, CF
   Tsui, I
   Guo, Y
   Ai, BB
   Han, FJ
AF Kong, Sai
   Zhang, Yue-Hui
   Liu, Chen-Fang
   Tsui, Ilene
   Guo, Ying
   Ai, Bei-Bei
   Han, Feng-Juan
TI The Complementary and Alternative Medicine for Endometriosis: A Review of Utilization and Mechanism
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID traditional chinese medicine; wenshen xiaozheng tang; tumor-necrosis-factor; cells in-vitro; peritoneal-fluid; curcumin; resveratrol; women; angiogenesis; expression
AB Endometriosis (EM) is one of the common gynecological conditions causing menstrual and pelvic pain and affects 10%-15% of women of reproductive age. In recent years, the complementary and alternative medical (CAM) treatment for EM has become popular due to the few adverse reactions reported. The CAM therapy for EM includes several different treatments such as herbs (herbal prescription, extract, and patent), acupuncture, microwave physiotherapy, and Chinese herb medicine enema (CHM enema). These CAM therapies are effective at relieving dysmenorrhoea, shrinking adnexal masses, and promoting pregnancy, with less unpleasant side effects when compared to hormonal and surgical treatments. In this review, we focus on the status quo of CAM on EM and try to identify therapeutic efficacy and mechanisms based on some clinical and experimental studies. We hope to provide some instructive suggestions for clinical treatment and experimental research in the future.
C1 [Kong, Sai; Liu, Chen-Fang; Guo, Ying; Ai, Bei-Bei] Heilongjiang Univ Chinese Med, Dept Obstet & Gynecol, Harbin 150040, Peoples R China.
   [Zhang, Yue-Hui; Han, Feng-Juan] Heilongjiang Univ Chinese Med, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150040, Peoples R China.
   [Zhang, Yue-Hui] Heilongjiang Univ Chinese Med, Ctr Postdoctoral Studies, Harbin 150040, Peoples R China.
   [Tsui, Ilene] Penn State Univ, Coll Med, Hershey, PA 17033 USA.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health
RP Han, FJ (corresponding author), Heilongjiang Univ Chinese Med, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150040, Peoples R China.
EM hanfengjuan2004@163.com
FU National Natural Science Fund of China [81273788]; Program for New Century Excellent Talents in Heilongjiang Provincial University [1155-NCET-015]
CR Altan ZM, 2010, J PHARMACOL EXP THER, V334, P460, DOI 10.1124/jpet.110.166488
   Bai RX, 1988, CHINESE J ORTHOPAEDI, V18, P290
   Barnes Patricia M, 2004, ADV DATA, V0, P1
   Batt RE, 2011, HISTORY OF ENDOMETRIOSIS, V0, PPXXIII, DOI 10.1007/978-0-85729-585-9
   Bruner-Tran KL, 2011, BIOL REPROD, V84, P106, DOI 10.1095/biolreprod.110.086744
   陈德甫, 2003, 中国中西医结合杂志 CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, V23, P170
   Chen DF, 1994, SHANGHAI J TRADITION, V28, P6
   [陈何红 CHEN Hehong], 2007, 北京中医药大学学报 JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V30, P643
   Chen JH, 2006, MODERN MED J CHINA, V8, P20
   Chen LJ, 2004, ACTA CHINESE MED PHA, V32, P39
   Chen LN, 2011, SHANDONG J TRADITION, V30, P403
   Chen Ming, 2010, ZHONGGUO ZHEN JIU, V30, P725
   Chen Q, 1996, CHINESE ACUPUNCTURE, V2, P25
   [陈蓉 CHEN Rong], 2011, 中成药 CHINESE TRADITIONAL PATENT MEDICINE, V33, P1145
   [陈蓉 Chen Rong], 2010, 生殖与避孕 REPRODUCTION AND CONTRACEPTION, V30, P659
   Chen Y, 2011, REPROD SCI, V18, P886, DOI 10.1177/1933719111398500
   Chen Yun-Fei, 2008, ZHONGGUO ZHEN JIU, V28, P675
   Cheng L, 1999, GUANGDONG MED J, V20, P565
   Cheng W, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0045529
   Chiu JH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/198584
   Coulter ID, 2004, MED J AUSTRALIA, V180, P587, DOI 10.5694/j.1326-5377.2004.tb06099.x
   Ding DF, 2013, J INTEGR MED-JIM, V11, P389, DOI 10.3736/jintegrmed2013039
   Dou CR, 1998, J GANSU COLL TRADITI, V15, P25
   Du LJ, 2010, CHINESE REMEDIES CLI, V10, P655
   DUAN YH, 2007, ZHEJIANG J TRAD CHIN, V42, P168
   Ergenoglu AM, 2013, REPROD SCI, V20, P1230, DOI 10.1177/1933719113483014
   Evian Annual Reprod EVAR Workshop, 2011, HUM REPROD UPDATE, V17, P829, DOI 10.1093/humupd/dmr033
   Fang DL, 2003, CLIN J ANHUI TRADITI, V15, P297
   Flower A, 2007, J ALTERN COMPLEM MED, V13, P969, DOI 10.1089/acm.2006.6283
   Fu BJ, 2008, SHANGHAI J TRADITION, V42, P53
   Fu JinRong Fu JinRong, 2012, CHINESE ARCHIVES OF TRADITIONAL CHINESE MEDICINE, V30, P537
   FU Y, 2005, SHANGHAI J ACUPUNCTU, V24, P3
   Gao AZ, 2012, GUANGMING J CHINESE, V27, P717
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5
   Gu JH, 2003, J TRADITIONAL CHINES, V10, P301
   Guo SW, 2009, MOL HUM REPROD, V15, P609, DOI 10.1093/molehr/gap075
   Hawkins RS, 2003, APPL PSYCHOPHYS BIOF, V28, P279, DOI 10.1023/A:1027378825194
   Hua XB, 1991, EXPT ANIMALS ANIMAL, V1, P1
   Huang ZH, 2007, CHIN J INTEGR TRADIT, V27, P748
   Hui XL, 2009, J SHAANXI COLL TRADI, V32, P45
   Huo GM, 2006, HUBEI J TRADITIONAL, V28, P8
   Jana S, 2012, INDIAN J BIOCHEM BIO, V49, P342
   Jana S, 2012, BIOCHEM PHARMACOL, V83, P797, DOI 10.1016/j.bcp.2011.12.030
   Ji XY, 2011, J ETHNOPHARMACOL, V134, P624, DOI 10.1016/j.jep.2011.01.003
   Jin Ya-bei, 2009, ZHEN CI YAN JIU, V34, P188
   Kanaoka Yasushi, 2004, OSAKA CITY MEDICAL JOURNAL, V50, P47
   Kellehear A, 2003, MED J AUSTRALIA, V179, P0
   Kim KH, 2012, PHYTOTHER RES, V26, P1037, DOI 10.1002/ptr.3694
   KOIKE H, 1992, PROSTAG LEUKOTR ESS, V46, P133, DOI 10.1016/0952-3278(92)90219-9
   Koike H, 1994, NIHON NAIBUNPI GAKKAI ZASSHI, V70, P43
   Laschke MW, 2008, HUM REPROD, V23, P2308, DOI 10.1093/humrep/den245
   Lei XP, 2002, PROGR PHYSL SCI, V33, P286
   Li J, 1999, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V19, P533
   Li SP, 2009, SHAANXI J TRADITIONA, V25, P49
   Li WL, 2009, MODERN TRADITIONAL C, V29, P19
   李兆艾, 2007, 中华妇产科杂志 CHINESE JOURNAL OF OBSTETRICS AND GYNECOLOGY, V42, P417
   Li ZX, 2002, CHINESE J INTEGRATED, V22, P294
   Lin HY, 2009, SUZHOU U J MED SCI, V29, P636
   Lin YanMing Lin YanMing, 2012, JOURNAL OF LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V14, P73
   Liu HZ, 2005, HERALD MED, V17, P566
   Liu YL, 2010, SHANDONG MED J, V50, P78
   Liu YY, 2009, HUBEI J TRADITIONAL, V3, P53
   Long JR, 2012, CHINESE REMEDIES CLI, V12, P720
   Loudon I, 2006, J ROY SOC MED, V99, P607, DOI 10.1258/jrsm.99.12.607
   LUO JY, 2006, MODERN J INTEGRATED, V15, P1626
   Ma MZ, 1993, SHANGHAI J TRADITION, V2, P16
   [马文光 MA Wenguang], 2007, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V22, P879
   Maia H, 2012, INT J WOMENS HEALTH, V4, P543, DOI 10.2147/IJWH.S36825
   Meissner K, 2010, FORSCH KOMPLEMENTMED, V17, P314, DOI 10.1159/000322890
   Mu LJ, 2012, CHINESE MAT MED, V19, P80
   NIH Consensus Development Program, 2007, AC CONS DEV C STAT, V0, P0
   Pan L, 2011, B MED RES, V40, P126
   Partadiredja G, 2013, J INTEGR MED-JIM, V11, P32, DOI 10.3736/jintegrmed2013006
   Pino M, 2009, REPRODUCTION, V138, P837, DOI 10.1530/REP-09-0196
   Pujol LAM, 2007, J AM OSTEOPATH ASSOC, V107, P0
   Qu F, 2006, J SICHUAN TRADITIONA, V12, P9
   Ren YL, 2005, J CHINESE PRACTICAL, V19, P279
   Rudzitis-Auth J, 2013, HUM REPROD, V28, P1339, DOI 10.1093/humrep/det031
   Ruhland B, 2011, MINERVA GINECOL, V63, P247
   Scholl B, 2009, GYNECOL ENDOCRINOL, V25, P701, DOI 10.3109/09513590903159680
   Sharma B, 2004, J OBSTET GYNAECOL, V24, P916
   Sharpe-Timms KL, 2010, HUM REPROD, V25, P1241, DOI 10.1093/humrep/deq032
   She C, 2012, SHANGHAI J ACUPUNCTU, V31, P178
   [史淑红 SHI Shuhong], 2007, 中成药 CHINESE TRADITIONAL PATENT MEDICINE, V29, P788
   Si CQ, 2012, HEBEI J TRADITIONAL, V34, P678
   Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715
   Song ZY, 2006, CHINESE REMEDIES CLI, V6, P255
   Song ZY, 2011, CHIN REM CLIN, V11, P768
   Sun QF, 2012, HUNAN J TRADITIONAL, V21, P62
   Sun YH, 2008, INFORM TRADITIONAL C, V25, P41
   Swarnakar S, 2009, INDIAN J BIOCHEM BIO, V46, P59
   Tang MB, 2012, J PRACTICAL TRADITIO, V26, P66
   Tang Yong-jiu, 2005, ZHONGGUO ZHONGYAO ZAZHI, V30, P1108
   The Cleveland Clinic, 2010, REC END SURG MAN END, V0, P0
   US National Center for Complementary and Alternative Medicine, 2006, AC, V0, P0
   Wang CF, 2007, MODERN J INTEGRATED, V16, P1931
   Wang CC, 2013, ANGIOGENESIS, V16, P59, DOI 10.1007/s10456-012-9299-4
   Wang D, 1998, J TRADIT CHIN MED, V18, P7
   Wang D Z, 1991, ZHONG XI YI JIE HE ZA ZHI, V11, P524
   Wang D, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0025011
   Wang HM, 2008, CHINESE J TRADITIONA, V15, P83
   Wang HM, 2004, CHINESE J TRADITIONA, V11, P361
   Wang HM, 2003, J FUJIAN COLL TRADIT, V13, P21
   Wang HM, 2004, SHANGHAI J ACUPUNCTU, V23, P39
   Wang Q, 2009, J TRADIT CHIN MED, V29, P296, DOI 10.1016/S0254-6272(09)60088-1
   王雪, 2011, 广东医学 GUANGDONG MEDICAL JOURNAL, V32, P163
   Wang Y, 1997, STRAIT PHARM J, V9, P101
   [王自能 Wang Zineng], 2004, 中国病理生理杂志 CHINESE JOURNAL OF PATHOPHYSIOLOGY, V20, P862
   Wellbery C, 1999, AM FAM PHYSICIAN, V60, P1753
   Wickiewicz D, 2013, ARCH GYNECOL OBSTET, V288, P805, DOI 10.1007/s00404-013-2828-6
   Wu F, 2003, J CHINESE MICROCIRCU, V7, P355
   Wu Fan Wu Fan, 2003, CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE, V10, P29
   Wu HY, 2009, CHINA MODERN DOCTOR, V47, P77
   Wu XH, 2011, GUANGMING J CHINESE, V26, P2467
   Xiang Dong-Fang, 2011, ZHONGGUO ZHEN JIU, V31, P113
   Xiao YH, 2002, EUR J GYNAECOL ONCOL, V23, P63
   Xu H, 2009, HUM REPROD, V24, P608, DOI 10.1093/humrep/den417
   Xu H, 2011, FERTIL STERIL, V96, P1021, DOI 10.1016/j.fertnstert.2011.07.008
   Xu K, 2007, CHINESE COMMUNITY DO, V23, P36
   Xu XY, 2011, MED INFORM, V24, P3172
   Xu XY, 2011, J SICHUAN TRADITIONA, V29, P28
   Yan XH, 2004, FUJIAN J TRADITIONAL, V35, P11
   Yang Chun-Bo, 2008, ZHONGGUO ZHONG YAO ZA ZHI, V33, P567
   Yang F, 2011, SHAANXI J TRADITIONA, V32, P1557
   Yang J, 2005, SHAANXI J TRADITIONA, V26, P1007
   Yang JB, 2007, YUNNAN J TRADITIONAL, V28, P36
   Yang JB, 2008, CHINESE ARCH TRADITI, V26, P979
   Yang JB, 2009, MODERN TRADITIONAL C, V29, P48
   Yang JB, 2006, YUNNAN J TRADITIONAL, V27, P32
   Yang JQ, 2008, ITESS: 2008 PROCEEDINGS OF INFORMATION TECHNOLOGY AND ENVIRONMENTAL SYSTEM SCIENCES, V0, P1, DOI 10.1109/CVPR.2008.4587647
   Yang WJ, 1997, JIANGSU J TRADITIONA, V18, P22
   Yang YanHuan Yang YanHuan, 2012, CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V27, P1911
   Yu BJ, 2009, CHINESE J MISDIAGNOS, V9, P2055
   Zeng R, 2010, ZHONG YI ZA ZHI, V25, P342
   Zhang HQ, 2009, MODERN MED J CHINA, V11, P0
   [张慧琴 Zhang Huiqin], 2011, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V52, P27
   Zhang JY, 2008, ZHEJIANG J TRADITION, V43, P455
   Zhang L, 2007, CHINA MED HERALD, V4, P136
   Zhang L, 2007, J SICHUAN TRADITIONA, V25, P84
   Zhang PH, 2012, J NEW CHINESE MED, V44, P60
   Zhang QinShu Zhang QinShu, 2012, JOURNAL OF THIRD MILITARY MEDICAL UNIVERSITY, V34, P2167
   Zhang SY, 2011, CHINESE J ETHNOMEDIC, V22, P84
   Zhang WJ, 2004, SHAANXI J TRADITIONA, V5, P468
   Zhang Xi, 2009, SICHUAN DA XUE XUE BAO YI XUE BAN, V40, P228
   Zhang Y, 2011, INT J MOL MED, V27, P87, DOI 10.3892/ijmm.2010.552
   Zhang ZZ, 2013, CLIMACTERIC, V16, P700, DOI 10.3109/13697137.2013.771331
   Zhang ZZ, 2013, REPROD SCI, V20, P1215, DOI 10.1177/1933719113483008
   Zhao F, 2008, TRADITIONAL CHINESE, V21, P14
   [赵瑞华 Zhao Ruihua], 2012, 北京中医药大学学报 JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V35, P826
   Zheng H, 2006, SHAANXI J TRADITIONA, V26, P1147
   Zheng H, 2005, LABELED IMMUNOASSAYS, V12, P35
   Zheng Hui, 2006, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V26 Suppl, P119
   Zhou SY, 2012, GUIDE CHINA MED, V10, P226
NR 154
TC 20
Z9 31
U1 1
U2 35
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/146383
PG 16
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AC1YF
UT WOS:000332293200001
DA 2026-01-16
ER

PT J
AU Zeng, K
   Dong, HJ
   Chen, HY
   Chen, Z
   Li, B
   Zhou, QH
AF Zeng, Ke
   Dong, Hui-Juan
   Chen, Hong-Yun
   Chen, Zhe
   Li, Bai
   Zhou, Qing-Hui
TI Wrist-ankle acupuncture for pain after transcatheter arterial chemoembolization
SO The American journal of Chinese medicine
LA English
DT Journal Article
AB This study was designed to evaluate the analgesic effect of wrist-ankle  acupuncture (WAA) for patients with primary liver cancer (PLC) after  transcatheter arterial chemoembolization (TACE). Sixty PLC patients with  post-TACE visual analog pain intensity scores greater than 3 were divided equally  into two groups receiving either WAA or oral morphine sulphate (MOR) for  post-TACE pain. Pain intensity scores were reassessed at 1, 2, 4, and 6 h after  analgesic intervention. Patients were also monitored for adverse reactions to  analgesic treatment. Pain scores recorded when the patients first felt pain after  TACE showed no statistical difference between the two groups (p > 0.05). WAA and  MOR had indistinguishable degrees of pain relief 1, 2, and 4 h after analgesic  intervention (p > 0.05). At 6 h after intervention, the WAA group experienced  significantly greater pain relief than the MOR group (p < 0.05). Incidence of  abdominal distension was lower in the WAA group than in the MOR group (p < 0.05).  The results suggest that WAA not only had an analgesic effect equal to or greater  than MOR in PLC patients with moderate to severe post-TACE pain, but also reduced  the incidence of post-operative abdominal distention.
C1 School of Traditional Chinese Medicine, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China.
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD APR 9
PY 2014
VL 42
IS 2
BP 289
EP 302
DI 10.1142/S0192415X14500190
PG 13
WC Acupuncture Analgesia; methods; Adult; Aged; Analgesics, Opioid; Ankle; Catheterization, Peripheral; adverse effects; Chemoembolization, Therapeutic; adverse effects; Female; Hepatic Artery; Humans; Liver Neoplasms; therapy; Male; Middle Aged; Morphine; administration & dosage; Pain, Postoperative; etiology; Treatment Outcome; Wrist
UT PubMed:24707863
PM 24707863
DA 2014-04-09
ER

PT J
AU Nagraj, SK
   Naresh, S
   Srinivas, K
   George, PR
   Shrestha, A
   Levenson, D
   Ferraiolo, DM
AF Nagraj, Sumanth Kumbargere
   Naresh, Shetty
   Srinivas, Kandula
   George, P. Renjith
   Shrestha, Ashish
   Levenson, David
   Ferraiolo, Debra M.
TI Interventions for the management of taste disturbances
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID placebo-controlled trial; double-blind; zinc supplementation; cancer-patients; pilocarpine treatment; gustatory function; uremic hypogeusia; oral zinc; smell; acuity
AB Background The sense of taste is very much essential to the overall health of the individual. It is a necessary component to enjoying one's food, which in turn provides nutrition to an individual. Any disturbance in taste perception can hamper the quality of life in such patients by influencing their appetite, body weight and psychological well-being. Taste disorders have been treated using different modalities of treatment and there is no consensus for the best intervention. Hence this Cochrane systematic review was undertaken. Objectives To assess the effects of interventions for the management of patients with taste disturbances. Search methods We searched the Cochrane Oral Health Group Trials Register (to 5 March 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2014), MEDLINE via OVID (1948 to 5 March 2014), EMBASE via OVID (1980 to 5 March 2014), CINAHL via EBSCO (1980 to 5 March 2014) and AMED via OVID (1985 to 5 March 2014). We also searched the relevant clinical trial registries and conference proceedings from the International Association of Dental Research/American Association of Dental Research (to 5 March 2014), Association for Research in Otolaryngology (to 5 March 2014), the US National Institutes of Health Trials Register (to 5 March 2014), metaRegister of Controlled Trials (mRCT) (to 5 March 2014), World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) (to 5 March 2014) and International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Clinical Trials Portal (to 5 March 2014). Selection criteria We included all randomised controlled trials (RCTs) comparing any pharmacological agent with a control intervention or any non-pharmacological agent with a control intervention. We also included cross-over trials in the review. Data collection and analysis Two authors independently, and in duplicate, assessed the quality of trials and extracted data. Wherever possible, we contacted study authors for additional information. We collected adverse events information from the trials. Main results We included nine trials (seven parallel and two cross-over RCTs) with 566 participants. We assessed three trials (33.3%) as having a low risk of bias, four trials (44.5%) at high risk of bias and two trials (22.2%) as having an unclear risk of bias. We only included studies on taste disorders in this review that were either idiopathic, or resulting from zinc deficiency or chronic renal failure. Of these, eight trials with 529 people compared zinc supplements to placebo for patients with taste disorders. The participants in two trials were children and adolescents with respective mean ages of 10 and 11.2 years and the other six trials had adult participants. Out of these eight, two trials assessed the patient reported outcome for improvement in taste acuity using zinc supplements (RR 1.45, 95% CI 1.0 to 2.1; very low quality evidence). We included three trials in the meta-analysis for overall taste improvement (effect size 0.44, 95% CI 0.23 to 0.65; moderate quality evidence). Two other trials described the results as taste acuity improvement and we conducted subgroup analyses due to clinical heterogeneity. One trial described the results as taste recognition improvement for each taste sensation and we analysed this separately. We also analysed one cross-over trial separately using the first half of the results. None of the zinc trials tested taste discrimination. Only one trial tested taste discrimination using acupuncture (effect size 2.80, 95% CI -1.18 to 6.78; low quality evidence). Out of the eight trials using zinc supplementation, four reported adverse events like eczema, nausea, abdominal pain, diarrhoea, constipation, decrease in blood iron, increase in blood alkaline phosphatase, and minor increase in blood triglycerides. No adverse events were reported in the acupuncture trial. None of the included trials could be included in the meta-analysis for health-related quality of life in taste disorder patients. Authors' conclusions We found very low quality evidence that was insufficient to conclude on the role of zinc supplements to improve taste perception by patients, however we found moderate quality evidence that zinc supplements improve overall taste improvement in patients with zinc deficiency/idiopathic taste disorders. We also found low quality evidence that zinc supplements improve taste acuity in zinc deficient/idiopathic taste disorders and very low quality evidence for taste recognition improvement in children with taste disorders secondary to chronic renal failure. We did not find any evidence to conclude the role of zinc supplements for improving taste discrimination, or any evidence addressing health-related quality of life due to taste disorders. We found low quality evidence that is not sufficient to conclude on the role of acupuncture for improving taste discrimination in cases of idiopathic dysgeusia (distortion of taste) and hypogeusia (reduced ability to taste). We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
C1 [Nagraj, Sumanth Kumbargere] Melaka Manipal Med Coll, Fac Dent, Dept Oral Med & Oral Radiol, Bukit Baru 75150, Melaka, Malaysia.
   [Naresh, Shetty] Int Med Univ, Sch Dent Oral & Maxillofacial Surg, Bukit Jalil, Malaysia.
   [Srinivas, Kandula] Manipal Hosp, Bangalore, Karnataka, India.
   [George, P. Renjith] Melaka Manipal Med Coll, Fac Dent, Dept Oral Pathol, Bukit Baru 75150, Melaka, Malaysia.
   [Shrestha, Ashish] BP Koirala Inst Hlth Sci, Coll Dent, Dharan, Nepal.
   [Levenson, David; Ferraiolo, Debra M.] NYU, Coll Dent, Dept Oral & Maxillofacial Pathol, New York, NY USA.
C3 Manipal Academy of Higher Education (MAHE); Manipal University College Malaysia; IMU University; Manipal Academy of Higher Education (MAHE); Manipal University College Malaysia; B.P. Koirala Institute of Health Sciences; New York University
RP Nagraj, SK (corresponding author), Melaka Manipal Med Coll, Fac Dent, Dept Oral Med & Oral Radiol, Jalan Batu Hampar, Bukit Baru 75150, Melaka, Malaysia.
EM sumikn@rediffmail.com
FU Faculty of Dentistry, Melaka Manipal Medical College, Manipal University, Melaka Campus, Malaysia; Faculty of Dentistry, International Medical University, Kuala Lumpur, Malaysia; National Institute for Health Research (NIHR), UK; NIHR; Cochrane Oral Health Group Global Alliance, UK; British Orthodontic Society, UK; British Society of Paediatric Dentistry, UK; Canadian Dental Hygienists Association, Canada; National Center for Dental Hygiene Research Practice, USA; New York University College of Dentistry, USA
CR Aframian DJ, 2007, ORAL DIS, V13, P88, DOI 10.1111/j.1601-0825.2006.01252.x
   Unknown -, 2012, Z 103 PHASE 3 CLIN S, V0, P0
   ATKINTHOR E, 1978, AM J CLIN NUTR, V31, P1948, DOI 10.1093/ajcn/31.10.1948
   BARRIE SA, 1987, AGENTS ACTIONS, V21, P222, DOI 10.1007/BF01974946
   BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1
   BICKNELL JM, 1988, WESTERN J MED, V149, P457
   Birks J, 2009, COCHRANE DATABASE OF, V0, P0, DOI DOI 10.1002/14651858.CD003120.pub3
   Brandt H, 2008, DTSCH Z AKUPUNKT, V51, P24, DOI 10.1016/j.dza.2008.01.003
   Brandt H HB, 2008, REV INT ACUPUNTURA, V2, P155
   Brisbois TD, 2011, ANN ONCOL, V22, P2086, DOI 10.1093/annonc/mdq727
   Bromley SM, 2000, AM FAM PHYSICIAN, V61, P427
   Christopher H Hawkes, 2002, THE MOST COMMON COMP, V0, P0
   DAHL H, 1984, ACTA OPHTHALMOL, V62, P739
   de Moraes M, 2012, J ORAL PATHOL MED, V41, P281, DOI 10.1111/j.1600-0714.2011.01100.x
   Doty RL, 1995, HANDBOOK OF OLFACTIO, V0, P521
   EGGERT JV, 1982, INT J PED NEPHROL, V3, P21
   Femiano F, 2002, INT J ORAL MAX SURG, V31, P625, DOI 10.1054/ijom.2002.0276
   FIKENTSCHER R, 1987, LARYNGO RHINO OTOL, V66, P355, DOI 10.1055/s-2007-998675
   Fujiyama R, 2010, ODONTOLOGY, V98, P82, DOI 10.1007/s10266-009-0110-y
   Gardiner J, 2008, BIOSCIENCE HYPOTHESE, V1, P251
   Gondivkar SM, 2009, ORAL SURG ORAL MED O, V108, P876, DOI 10.1016/j.tripleo.2009.08.015
   Green A, 2013, J PSYCHOPHARMACOL, V27, P265, DOI 10.1177/0269881112472567
   Greenway FL, 2011, J AM COLL NUTR, V30, P178, DOI 10.1080/07315724.2011.10719958
   Halyard MY, 2007, INT J RADIAT ONCOL, V67, P1318, DOI 10.1016/j.ijrobp.2006.10.046
   Hebuterne Xaviere, 2013, IMPACT OF EARLY AND, V0, P0
   Heckmann SM, 2005, J DENT RES, V84, P35, DOI 10.1177/154405910508400105
   Henkin RI, 2000, J COMPUT ASSIST TOMO, V24, P106, DOI 10.1097/00004728-200001000-00022
   HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006
   HENKIN RI, 1963, J CLIN INVEST, V42, P727, DOI 10.1172/JCI104765
   Henkin RI, 1999, AM J MED SCI, V318, P392, DOI 10.1097/00000441-199912000-00006
   Henkin RI, 2013, NUTRITION, V0, P0
   Henkin RI, 2007, AM J MED SCI, V334, P431, DOI 10.1097/MAJ.0b013e3180de4d97
   Henkin RI, 2012, ARCH OTOLARYNGOL, V138, P1064, DOI 10.1001/2013.jamaoto.342
   Henkin RI, 2011, AM J OTOLARYNG, V32, P38, DOI 10.1016/j.amjoto.2009.10.001
   Henkin RI, 2011, AM J OTOLARYNG, V32, P178, DOI 10.1016/j.amjoto.2010.05.005
   Henkin RI, 2010, AM J MED SCI, V339, P249, DOI 10.1097/MAJ.0b013e3181cda0e3
   Henkin RI, 2009, METABOLISM, V58, P1717, DOI 10.1016/j.metabol.2009.05.027
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Hovan AJ, 2010, SUPPORT CARE CANCER, V18, P1081, DOI 10.1007/s00520-010-0902-1
   Ikeda M, 2005, ACTA OTO-LARYNGOL, V125, P1203, DOI 10.1080/00016480510040173
   Ikeda Minoru, 2013, NIHON JIBIINKOKA GAKKAI KAIHO, V116, P17
   Ishimaru T, 2001, CHEM SENSES, V26, P91, DOI 10.1093/chemse/26.1.91
   Iwatsuki K, 2012, J PHARMACOL SCI, V118, P123, DOI 10.1254/jphs.11R08CP
   Jham Bruno C, 2009, J ORAL SCI, V51, P565
   Kamphuis MMJW, 2003, BRIT J NUTR, V90, P199, DOI 10.1079/BJN2003858
   Kashihara K, 2011, INTERNAL MED, V50, P2311, DOI 10.2169/internalmedicine.50.5935
   Kinnamon SC, 2012, ACTA PHYSIOL, V204, P158, DOI 10.1111/j.1748-1716.2011.02308.x
   Leek H, 2002, MICRON, V33, P153, DOI 10.1016/S0968-4328(01)00004-X
   Lyckholm Laurel, 2012, J PAIN PALLIAT CARE PHARMACOTHER, V26, P111, DOI 10.3109/15360288.2012.676618
   MAHAJAN S K, 1992, JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE, V5, P33
   MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517
   MAHAJAN SK, 1982, AM J CLIN NUTR, V36, P1177, DOI 10.1093/ajcn/36.6.1177
   MAHAJAN SK, 1979, T AM SOC ART INT ORG, V25, P443
   Mattes RD, 2004, HUM PSYCHOPHARM CLIN, V19, P81, DOI 10.1002/hup.562
   Mattes RD, 2009, ANNU REV NUTR, V29, P305, DOI 10.1146/annurev-nutr-080508-141108
   MISTRETTA CM, 1984, J ANAT, V138, P323
   MOSSMAN KL, 1978, INT J RADIAT ONCOL, V4, P663, DOI 10.1016/0360-3016(78)90190-6
   Mueller C, 2003, RHINOLOGY, V41, P2
   Nagao Y, 2010, MEDICAL SCIENCE MONI, V16, P0
   Najafizade N, 2013, J RES MED SCI, V18, P123
   Ohno Tomohisa, 2003, JOURNAL OF MEDICAL AND DENTAL SCIENCES, V50, P101
   Padala Kalpana P, 2006, PRIM CARE COMPANION J CLIN PSYCHIATRY, V8, P178
   Porter SR, 2010, ORAL ONCOL, V46, P457, DOI 10.1016/j.oraloncology.2010.03.011
   Ripamonti C, 1998, CANCER-AM CANCER SOC, V82, P1938, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1938::AID-CNCR18>3.0.CO;2-U
   RUSSELL RM, 1980, AM J CLIN NUTR, V33, P2741, DOI 10.1093/ajcn/33.12.2741
   Sakagami M, 2009, ACTA OTO-LARYNGOL, V129, P1115, DOI 10.1080/00016480802552550
   Sakai F, 2002, ACTA OTO-LARYNGOL, V122, P129, DOI 10.1080/00016480260046517
   Sakai F, 1995, NIHON JIBIINKOKA GAKKAI KAIHO, V98, P1135
   Sanchez Nebra J, 1993, NUTR HOSP, V8, P561
   Sasano T, 2010, BIOL PHARM BULL, V33, P1791, DOI 10.1248/bpb.33.1791
   Silverman J E, 1983, J ORAL MED, V38, P14
   Smutzer G, 2008, LARYNGOSCOPE, V118, P1411, DOI 10.1097/MLG.0b013e31817709a0
   SOLOMONS N, 1974, CLIN RES, V22, P582
   Soter A, 2008, LARYNGOSCOPE, V118, P611, DOI 10.1097/MLG.0b013e318161e53a
   SPIELMAN AI, 1992, CHEM SENSES, V17, P451, DOI 10.1093/chemse/17.4.451
   Sprenger K B, 1983, KIDNEY INT SUPPL, V16, P0
   Stewart-Knox BJ, 2008, BRIT J NUTR, V99, P129, DOI 10.1017/S0007114507781485
   Strasser F, 2008, ONCOLOGIST, V13, P337, DOI 10.1634/theoncologist.2007-0217
   Sturniolo GC, 1985, JOURNAL OF HEPATOLOG, V1, P0
   Tomita H, 1986, AURIS NASUS LARYNX, V13 Suppl 1, P0
   Tupe RP, 2009, J AM COLL NUTR, V28, P388, DOI 10.1080/07315724.2009.10718101
   Vent J, 2010, OTOLARYNG HEAD NECK, V142, P505, DOI 10.1016/j.otohns.2010.01.012
   WATSON AR, 1983, HUM NUTR-CLIN NUTR, V37, P219
   Wickham R S, 1999, ONCOL NURS FORUM, V26, P697
   Wilken Marlene K, 2012, CLIN J ONCOL NURS, V16, P0
   Winkler S, 1999, J AM DENT ASSOC, V130, P1759, DOI 10.14219/jada.archive.1999.0133
   YOSHIDA S, 1991, AURIS NASUS LARYNX, V18, P153
NR 91
TC 20
Z9 23
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2014
VL 0
IS 11
BP 
EP 
DI 10.1002/14651858.CD010470.pub2
PG 71
WC Medicine, General & Internal
SC General & Internal Medicine
GA AY5YY
UT WOS:000347646200055
PM 25425011
DA 2026-01-16
ER

PT J
AU Li, XM
   Zhu, JH
   Li, PP
   Zhu, GQ
   Wu, XM
   Chen, HM
   Zhao, HX
   Wang, W
   Zhang, Y
   Xiao, WH
   Liu, DQ
AF Li, Xiaomei
   Zhu, Jianhua
   Li, Pingping
   Zhu, Guangqing
   Wu, Xiaoming
   Chen, Huoming
   Zhao, Huixia
   Wang, Wei
   Zhang, Ying
   Xiao, Wenhua
   Liu, Duanqi
TI A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain
SO CHINESE JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Cancer pain; opioid tolerance; Han's Acupoint Nerve Stimulator (HANS)
ID electrical nerve-stimulation; quality-of-life; chinese version; eortc qlq-c30; electroacupuncture; outpatients; receptors; oncology; requirement; validation
AB Objective: To observe the adjuvant analgesic efficacy of Han's Acupoint Nerve Stimulator (HANS) in opioid tolerant patients with cancer pain. Methods: A prospective non-controlled study was conducted. Opioid tolerant patients with cancer pain were enrolled and treated with both routinely analgesics and adjuvant HANS (2/100 Hz for 30 min/d, 5 d on and 2 d off for two weeks). Cancer pain, quality of life (QOL), anxiety and depression were assessed before enrollment and on d 8 and d 15 with the BPI-C, EORTC QLQ-C30, and self-rating anxiety scale (SAS)/self-rating depression scale (SDS), respectively; the therapeutic frequency of breakthrough pain (BP) and daily opioid dose were also recorded. Results: Totally 47 patients meeting the inclusion criteria participated in this study; 43 patients completed the two-week treatment and assessment. The mean scores of patient's "worst" and "least" pain intensity assessed with BPI-C decreased significantly on d 8 and d 15; the therapeutic frequency of BP also significantly decreased; but the average daily dose of opioids did not change significantly. For the nine 'symptoms in EORTC QLQ-C30 assessment, the mean scores of pain, fatigue, constipation and insomnia were significantly lower on d 8 and d 15 compared with baseline; the mean scores of the overall health status, nausea/vomiting and the incidence rates of both anxiety and depression also decreased significantly on d 15. Conclusions: To opioid tolerant patients with cancer pain, adjuvant treatment with HANS could improve pain release and patients' QOL by decreasing the severity of pain, fatigue, constipation, insomnia and other concomitant symptoms; it could also decrease the incidence rates of anxiety and depression.
C1 [Li, Xiaomei; Zhu, Jianhua; Zhao, Huixia; Xiao, Wenhua] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Med Oncol, Beijing 100048, Peoples R China.
   [Li, Xiaomei; Liu, Duanqi] Beijing Army Gen Hosp, Expert Grp, Dept Cadre Ward 3, Beijing 100700, Peoples R China.
   [Li, Pingping; Wang, Wei; Zhang, Ying] Peking Univ, Canc Hosp & Inst, Dept Integrated Tradit Chinese & Western Med, Key Lab Carcinogenesis & Tradit Res,Minist Educ, Beijing 100142, Peoples R China.
   [Zhu, Guangqing] Chinese PLA, Gen Hosp Air Force, Dept Med Oncol, Beijing 100142, Peoples R China.
   [Wu, Xiaoming] Chinese Acad Med Sci, Canc Inst & Hosp, Integrated Dept, Beijing 100021, Peoples R China.
   [Chen, Huoming] Second Artillery Gen Hosp, Dept Med Oncol, Beijing 100088, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS
RP Xiao, WH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Med Oncol, Beijing 100048, Peoples R China.
EM w_hxiao@hotmail.com
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028
   CHEN XH, 1992, BEHAV BRAIN RES, V47, P143, DOI 10.1016/S0166-4328(05)80120-2
   CHEN XH, 1992, EUR J PHARMACOL, V211, P203
   Claydon LS, 2011, CLIN J PAIN, V27, P635, DOI 10.1097/AJP.0b013e31821962b4
   Collett BJ, 1998, BRIT J ANAESTH, V81, P58, DOI 10.1093/bja/81.1.58
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Fisch MJ, 2012, J CLIN ONCOL, V30, P1980, DOI 10.1200/JCO.2011.39.2381
   Han ZR, 1999, CHINESE LITERATURE, V0, P100
   Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035
   Henderson JM, 2008, CURR PAIN HEADACHE R, V12, P28, DOI 10.1007/s11916-008-0006-5
   Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X
   Kim HS, 2013, SUPPORT CARE CANCER, V21, P1751, DOI 10.1007/s00520-013-1722-x
   Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003
   Lan F, 2012, MINERVA ANESTESIOL, V78, P887
   Li AL, 2009, ASIAN PAC J CANCER P, V10, P895
   Liang SY, 2013, ASIAN PAC J CANCER P, V14, P713, DOI 10.7314/APJCP.2013.14.2.713
   Liang T, 2008, BIOMED ENVIRON SCI, V21, P308, DOI 10.1016/S0895-3988(08)60047-1
   Liebano RE, 2011, PAIN, V152, P335, DOI 10.1016/j.pain.2010.10.040
   Liu Ya-Li, 2012, ZHONGGUO ZHEN JIU, V32, P409
   OMahony Sean, 2010, J OPIOID MANAG, V6, P211
   Quispe-Cabanillas JG, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-209
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   Twillman Robert K, 2007, J PAIN PALLIAT CARE PHARMACOTHER, V21, P13
   Wan C, 2008, ANN ONCOL, V19, P2053, DOI 10.1093/annonc/mdn417
   Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8
   Yang Qiong-Hui, 2012, ZHONGGUO ZHEN JIU, V32, P59
   Zhao H, 2000, QUAL LIFE RES, V9, P129, DOI 10.1023/A:1008981520920
NR 29
TC 4
Z9 6
U1 0
U2 10
PU CHINESE JOURNAL CANCER RESEARCH CO
PI BEIJING
PA LTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING, 100142, PEOPLES R CHINA
SN 1000-9604
EI 1993-0631
J9 CHINESE J CANCER RES
JI Chin. J. Cancer Res.
PD APR 15
PY 2014
VL 26
IS 2
BP 174
EP 182
DI 10.3978/j.issn.1000-9604.2014.04.02
PG 9
WC Oncology
SC Oncology
GA AG7TR
UT WOS:000335622200008
PM 24826058
DA 2026-01-16
ER

PT J
AU Pachman, DR
   Watson, JC
   Loprinzi, CL
AF Pachman, Deirdre R
   Watson, James C
   Loprinzi, Charles L
TI Therapeutic strategies for cancer treatment related peripheral neuropathies.
SO Current treatment options in oncology
LA English
DT Review
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated  with multiple chemotherapeutic agents. CIPN may have a detrimental impact on  patients' quality of life and functional ability, as well as result in  chemotherapy dose reductions. Although symptoms of CIPN can improve with  treatment completion, symptoms may persist. Currently, the treatment options for  CIPN are quite limited. Duloxetine, a serotonin-norepinephrine reuptake  inhibitor, has the most evidence supporting its use in the treatment of CIPN.  Other agents with potential benefit for the treatment of established CIPN include  gabapentinoids, venlafaxine, tricyclic antidepressants, and a topical gel  consisting of the combination of amitriptyline, ketamine, and baclofen; none of  these, however, has been proven to be helpful and ongoing/future studies may well  show that they are not beneficial. The use of these agents is often based on  their efficacy in the treatment of non-CIPN neuropathic pain, but this does not  necessarily mean that they will be helpful for CIPN-related symptoms. Other  nonpharmacologic interventions including acupuncture and Scrambler therapy are  supported by positive preliminary data; however, further larger,  placebo-controlled trial data are needed to confirm or refute their  effectiveness.
C1 Mayo Clinic Rochester, 200 First Street SW, Rochester, MN, 55905, USA, pachman.deirdre@mayo.edu.
NR 0
TC 0
SN 1534-627
EI 
J9 Curr Treat Options Oncol
PD AUG 15
PY 2014
VL 15
IS 4
BP 567
EP 80
DI 10.1007/s11864-014-0303-7
PG -487
WC Antineoplastic Agents; adverse effects; Humans; Neoplasms; complications; Peripheral Nervous System Diseases; etiology
UT PubMed:25119581
PM 25119581
DA 2014-08-15
ER

PT J
AU Trevisani, L
   Zelante, A
   Sartori, S
AF Trevisani, Lucio
   Zelante, Angelo
   Sartori, Sergio
TI Colonoscopy, pain and fears: Is it an indissoluble trinomial?
SO World journal of gastrointestinal endoscopy
LA English
DT Review
DE Anxiety; Colonoscopy; Conscious sedation; Discomfort; Fear; Pain
AB Colonoscopy is the reference method in the secondary prevention, diagnosis and,  in some cases, treatment of colorectal cancer. It can often cause pain associated  with embarrassment, anxiety, and physical and emotional discomfort. Pain  intensity is influenced by a lot of factors, and there is a strict relationship  among pain, pain perception, and mind. Several methods can be used to break the  trinomial colonoscopy, pain and fear. Sedoanalgesia is recommended by several  guidelines. If no sedation is offered, the patient must accept a higher chance of  unacceptable discomfort and the endoscopist a lower chance of completing the  procedure because of patient discomfort. Other non-pharmacologic methods such as  acupuncture, music, and hydrocolonoscopy can be used as alternatives to  pharmacologic sedoanalgesia. Furthermore, new endoscopic technologies such as  variable-stiffness colonoscopes and ultrathin colonoscopes, or the use of carbon  dioxide instead of air for colon insufflation, can reduce the pain caused by  colonoscopy. In the future, technical improvements such as wireless capsules or  robotic probes, will probably enable to overcome the present concept of  colonoscopy, avoiding the use of traditional endoscopes. However, at present the  poor attention paid by endoscopists to the pain and discomfort caused by  colonoscopy can not be justified. There are several methods to reduce pain and  anxiety and to break the trinomial colonoscopy, pain and fear. We must use them.
C1 Lucio Trevisani, Angelo Zelante, Sergio Sartori, Digestive Endoscopy Unit, Department of Medicine, University Hospital "S. Anna", 44124 Cona (FE), Italy.
   Lucio Trevisani, Angelo Zelante, Sergio Sartori, Digestive Endoscopy Unit, Department of Medicine, University Hospital "S. Anna", 44124 Cona (FE), Italy.
   Lucio Trevisani, Angelo Zelante, Sergio Sartori, Digestive Endoscopy Unit, Department of Medicine, University Hospital "S. Anna", 44124 Cona (FE), Italy.
NR 0
TC 0
SN 1948-519
EI 1948-519
J9 World J Gastrointest Endosc
PD JUN 17
PY 2014
VL 6
IS 6
BP 227
EP 33
DI 10.4253/wjge.v6.i6.227
PG -194
UT PubMed:24932374
PM 24932374
DA 2014-06-17
ER

PT J
AU Yu, JN
   Guo, CQ
   Hu, B
   Liu, NG
   Sun, HM
   Xu, H
   Wu, HX
   Guo, Y
   Liang, CX
   Chen, ZX
   Li, XH
AF Yu, Jia Ni
   Guo, Chang Qing
   Hu, Bo
   Liu, Nai Gang
   Sun, Hong Mei
   Xu, Hong
   Wu, Hai Xia
   Guo, Yan
   Liang, Chu Xi
   Chen, Zhan Xia
   Li, Xiao Hong
TI Effects of Acupuncture Knife on Inflammatory Factors and Pain in Third Lumbar Vertebrae Transverse Process Syndrome Model Rats
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID growth-factor-beta; substance-p; neuroinflammation
AB The aim of this paper was to explore the long-term effects and pain relief mechanism of acupuncture knife on third lumbar vertebrae (L-3) transverse process syndrome. Forty SD rats were randomized into control, model, electroacupuncture (EA), and acupuncture knife (AK) group. Except control rats, other rats were subjected to an operation to emulate L-3 transverse process syndrome. Fourteen days after the operation, EA and AK rats were given electroacupuncture and acupuncture knife treatments, respectively. Fifty-six days after the operation, enzyme-linked immunosorbent assay was used to measure substance P (SP), 5-hydroxytryptamine (5-HT), interleukin-1 beta (IL-1 beta), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta) in peripheral blood. The tail flick test was used to observe pain threshold. We found that rats with the simulation operation had significantly higher levels of SP, 5-HT, IL-1, IL-10, TNF-alpha, and TGF-beta, while the AK rats had lower levels. In addition, the pain threshold of AK rats was similar to that of control rats. AK pretreatment could alleviate pain through modulating inflammatory response.
C1 [Yu, Jia Ni; Guo, Chang Qing; Guo, Yan; Liang, Chu Xi; Chen, Zhan Xia; Li, Xiao Hong] Beijing Univ Chinese Med, Sch Acupuncture & Moxibust, Beijing 100029, Peoples R China.
   [Hu, Bo] Beijing Shuili Hosp, Acupuncture & Moxibust & Physiotherapy Dept, Beijing 100036, Peoples R China.
   [Liu, Nai Gang] China Japan Friendship Hosp, Acupuncture & Moxibust Dept, Beijing 100029, Peoples R China.
   [Sun, Hong Mei; Xu, Hong; Wu, Hai Xia] Beijing Univ Chinese Med, Sch Basic Med Sci, Beijing 100029, Peoples R China.
C3 Beijing University of Chinese Medicine; China-Japan Friendship Hospital; Beijing University of Chinese Medicine
RP Guo, CQ (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture & Moxibust, 11 North 3rd Ring East Rd, Beijing 100029, Peoples R China.
EM guochangqing818@163.com
CR Bardin L, 2011, BEHAV PHARMACOL, V22, P390, DOI 10.1097/FBP.0b013e328349aae4
   Bie BH, 2011, EUR J PHARMACOL, V670, P495, DOI 10.1016/j.ejphar.2011.09.004
   Chen NF, 2013, J PAIN, V14, P1671, DOI 10.1016/j.jpain.2013.08.010
   de Avila ED, 2014, J INVESTIG CLIN DENT, V5, P91, DOI 10.1111/jicd.12087
   de Goeij M, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0084159
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Ferjan I, 2013, MEDIAT INFLAMM, V2013, P0, DOI 10.1155/2013/340473
   Guo CQ, 2012, J CHENGDU U CHINESE, V35, P20
   Guo Chang-Qing, 2012, ZHONGGUO ZHEN JIU, V32, P617
   Hu Bo, 2008, ZHEN CI YAN JIU, V33, P22
   Lantero A, 2012, MOL NEUROBIOL, V45, P76, DOI 10.1007/s12035-011-8221-1
   Liu QH, 2013, SPINE, V38, P1443, DOI 10.1097/BRS.0b013e31828fc6b7
   Milligan ED, 2006, PAIN, V126, P294, DOI 10.1016/j.pain.2006.07.009
   Muñoz M, 2014, AMINO ACIDS, V46, P1727, DOI 10.1007/s00726-014-1736-9
   Ni CM, 1992, J ANHUI MED U, V27, P11
   Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234
   Shah JP, 2008, ARCH PHYS MED REHAB, V89, P16, DOI 10.1016/j.apmr.2007.10.018
   [孙红梅 SUN Hongmei], 2008, 北京中医药大学学报 JOURNAL OF BEIJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V31, P176
   [王健瑞 Wang Jianrui], 2003, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V25, P394
   Willemen HLDM, 2014, J PAIN, V15, P496, DOI 10.1016/j.jpain.2014.01.491
   Witt KL, 2014, CLIN ANAT, V27, P451, DOI 10.1002/ca.22120
   Zhu YH, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-65
NR 22
TC 14
Z9 17
U1 0
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/892406
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AW5CS
UT WOS:000346294100001
PM 25544854
DA 2026-01-16
ER

PT J
AU Axelsson, CK
   Ballegaard, S
   Karpatschof, B
   Schousen, P
AF Axelsson, Christen K
   Ballegaard, Søren
   Karpatschof, Benny
   Schousen, Peer
TI Pressure pain sensitivity as a marker for stress and pressure pain
SO Scandinavian journal of clinical and laboratory investigation
LA English
DT Journal Article
DE Acupuncture; EORTC questionnaire; HADS questionnaire; SF 36 questionnaire; acupressure; clinical stress score; patient education; self-evaluated stress
AB OBJECTIVES: To validate (1) Pressure Pain Sensitivity (PPS) as a marker for  stress and (2) a PPS-guided intervention in women with primary Breast Cancer  (BC). METHODS: (1) A total of 58 women with BC were examined before and after 6  months of intervention. A control group of 165 women office employees was divided  in a High Stress Group (HSG, n = 37) and a Low Stress Group (LSG, n = 128) to  evaluate the association between PPS, questionnaire-related Quality of Life (QOL)  and self-evaluated stress. (2) A PPS-guided stress management program (n = 40)  was compared to a Psychosocial Group Intervention (PGI, n = 91) and no treatment  (n = 86) with respect to a European Organization for Research and Treatment of  Cancer (EORTC) questionnaire measured QOL. RESULTS: (1) Resting PPS and changes  in PPS during the intervention period correlated significantly to EORTC and Short  Form 36 (SF 36) main scores: (all p < 0.05). Between BC, HSG and LSG there was a  significant and positive correlation with respect to PPS, SF 36 main scores,  depression, and clinical stress scores (all p < 0.05). However, the BC group  scored significantly lower than both HSG and LSG (both p < 0.05) with respect to  self-evaluated stress. (2) The PPS-guided intervention group improved EORTC main  score, pain and nausea, when compared to the control groups (all p < 0.05).  CONCLUSIONS: PPS was positively associated with QOL, which was in contrast to  self-evaluated stress. PPS-guided intervention improved QOL in women with breast  cancer.
C1 Department of Breast Surgery, Herlev Hospital, Herlev, University of Copenhagen , Denmark.
NR 0
TC 0
SN 1502-768
EI 
J9 Scand J Clin Lab Invest
PD APR 5
PY 2014
VL 74
IS 5
BP 399
EP 407
DI 10.3109/00365513.2014.900187
PG 8
WC Breast Neoplasms; physiopathology; Case-Control Studies; Cross-Sectional Studies; Disease Management; Female; Humans; Male; Pain Threshold; Patient Compliance; Pressure; Quality of Life; Stress, Psychological; diagnosis; Surveys and Questionnaires
UT PubMed:24697620
PM 24697620
DA 2014-04-05
ER

PT J
AU Chien, TJ
   Liu, CY
   Hsu, CH
AF Chien, Tsai-Ju
   Liu, Chia-Yu
   Hsu, Chung-Hua
TI Integrating acupuncture into cancer care.
SO Journal of traditional and complementary medicine
LA English
DT Review
DE Acupuncture; Cancer; Oncology
AB Oncology acupuncture has become a new and promising field of research because  more and more cancer patients have sought non-pharmacological alternatives for  symptom management. While different mechanisms have been proposed to explain its  efficacy, including theories of the neural system, endocrine cytokine or  immunological regulation, its eventual role has become that of alleviating the  side effects induced by chemotherapy or radiotherapy. In this paper, we have  reviewed the related articles focusing on acupuncture mechanisms and applications  in cancer care to provide a quick sketch of acupuncture in cancer care. A  detailed search was performed to identify the randomized controlled trials (RCTs)  and systematic reviews on acupuncture in oncology, using PUBMED and Cochrane. The  search terms included: Acupuncture, acupressure, and cancer. Additional terms  were used to target specific symptoms (i.e., breast cancer, hot flash,  xerostomia, nausea, vomiting, cancer pain, insomnia, fatigue). Two authors  independently extracted data for analysis and review. Ultimately, 25 articles  underwent full-text review. Recent trials made efforts in studying (a) hot  flashes in breast cancer, (b) xerostomia induced by radiotherapy in head and neck  cancer, (c) nausea and vomiting post-chemotherapy, (d) cancer pain, and (e)  fatigue and insomnia in cancer patients. Controversial results for acupuncture  application in cancer care appeared in different categories, but a trend emerged  that acupuncture can palliate cancer-related symptoms. The research to date  certainly offers us a valid complementary therapy in treating cancer-related  symptoms. Meanwhile, practical strategies with safe measures for enhancing the  efficacy are needed in further interventions, as well as continuing research with  a validated methodology.
C1 Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. 
   Department of Internal Medicine, Division of Hemato-Oncology, Branch ofZhong-xing, Taipei City Hospital, Taipei, Taiwan.
   Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. 
   Department of Traditional Chinese Medicine,Branch of Linsen and ChineseMedicine, Taipei City Hospital, Taipei, Taiwan. 
   Taiwan InternationalTraditional Chinese Medicine Training Center, Taiwan.
   Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan. 
   Department of Traditional Chinese Medicine,Branch of Linsen and ChineseMedicine, Taipei City Hospital, Taipei, Taiwan. 
   Taiwan InternationalTraditional Chinese Medicine Training Center, Taiwan.
NR 0
TC 0
SN 2225-411
EI 2225-411
J9 J Tradit Complement Med
PD APR 10
PY 2014
VL 3
IS 4
BP 234
EP 9
DI 10.4103/2225-4110.119733
PG -225
UT PubMed:24716183
PM 24716183
DA 2014-04-10
ER

PT J
AU Garcia, MK
   Cohen, L
   Guo, Y
   Zhou, Y
   You, B
   Chiang, J
   Orlowski, RZ
   Weber, D
   Shah, J
   Alexanian, R
   Thomas, S
   Romaguera, J
   Zhang, L
   Badillo, M
   Chen, Y
   Wei, Q
   Lee, R
   Delasalle, K
   Green, V
   Wang, M
AF Garcia, M Kay
   Cohen, Lorenzo
   Guo, Ying
   Zhou, Yuhong
   You, Bing
   Chiang, Joseph
   Orlowski, Robert Z
   Weber, Donna
   Shah, Jatin
   Alexanian, Raymond
   Thomas, Sheeba
   Romaguera, Jorge
   Zhang, Liang
   Badillo, Maria
   Chen, Yiming
   Wei, Qi
   Lee, Richard
   Delasalle, Kay
   Green, Vivian
   Wang, Michael
TI Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in
SO Journal of hematology & oncology
LA English
DT Journal Article
AB BACKGROUND: This single-arm study evaluated feasibility, safety, and initial  efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral  neuropathy (PN) in cancer patients with multiple myeloma. METHODS: Patients with  neuropathy ≥ grade 2 received 20 acupuncture treatments over 9 weeks. RESULTS:  For the 19 evaluable patients, Functional Assessment of Cancer  Therapy/Gynecological Oncology Group-Neurotoxicity (FACT/GOG/NTX) mean (SD)  scores improved significantly between baseline and week 13 (20.8 [9.6] vs 13.2  [8.5], p = 0.0002). Moderate effect size differences began on week 4, with the  largest effect size differences found at week 9 for FACT/GOG/NTX scores, worst  pain in the last 24 hours, and pain severity (Cohen's d = 1.43, 1.19, and 1.08,  respectively) and continuing through week 13 (Cohen's d = 0.86, 0.88, and 0.90,  respectively). From baseline to week 13, additional significant improvements were  seen as follows: postural stability (1.0 [0.6] vs 0.8 [0.4], p = 0.02); coin test  (10.0 [7.4] vs 5.6 [1.9], p < 0.0001); button test (96.1 [144.4] vs 54.9 [47.3],  p < 0.0001); and walking test (21.6 [10.0] vs 17.2 [7.7], p = 0.0003). No  significant changes were seen with NCS. CONCLUSIONS: Acupuncture may help  patients experiencing thalidomide- or bortezomib-induced PN. Larger, randomized,  clinical trials are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier:  NCT00891618.
C1 Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, Texas 77030, USA.miwang@mdanderson.org.
NR 0
TC 0
SN 1756-872
EI 
J9 J Hematol Oncol
PD JUN 3
PY 2014
VL 7
IS 
BP 41
EP 41
DI 10.1186/1756-8722-7-41
PG 0
WC Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; Boronic Acids; administration & dosage; Bortezomib; Electroacupuncture; methods; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; drug therapy; Pain Measurement; methods; Peripheral Nervous System Diseases; chemically induced; Pyrazines; administration & dosage; Thalidomide; administration & dosage; Time Factors; Treatment Outcome
UT PubMed:24886772
PM 24886772
DA 2014-06-03
ER

PT J
AU Cai, GW
   Li, J
   Xu, XJ
   Xue, YZ
   Li, G
   Wu, M
   Li, PF
AF Cai, Guo-Wei
   Li, Jing
   Xu, Xiao-Juan
   Xue, Yuan-Zhi
   Li, Gang
   Wu, Man
   Li, Peng-Fei
TI [Clinical research on warm acupuncture therapy for pain in postmenopausal
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
AB OBJECTIVE: To observe the clinical efficacy on pain in postmenopausal  osteoporosis treated with the warm acupuncture therapy and discuss its effect  mechanism. METHODS: Ninety cases of postmenopausal osteoporosis were randomized  into a warm acupuncture group, an electroacupuncture group and a medication  group, 30 cases in each group. In the warm acupuncture group and the  electroacupuncture group, Dazhu (BL 11), Shenshu (BL 23) and Xuanzhong (GB 39)  were selected bilaterally and stimulated with the warm acupuncture and  electroacupuncture therapies respectively, once a day for 30 days totally. In the  medication group, caltrate-D tablets were prescribed, 600 mg, once a day for 30  days totally. The changes in the bone density T value, visual analogue scale  (VAS) score, serum insulin like growth factor 1 (IGF-1), interleukin 6 (IL-6) and  tumor necrosis factor (TNF-alpha) were observed before and after treatment in the  three groups. RESULTS: (1) The bone density T value in the patients of  postmenopausal osteoporosis did not change obviously after 30 days treatment with  the three therapies; (2) VAS score was all reduced after treatment, in which, the  result in the warm acupuncture group was the most obvious (6.73 +/- 0.24 before  treatment vs 4.43 +/- 0.26 after treatment). The value after treatment in the  warm acupuncture group was different significantly as compared with the  electroacupuncture group (5.13 +/- 0.31) and the medication group (5.17 +/- 0.33,  both P < 0.05). (3) The level of serum IGF-1 was improved after treatment in the  warm acupuncture therapy [(119.5 +/- 20.1) ng/mL before treatment vs (156.5 +/-  23.9) ng/mL after treatment], which was more apparent as compared with the  electroacupuncture group [(136.3 +/- 24.5) ng/mL] and the medication group  [(127.7 +/- 22.1) ng/mL, all P < 0.05]. Concerning to reducing the levels of IL-6  and TNF-alpha in serum, the results in the warm acupuncture group were superior  to the other two groups (all P < 0.05). CONCLUSION: The warm acupuncture therapy  achieves the significant efficacy on pain in postmenopausal osteoporosis, which  could be related to increasing the level of IGF-1, decreasing the levels of IL-6  and TNF-alpha, promoting bone formation and inhibting bone absorption.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAR 29
PY 2014
VL 34
IS 1
BP 25
EP 7
DI 
PG -18
WC Acupuncture Therapy; methods; Bone Density; Female; Humans; Insulin-Like Growth Factor I; metabolism; Interleukin-6; blood; Middle Aged; Osteoporosis, Postmenopausal; blood; Pain Management; Tumor Necrosis Factor-alpha; blood
UT PubMed:24673048
PM 24673048
DA 2014-03-29
ER

PT J
AU Lee, JH
   Li, DX
   Yoon, H
   Go, D
   Quan, FS
   Min, BI
   Kim, SK
AF Lee, Ji-Hye
   Li, Dong Xing
   Yoon, Heera
   Go, Donghyun
   Quan, Fu Shi
   Min, Byung-Il
   Kim, Sun Kwang
TI Serotonergic mechanism of the relieving effect of bee venom acupuncture on oxaliplatin-induced neuropathic cold allodynia in rats
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Bee venom acupuncture; Cold allodynia; Oxaliplatin; Rat; Serotonin
ID induced peripheral neuropathy; receptor subtypes; 5-ht3 receptors; pain; stimulation; model; transmission; antinociception; chemotherapy; apipuncture
AB Background: Oxaliplatin, an important chemotherapy drug for advanced colorectal cancer, often induces peripheral neuropathy, especially cold allodynia. Our previous study showed that bee venom acupuncture (BVA), which has been traditionally used in Korea to treat various pain symptoms, potently relieves oxaliplatin-induced cold allodynia in rats. However, the mechanism for this anti-allodynic effect of BVA remains poorly understood. We investigated whether and how the central serotonergic system, a well-known pathway for acupuncture analgesia, mediates the relieving effect of BVA on cold allodynia in oxaliplatin-injected rats. Methods: The behavioral signs of cold allodynia in Sprague-Dawley (SD) rats were induced by a single injection of oxaliplatin (6 mg/kg, i.p.). Before and after BVA treatment, the cold allodynia signs were evaluated by immersing the rat's tail into cold water (4 degrees C) and measuring the withdrawal latency. For BVA treatment, a diluted BV (0.25 mg/kg) was subcutaneously administered into Yaoyangguan (GV3) acupoint, which is located between the spinous processes of the fourth and the fifth lumbar vertebra. Serotonin was depleted by a daily injection of DL-p-chlorophenylalanine (PCPA, 150 mg/kg, i.p.) for 3 days. The amount of serotonin in the spinal cord was measured by ELISA. Serotonergic receptor antagonists were administered intraperitoneally or intrathecally before BVA treatment. Results: The serotonin levels in the spinal cord were significantly increased by BVA treatment and such increase was significantly reduced by PCPA. This PCPA pretreatment abolished the relieving effect of BVA on oxaliplatin-induced cold allodynia. Either of methysergide (mixed 5-HT1/5-HT2 receptor antagonist, 1 mg/kg, i.p.) or MDL-72222 (5-HT3 receptor antagonist, 1 mg/kg, i.p) blocked the anti-allodynic effect of BVA. Further, an intrathecal injection of MDL-72222 (12 mu g) completely blocked the BVA-induced anti-allodynic action, whereas NAN-190 (5-HT1A receptor antagonist, 15 mu g, i.t.) or ketanserin (5-HT2A receptor antagonist, 30 mu g, i.t.) did not. Conclusions: These results suggest that BVA treatment alleviates oxaliplatin-induced acute cold allodynia in rats via activation of the serotonergic system, especially spinal 5-HT3 receptors. Thus, our findings may provide a clinically useful evidence for the application of BVA as an alternative therapeutic option for the management of peripheral neuropathy, a dose-limiting side effect that occurs after an administration of oxaliplatin.
C1 [Lee, Ji-Hye; Go, Donghyun; Min, Byung-Il; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 130701, South Korea.
   [Li, Dong Xing; Yoon, Heera; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 130701, South Korea.
   [Quan, Fu Shi] Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 130701, South Korea.
   [Min, Byung-Il] Kyung Hee Univ, Sch Med, Dept Physiol, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 130701, South Korea.
EM skkim77@khu.ac.kr
FU National Research Foundation of Korea (NRF) grant - Korea government [NRF-2013R1A1A1012403]
CR AIMONE LD, 1987, PAIN, V31, P123, DOI 10.1016/0304-3959(87)90012-1
   Argyriou AA, 2013, EUR J NEUROL, V20, P788, DOI 10.1111/ene.12061
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Bardin L, 1997, EXP BRAIN RES, V113, P81, DOI 10.1007/BF02454144
   Bardin L, 2011, BEHAV PHARMACOL, V22, P390, DOI 10.1097/FBP.0b013e328349aae4
   Bilge SS, 2012, EUR J PHARMACOL, V681, P44, DOI 10.1016/j.ejphar.2012.01.043
   BILLINGHAM ME, 1973, NATURE, V245, P163, DOI 10.1038/245163a0
   Broomand A, 2009, J NEGAT RESULTS BIOM, V8, P0, DOI 10.1186/1477-5751-8-2
   De la Calle JL, 2002, BRAIN RES BULL, V59, P245, DOI 10.1016/S0361-9230(02)00866-3
   Giordano James, 2004, PAIN PHYSICIAN, V7, P141
   GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x
   HAMMOND DL, 1984, BRAIN RES, V298, P329, DOI 10.1016/0006-8993(84)91432-X
   Jeong HJ, 2012, BRIT J PHARMACOL, V165, P1956, DOI 10.1111/j.1476-5381.2011.01685.x
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kang SY, 2011, BRAIN RES BULL, V86, P412, DOI 10.1016/j.brainresbull.2011.08.012
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Kim YI, 1997, NEUROREPORT, V8, P2149, DOI 10.1097/00001756-199707070-00011
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/36932424058370
   Ling B, 2008, NEUROPHARMACOLOGY, V55, P724, DOI 10.1016/j.neuropharm.2008.06.007
   Ling B, 2007, TOXICOLOGY, V234, P176, DOI 10.1016/j.tox.2007.02.013
   Maleki N, 2005, INT IMMUNOPHARMACOL, V5, P1723, DOI 10.1016/j.intimp.2005.05.012
   Mannelli LD, 2013, J PAIN, V14, P1585, DOI 10.1016/j.jpain.2013.08.002
   MJELLEM N, 1993, BRAIN RES, V626, P78, DOI 10.1016/0006-8993(93)90565-5
   Moon HJ, 2014, J PHYSIOL SCI, V64, P151, DOI 10.1007/s12576-013-0297-0
   NA HS, 1994, NEUROSCI LETT, V177, P50, DOI 10.1016/0304-3940(94)90042-6
   Paul D, 2001, J PHARMACOL EXP THER, V298, P674
   Radhakrishnan R, 2003, PAIN, V105, P205, DOI 10.1016/S0304-3959(03)00207-0
   Renn CL, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-29
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Sasaki M, 2001, EUR J PHARMACOL, V424, P45, DOI 10.1016/S0014-2999(01)01117-7
   SCHMAUSS C, 1983, EUR J PHARMACOL, V90, P349, DOI 10.1016/0014-2999(83)90556-3
   SOLOMON RE, 1989, J PHARMACOL EXP THER, V251, P27
   SOMERFIELD SD, 1988, J RHEUMATOL, V15, P1878
   Wilson RH, 2002, J CLIN ONCOL, V20, P1767, DOI 10.1200/JCO.2002.07.056
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Xie DJ, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-58
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Yoon SY, 2013, BIOL PHARM BULL, V36, P1787, DOI 10.1248/bpb.b13-00469
   Zedan AH, 2014, CLIN COLORECTAL CANC, V13, P73, DOI 10.1016/j.clcc.2013.11.004
   Zhu JX, 2001, J PHYSIOL-LONDON, V530, P431, DOI 10.1111/j.1469-7793.2001.0431k.x
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 45
TC 38
Z9 44
U1 1
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6882
EI 
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD DEC 6
PY 2014
VL 14
IS 
BP 
EP 
DI 10.1186/1472-6882-14-471
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AX0WM
UT WOS:000346670600002
PM 25481535
DA 2026-01-16
ER

PT J
AU Cheon, S
   Zhang, X
   Lee, IS
   Cho, SH
   Chae, Y
   Lee, H
AF Cheon, Soyeon
   Zhang, Xiuyu
   Lee, In-Seon
   Cho, Seung-Hun
   Chae, Younbyoung
   Lee, Hyangsook
TI Pharmacopuncture for cancer care: a systematic review.
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB Background. Pharmacopuncture, injection to acupoints with pharmacological  medication or herbal medicine, is a new acupuncture therapy widely available in  Korea and China for cancer-related symptoms. However, the evidence is yet to be  clear. Objective. To determine pharmacopuncture's effectiveness on cancer-related  symptoms. Methods. Eleven databases were searched for randomized controlled  trials of pharmacopuncture in cancer patients. The Cochrane risk of bias (ROB)  assessment tool was used for quality assessment. Results. Twenty-two studies  involving 2,459 patients were included. Five trials of chemotherapy-induced  nausea and vomiting (CINV) underwent meta-analysis. Pharmacopuncture  significantly relieved severity of CINV compared with control group (3 trials,  risk ratio (RR) 1.28, 95% confidence interval (CI) = 1.14-1.44). The frequency of  CINV was also significantly reduced with pharmacopuncture (2 trials, RR 2.47, 95%  CI = 2.12-2.89). Seventeen trials studied various symptoms, and in most studies,  pharmacopuncture significantly relieved pain, ileus, hiccup, fever, and  gastrointestinal symptoms and improved quality of life in various cancer  patients. ROB was generally high. Conclusion. It may be suggested with caution  that pharmacopuncture may help various symptom relief in cancer patients, but it  is hard to draw a firm conclusion due to clinical heterogeneity and high ROB of  the included studies, hence warranting further investigation.
C1 Department of Korean Medical Science, Graduate School, Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republic of Korea ;Acupuncture and Meridian Science Research Center, College of Korean Medicine,Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republicof Korea.
   Department of Korean Medical Science, Graduate School, Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republic of Korea ;Acupuncture and Meridian Science Research Center, College of Korean Medicine,Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republicof Korea.
   Department of Korean Medical Science, Graduate School, Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republic of Korea ;Acupuncture and Meridian Science Research Center, College of Korean Medicine,Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republicof Korea.
   Hospital of Korean Medicine, Kyung Hee University Medical Center, Kyung Hee Dae-ro 23, Dongdaemun-gu, Seoul 130-701, Republic of Korea.
   Department of Korean Medical Science, Graduate School, Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republic of Korea ;Acupuncture and Meridian Science Research Center, College of Korean Medicine,Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republicof Korea.
   Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University, Kyung Hee Dae-ro 26, Dongdaemun-gu, Seoul 130-701, Republicof Korea.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD JUN 6
PY 2014
VL 2014
IS 
BP 804746
EP 804746
DI 10.1155/2014/804746
PG 0
UT PubMed:24899911
PM 24899911
DA 2014-06-06
ER

PT J
AU Garcia, MK
   Cohen, L
   Guo, Y
   Zhou, YH
   You, B
   Chiang, J
   Orlowski, RZ
   Weber, D
   Shah, J
   Alexanian, R
   Thomas, S
   Romaguera, J
   Zhang, L
   Badillo, M
   Chen, YM
   Wei, Q
   Lee, R
   Delasalle, K
   Green, V
   Wang, M
AF Garcia, M. Kay
   Cohen, Lorenzo
   Guo, Ying
   Zhou, Yuhong
   You, Bing
   Chiang, Joseph
   Orlowski, Robert Z.
   Weber, Donna
   Shah, Jatin
   Alexanian, Raymond
   Thomas, Sheeba
   Romaguera, Jorge
   Zhang, Liang
   Badillo, Maria
   Chen, Yiming
   Wei, Qi
   Lee, Richard
   Delasalle, Kay
   Green, Vivian
   Wang, Michael
TI Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Acupuncture; Myeloma; Chemotherapy; Peripheral neuropathy; Integrative medicine
ID randomized controlled-trial; acupuncture treatment; bortezomib; placebo; dexamethasone; management; therapy; pain; cipn
AB Background: This single-arm study evaluated feasibility, safety, and initial efficacy of electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy (PN) in cancer patients with multiple myeloma. Methods: Patients with neuropathy >= grade 2 received 20 acupuncture treatments over 9 weeks. Results: For the 19 evaluable patients, Functional Assessment of Cancer Therapy/Gynecological Oncology Group-Neurotoxicity (FACT/GOG/NTX) mean (SD) scores improved significantly between baseline and week 13 (20.8 [9.6] vs 13.2 [8.5], p = 0.0002). Moderate effect size differences began on week 4, with the largest effect size differences found at week 9 for FACT/GOG/NTX scores, worst pain in the last 24 hours, and pain severity (Cohen's d = 1.43, 1.19, and 1.08, respectively) and continuing through week 13 (Cohen's d = 0.86, 0.88, and 0.90, respectively). From baseline to week 13, additional significant improvements were seen as follows: postural stability (1.0 [0.6] vs 0.8 [0.4], p = 0.02); coin test (10.0 [7.4] vs 5.6 [1.9], p < 0.0001); button test (96.1 [144.4] vs 54.9 [47.3], p < 0.0001); and walking test (21.6 [10.0] vs 17.2 [7.7], p = 0.0003). No significant changes were seen with NCS. Conclusions: Acupuncture may help patients experiencing thalidomide- or bortezomib-induced PN. Larger, randomized, clinical trials are needed. Trial registration: ClinicalTrials.gov Identifier: NCT00891618.
C1 [Garcia, M. Kay; Cohen, Lorenzo; Wei, Qi; Lee, Richard] Univ Texas MD Anderson Canc Ctr, Integrat Med Program, Houston, TX 77030 USA.
   [Guo, Ying] Univ Texas MD Anderson Canc Ctr, Dept Rehabil Med, Houston, TX 77030 USA.
   [Zhou, Yuhong] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China.
   [You, Bing] Amer Coll Acupuncture & Oriental Med, Houston, TX 77063 USA.
   [Chiang, Joseph] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA.
   [Orlowski, Robert Z.; Weber, Donna; Shah, Jatin; Alexanian, Raymond; Thomas, Sheeba; Romaguera, Jorge; Zhang, Liang; Badillo, Maria; Chen, Yiming; Delasalle, Kay; Green, Vivian; Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA.
   [Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Fudan University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, 1515 Holcombe Blvd,Unit 0429, Houston, TX 77030 USA.
EM miwang@mdanderson.org
FU Millennium Pharmaceuticals, Inc; Marvin Kimmel Research Funds at MD Anderson Cancer Center; National Cancer Institute [P50 CA142509, U10 CA032102]; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Argyriou AA, 2008, BLOOD, V112, P1593, DOI 10.1182/blood-2008-04-149385
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Atkinson TM, 2010, PAIN MED, V11, P337, DOI 10.1111/j.1526-4637.2009.00774.x
   Buschbacher RM, 2005, MANUAL OF NERVE CONDUCTION STUDIES, V0, P0
   Cavo M, 2012, BLOOD, V120, P9, DOI 10.1182/blood-2012-02-408898
   Chang SA, 2005, INT J CARDIOL, V104, P241, DOI 10.1016/j.ijcard.2004.12.035
   Dedman P, 1998, MANUAL ACUPUNCTURE E, V0, P0
   Deng L, 1997, CHINESE ACUPUNCTURE, V0, P0
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Jiang Hequn, 2006, J TRADIT CHIN MED, V26, P8
   Johnson DC, 2011, J CLIN ONCOL, V29, P797, DOI 10.1200/JCO.2010.28.0792
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kaufmann H, 2004, BLOOD, V104, P2269, DOI 10.1182/blood-2004-03-1091
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   MacPherson H, 2004, QUAL SAF HEALTH CARE, V13, P349, DOI 10.1136/qshc.2003.009134
   Mittleman E, 2000, J AM VET MED ASSOC, V217, P1201, DOI 10.2460/javma.2000.217.1201
   Peuker E, 2001, ACUPUNCT MED, V19, P103
   Phillips KD, 2004, J ALTERN COMPLEM MED, V10, P449, DOI 10.1089/1075553041323678
   Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X
   Richardson PG, 2012, LEUKEMIA, V26, P595, DOI 10.1038/leu.2011.346
   Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shiflett SC, 2011, EXPLORE-NY, V7, P148, DOI 10.1016/j.explore.2011.02.004
   Su J W, 2007, SINGAPORE MED J, V48, P0
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Umapathi T, 2005, CURR OPIN NEUROL, V18, P574, DOI 10.1097/01.wco.0000180158.34713.aa
   Velasco R, 2010, J PERIPHER NERV SYST, V15, P17, DOI 10.1111/j.1529-8027.2010.00248.x
   Wang Yu-ping, 2005, ZHONGGUO ZHEN JIU, V25, P542
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 40
TC 49
Z9 56
U1 3
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-8722
EI 
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD MAY 9
PY 2014
VL 7
IS 
BP 
EP 
DI 10.1186/1756-8722-7-41
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA AK7DF
UT WOS:000338585700001
PM 24886772
DA 2026-01-16
ER

PT J
AU Zhang, RX
   Lao, LX
   Ren, K
   Berman, BM
AF Zhang, Ruixin
   Lao, Lixing
   Ren, Ke
   Berman, Brian M.
TI Mechanisms of Acupuncture-Electroacupuncture on Persistent Pain
SO ANESTHESIOLOGY
LA English
DT Review
ID spinal dorsal-horn; anterior cingulate cortex; induced inflammatory pain; tumor-necrosis-factor; peripheral electrical-stimulation; metabotropic glutamate receptors; low-frequency electroacupuncture; corticotropin-releasing hormone; randomized controlled-trial; irritable-bowel-syndrome
AB In the last decade, preclinical investigations of electroacupuncture mechanisms on persistent tissue injury (inflammatory), nerve injury (neuropathic), cancer, and visceral pain have increased. These studies show that electroacupuncture activates the nervous system differently in health than in pain conditions, alleviates both sensory and affective inflammatory pain, and inhibits inflammatory and neuropathic pain more effectively at 2 to 10 Hz than at 100 Hz. Electroacupuncture blocks pain by activating a variety of bioactive chemicals through peripheral, spinal, and supraspinal mechanisms. These include opioids, which desensitize peripheral nociceptors and reduce proinflammatory cytokines peripherally and in the spinal cord, and serotonin and norepinephrine, which decrease spinal N-methyl-d-aspartate receptor subunit GluN1 phosphorylation. Additional studies suggest that electroacupuncture, when combined with low dosages of conventional analgesics, provides effective pain management which can forestall the side effects of often-debilitating pharmaceuticals.
C1 [Zhang, Ruixin; Lao, Lixing; Berman, Brian M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA.
   [Ren, Ke] Univ Maryland, Sch Dent, Dept Neural & Pain Sci, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore
RP Zhang, RX (corresponding author), Ctr Integrat Med, 685 W Baltimore St,MSTF Rm 8-22, Baltimore, MD 21201 USA.
EM rzhan001@umaryland.edu
FU National Center for Complementary and Alternative Medicine at the National Institutes of Health, Bethesda, Maryland [P01AT002605, R21AT005474]
CR Anand P, 2009, BRAIN RES REV, V60, P255, DOI 10.1016/j.brainresrev.2008.12.003
   Baek YH, 2005, BRAIN RES, V1057, P181, DOI 10.1016/j.brainres.2005.07.014
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Beaudry H, 2011, J NEUROSCI, V31, P13068, DOI 10.1523/JNEUROSCI.1817-11.2011
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   BESSE D, 1990, BRAIN RES, V521, P15, DOI 10.1016/0006-8993(90)91519-M
   Binder W, 2004, EUR J NEUROSCI, V20, P92, DOI 10.1111/j.1460-9568.2004.03459.x
   Bonnet MP, 2008, ANESTH ANALG, V106, P1142, DOI 10.1213/ane.0b013e318165de89
   Cabot PJ, 1997, J CLIN INVEST, V100, P142, DOI 10.1172/JCI119506
   Carpenter KJ, 2000, PAIN, V85, P433, DOI 10.1016/S0304-3959(99)00301-2
   Cha MH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/792765
   Cha MH, 2010, NEUROL RES, V32, PS96, DOI 10.1179/016164109X12537002794363
   Chang KH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/324039
   CHAO CC, 1993, INT J IMMUNOPHARMACO, V15, P447, DOI 10.1016/0192-0561(93)90057-6
   Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012
   Chen WH, 2011, J BIOMED SCI, V18, P0, DOI 10.1186/1423-0127-18-82
   Chen XH, 1998, NEUROPHARMACOLOGY, V37, P751, DOI 10.1016/S0028-3908(98)00028-8
   CHENG RSS, 1981, BRAIN RES, V215, P77
   Chiechio S, 2012, CURR OPIN PHARMACOL, V12, P28, DOI 10.1016/j.coph.2011.10.010
   Choe ES, 2006, NEUROSCI LETT, V394, P246, DOI 10.1016/j.neulet.2005.10.072
   Choi BT, 2005, ACTA HISTOCHEM, V107, P67, DOI 10.1016/j.acthis.2004.07.008
   Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014
   Choi IS, 2012, BRIT J PHARMACOL, V167, P356, DOI 10.1111/j.1476-5381.2012.01964.x
   Chu D, 2011, INT J COLORECTAL DIS, V26, P569, DOI 10.1007/s00384-010-1087-2
   Chu HC, 2012, NEUROL RES, V34, P871, DOI 10.1179/1743132812Y.0000000085
   Chu WCW, 2012, J NEUROGASTROENTEROL, V18, P305, DOI 10.5056/jnm.2012.18.3.305
   Cidral FJ, 2011, NEUROSCIENCE, V193, P370, DOI 10.1016/j.neuroscience.2011.07.076
   CRAIN SM, 1995, P NATL ACAD SCI USA, V92, P10540, DOI 10.1073/pnas.92.23.10540
   Cui KM, 2005, NEUROSCI LETT, V376, P20, DOI 10.1016/j.neulet.2004.11.018
   Dai Y, 2001, J PAIN, V2, P151, DOI 10.1054/jpai.2001.19964
   Delvaux M, 1998, ALIMENT PHARM THER, V12, P849, DOI 10.1046/j.1365-2036.1998.00375.x
   Dong ZQ, 2006, BRAIN RES BULL, V69, P30, DOI 10.1016/j.brainresbull.2005.08.027
   Dong ZQ, 2005, NEUROSCI LETT, V385, P189, DOI 10.1016/j.neulet.2005.05.051
   Dong ZQ, 2005, NEUROSCI LETT, V376, P143, DOI 10.1016/j.neulet.2004.11.044
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Fillingim RB, 2009, J PAIN, V10, P447, DOI 10.1016/j.jpain.2008.12.001
   Fioravanti B, 2008, CURR TOP MED CHEM, V8, P1442, DOI 10.2174/156802608786264227
   Flatters SJL, 2006, PAIN, V122, P245, DOI 10.1016/j.pain.2006.01.037
   Fu X, 2007, NEUROSCIENCE, V144, P275, DOI 10.1016/j.neuroscience.2006.09.016
   Fu X, 2006, BRAIN RES, V1078, P212, DOI 10.1016/j.brainres.2006.01.026
   Fu X, 2007, PEPTIDES, V28, P1220, DOI 10.1016/j.peptides.2007.03.022
   Gim GT, 2011, BRAIN RES BULL, V86, P403, DOI 10.1016/j.brainresbull.2011.09.010
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gong S, 1992, SHENG LI XUE BAO, V44, P434
   Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hara K, 1999, ANESTH ANALG, V89, P422, DOI 10.1097/00000539-199908000-00032
   Heinisch S, 2011, BRAIN BEHAV IMMUN, V25, P360, DOI 10.1016/j.bbi.2010.10.020
   Honda K, 2004, NEUROSCI LETT, V371, P235, DOI 10.1016/j.neulet.2004.09.003
   Honda K, 2003, BIOL PHARM BULL, V26, P1178
   Huang C, 2007, BRAIN RES BULL, V71, P447, DOI 10.1016/j.brainresbull.2006.11.008
   Humes DJ, 2012, NEUROGASTROENT MOTIL, V24, P318
   Hutchinson AJP, 2012, J ORTHOP SURG RES, V7, P0, DOI 10.1186/1749-799X-7-36
   Hwang BG, 2002, NEUROSCI LETT, V320, P49, DOI 10.1016/S0304-3940(02)00027-7
   HYLDEN JLK, 1991, EUR J PHARMACOL, V194, P135, DOI 10.1016/0014-2999(91)90097-A
   Institute of Medicine (US) Committee on Advancing, 2011, PAIN RES CAR ED REL, V0, P0
   Jang JY, 2011, INT J MOL MED, V28, P669, DOI 10.3892/ijmm.2011.728
   Jensen TS, 1997, ACTA ANAESTH SCAND, V41, P123, DOI 10.1111/j.1399-6576.1997.tb04626.x
   Jhaveri MD, 2007, BRIT J PHARMACOL, V152, P624, DOI 10.1038/sj.bjp.0707433
   [姬广臣 Ji Guangchen], 2003, 针刺研究 ACUPUNCTURE RESEARCH, V28, P111
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Kapitzke Daniel, 2005, THER CLIN RISK MANAG, V1, P279
   Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170
   KELLSTEIN DE, 1988, PAIN, V34, P85, DOI 10.1016/0304-3959(88)90185-6
   Keszthelyi D, 2012, EUR J PAIN, V16, P1444, DOI 10.1002/j.1532-2149.2012.00147.x
   Kim HN, 2012, BRAIN RES BULL, V87, P199, DOI 10.1016/j.brainresbull.2011.11.010
   Kim HY, 2009, PAIN, V145, P332, DOI 10.1016/j.pain.2009.06.035
   Kim HJ, 2012, EVID BASED COMPLEMEN, V2012, P0
   Kim HW, 2008, BRAIN RES BULL, V75, P698, DOI 10.1016/j.brainresbull.2007.11.015
   Kim JH, 2011, J NEUROPHYSIOL, V105, P2050, DOI 10.1152/jn.00853.2010
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim SK, 2005, EXP NEUROL, V195, P430, DOI 10.1016/j.expneurol.2005.06.018
   Kim SK, 2007, BRAIN RES BULL, V74, P357, DOI 10.1016/j.brainresbull.2007.07.006
   Kimura K, 2006, AM J CHINESE MED, V34, P189, DOI 10.1142/S0192415X06003758
   Koo ST, 2002, PAIN, V99, P423, DOI 10.1016/S0304-3959(02)00164-1
   Koo ST, 2008, PAIN, V135, P11, DOI 10.1016/j.pain.2007.04.034
   LaGraize SC, 2006, EXP NEUROL, V197, P22, DOI 10.1016/j.expneurol.2005.05.008
   Lao LX, 2004, BRAIN RES, V1020, P18, DOI 10.1016/j.brainres.2004.01.092
   Lau WK, 2008, NEUROSCIENCE, V155, P463, DOI 10.1016/j.neuroscience.2008.06.016
   Lee G, 2002, NEUROSCI LETT, V325, P17, DOI 10.1016/S0304-3940(02)00214-8
   Lee GS, 2003, BRAIN RES BULL, V62, P161, DOI 10.1016/j.brainresbull.2003.09.007
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Lee JH, 2006, AM J CHINESE MED, V34, P981, DOI 10.1142/S0192415X06004454
   Li A, 2011, EVID BASED COMPLEMEN, V2011, P0
   Li A, 2007, BRAIN RES, V1186, P171, DOI 10.1016/j.brainres.2007.10.022
   Li Aihui, 2007, BMC COMPLEMENT ALTERN MED, V7, P27
   Li AH, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-20
   Li CH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/102987
   Li TT, 2009, PAIN, V146, P183, DOI 10.1016/j.pain.2009.07.027
   Li XH, 2001, J PHARMACOL EXP THER, V299, P939
   Liang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/568273
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Lin Ya-Ping, 2009, ZHEN CI YAN JIU, V34, P252
   Liu B, 2005, BRAIN RES, V1044, P87, DOI 10.1016/j.brainres.2005.03.006
   Liu PY, 2012, GASTROENTEROLOGY, V142, P165, DOI 10.1053/j.gastro.2011.09.041
   Ma Cheng, 2008, ZHEN CI YAN JIU, V33, P250
   Ma XP, 2009, WORLD J GASTROENTERO, V15, P5211, DOI 10.3748/wjg.15.5211
   Maneepak M, 2009, HEADACHE, V49, P375, DOI 10.1111/j.1526-4610.2009.01341.x
   Martin G, 1997, J NEUROSCI, V17, P11, DOI 10.1523/JNEUROSCI.17-01-00011.1997
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   Mayer DJ, 2000, PROG BRAIN RES, V122, P457
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Meng XZ, 2013, OPEN PAIN J, V6, P183, DOI 10.2174/1876386320130624001
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Mi WL, 2011, J PAIN, V12, P974, DOI 10.1016/j.jpain.2011.03.002
   Mogil JS, 2012, NAT REV NEUROSCI, V13, P859, DOI 10.1038/nrn3360
   Mousa SA, 2007, NEUROPSYCHOPHARMACOL, V32, P2530, DOI 10.1038/sj.npp.1301393
   Mousa SA, 2010, BRAIN BEHAV IMMUN, V24, P1310, DOI 10.1016/j.bbi.2010.06.008
   Munro G, 2007, EUR J PHARMACOL, V575, P66, DOI 10.1016/j.ejphar.2007.07.062
   Özaktay AC, 2006, EUR SPINE J, V15, P1529, DOI 10.1007/s00586-005-0058-8
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Park JH, 2009, J PHYSIOL SCI, V59, P291, DOI 10.1007/s12576-009-0035-9
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Pereira EAC, 2013, NEUROSURGERY, V60, P178, DOI 10.1227/01.neu.0000432766.67364.eb
   Pettersen VLA, 2009, ANESTH ANALG, V109, P1312, DOI 10.1213/ane.0b013e3181b16ff5
   Pettersson LME, 2002, BRAIN RES, V945, P266, DOI 10.1016/S0006-8993(02)02817-2
   Pu L, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/818451
   Qi De-bo, 2012, ZHONG XI YI JIE HE XUE BAO, V10, P416
   Qu SS, 2013, J PSYCHIATR RES, V47, P726, DOI 10.1016/j.jpsychires.2013.02.004
   Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036
   Roh DH, 2008, ANESTH ANALG, V107, P693, DOI 10.1213/ane.0b013e31817e7319
   Rong PJ, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1093/ecam/nep103
   Rutten K, 2011, EUR J PAIN, V15, P299, DOI 10.1016/j.ejpain.2010.07.011
   Salazar-Colocho P, 2007, J PHYSIOL BIOCHEM, V63, P203, DOI 10.1007/BF03165783
   Sangdee Chaichan, 2002, BMC COMPLEMENT ALTERN MED, V2, P3, DOI 10.1186/1472-6882-2-3
   Sanoja R, 2010, EUR J PAIN, V14, P0, DOI 10.1016/j.ejpain.2009.04.006
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x
   Sekido R, 2004, AM J CHINESE MED, V32, P269, DOI 10.1142/S0192415X04001928
   Sekido R, 2003, AM J CHINESE MED, V31, P955, DOI 10.1142/S0192415X03001491
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   Shi TF, 2011, NEUROCHEM RES, V36, P129, DOI 10.1007/s11064-010-0281-5
   Shimoyama M, 2012, PHARMACOLOGY, V89, P145, DOI 10.1159/000336770
   Shinoda M, 2008, J PAIN, V9, P687, DOI 10.1016/j.jpain.2008.02.007
   Silva JRT, 2011, J PAIN, V12, P51, DOI 10.1016/j.jpain.2010.04.008
   Simpson J, 2009, NEUROGASTROENT MOTIL, V21, P847, DOI 10.1111/j.1365-2982.2009.01308.x
   Sluka KA, 2002, J PHARMACOL EXP THER, V302, P1146, DOI 10.1124/jpet.102.033167
   Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd
   Song MJ, 2009, BRAIN RES BULL, V78, P335, DOI 10.1016/j.brainresbull.2008.10.009
   Song ZY, 2011, PAIN, V152, P1666, DOI 10.1016/j.pain.2011.03.012
   Stone LS, 1999, NEUROSCIENCE, V93, P1399, DOI 10.1016/S0306-4522(99)00209-2
   Su TF, 2012, EUR J PAIN, V16, P624, DOI 10.1002/j.1532-2149.2011.00055.x
   Su TF, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-98
   Sudo RT, 2010, J PAIN, V11, P71, DOI 10.1016/j.jpain.2009.08.001
   Sun RQ, 2004, EXP NEUROL, V187, P23, DOI 10.1016/j.expneurol.2003.12.011
   Sun Rui-Qing, 2002, ZHONGGUO YING YONG SHENG LI XUE ZA ZHI, V18, P128
   Sun S, 2008, BRAIN RES BULL, V75, P83, DOI 10.1016/j.brainresbull.2007.07.027
   Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x
   Taguchi R, 2010, BRAIN RES, V1355, P97, DOI 10.1016/j.brainres.2010.08.014
   Takasu K, 2011, J PAIN, V12, P1130, DOI 10.1016/j.jpain.2011.04.003
   TAKESHIGE C, 1992, BRAIN RES BULL, V29, P617, DOI 10.1016/0361-9230(92)90131-G
   Tang NM, 1997, PAIN, V71, P71, DOI 10.1016/S0304-3959(97)03341-1
   Tao YX, 2010, ANESTHESIOLOGY, V112, P1259, DOI 10.1097/ALN.0b013e3181d3e1ed
   Tian L, 2003, WORLD J GASTROENTERO, V9, P1028
   Torigoe K, 2012, ANESTHESIOLOGY, V116, P159, DOI 10.1097/ALN.0b013e31823c7e56
   Tsuchioka M, 2008, J NEUROCHEM, V106, P244, DOI 10.1111/j.1471-4159.2008.05357.x
   Vas J, 2004, BMJ-BRIT MED J, V329, P1216, DOI 10.1136/bmj.38238.601447.3A
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Vidal-Torres A, 2012, J PHARMACOL SCI, V120, P129, DOI 10.1254/jphs.12105SC
   Wang KL, 2010, COMPLEMENT THER MED, V18, P249, DOI 10.1016/j.ctim.2010.09.005
   Wang LN, 2006, BRAIN RES, V1120, P46, DOI 10.1016/j.brainres.2006.08.077
   Wang YY, 2009, J CHEM NEUROANAT, V38, P75, DOI 10.1016/j.jchemneu.2009.04.003
   Wang YQ, 2010, ACUPUNCTURE THERAPY FOR NEUROLOGICAL DISEASES: A NEUROBIOLOGICAL VIEW, V0, PP194, DOI 10.1007/978-3-642-10857-0_8
   Wang ZY, 2010, PAIN, V151, P194, DOI 10.1016/j.pain.2010.07.006
   Watkins LR, 2003, NAT REV DRUG DISCOV, V2, P973, DOI 10.1038/nrd1251
   White JPM, 2010, ANESTHESIOLOGY, V112, P729, DOI 10.1097/ALN.0b013e3181ca3179
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Wu HG, 2008, DIGEST DIS SCI, V53, P1644, DOI 10.1007/s10620-007-0062-4
   Wu HG, 2009, NEUROSCI LETT, V465, P235, DOI 10.1016/j.neulet.2009.09.018
   Wu Justin Cy, 2010, J NEUROGASTROENTEROL MOTIL, V16, P306, DOI 10.5056/jnm.2010.16.3.306
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Xu GY, 2009, NEUROGASTROENT MOTIL, V21, P0
   Xu KD, 2010, CHINESE MED J-PEKING, V123, P1176, DOI 10.3760/cma.j.issn.0366-6999.2010.09.014
   Xu QH, 2011, CURR OPIN ANESTHESIO, V24, P400, DOI 10.1097/ACO.0b013e32834871df
   Xu QH, 2011, J NEUROSCI, V31, P2113, DOI 10.1523/JNEUROSCI.2139-10.2011
   Yan Li-ping, 2011, ZHEN CI YAN JIU, V36, P353
   Yan LP, 2011, ZHEN CI YAN JIU, V36, P379
   Yang EJ, 2011, RHEUMATOL INT, V31, P725, DOI 10.1007/s00296-010-1364-y
   Yi M, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-61
   YONEHARA N, 1992, NEUROSCI LETT, V142, P53, DOI 10.1016/0304-3940(92)90618-H
   Yoo YC, 2011, YONSEI MED J, V52, P1016, DOI 10.3349/ymj.2011.52.6.1016
   Yoshida N, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-41
   Yu JB, 2013, ANESTH ANALG, V116, P239, DOI 10.1213/ANE.0b013e31826f0a4a
   Zhang GG, 2005, EXPLORE-NY, V1, P365, DOI 10.1016/j.explore.2005.06.006
   Zhang JL, 2009, EUR J PAIN, V13, P366, DOI 10.1016/j.ejpain.2008.04.016
   Zhang J, 2010, J PAIN, V11, P1250, DOI 10.1016/j.jpain.2010.02.013
   Zhang KM, 1996, BRAIN RES, V719, P229, DOI 10.1016/0006-8993(96)00123-0
   Zhang L, 2011, PAIN, V152, P419, DOI 10.1016/j.pain.2010.11.014
   Zhang LX, 1997, BRAIN RES, V745, P158, DOI 10.1016/S0006-8993(96)01095-5
   Zhang RX, 2008, NEUROSCIENCE, V154, P1533, DOI 10.1016/j.neuroscience.2008.04.072
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2008, PAIN, V135, P232, DOI 10.1016/j.pain.2007.05.023
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang RX, 2005, NEUROSCI LETT, V384, P339, DOI 10.1016/j.neulet.2005.05.001
   Zhang RX, 2005, PHARMACOL BIOCHEM BE, V81, P146, DOI 10.1016/j.pbb.2005.03.002
   Zhang RX, 2005, J ALTERN COMPLEM MED, V11, P135, DOI 10.1089/acm.2005.11.135
   Zhang RX, 2004, PHARMACOL BIOCHEM BE, V78, P793, DOI 10.1016/j.pbb.2004.05.010
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   Zhang X, 2005, MOL BRAIN RES, V138, P264, DOI 10.1016/j.molbrainres.2005.05.001
   Zhang Y, 2012, BRIT J ANAESTH, V109, P245, DOI 10.1093/bja/aes136
   Zhang Y, 2012, EUR J PAIN, V16, P170, DOI 10.1016/j.ejpain.2011.07.002
   Zhang YQ, 2002, PAIN, V99, P525, DOI 10.1016/S0304-3959(02)00268-3
   Zhang Y, 2011, NEUROCHEM RES, V36, P1785, DOI 10.1007/s11064-011-0495-1
   Zhang Y, 2011, BRAIN RES, V1395, P38, DOI 10.1016/j.brainres.2011.04.037
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 207
TC 636
Z9 770
U1 6
U2 376
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB 15
PY 2014
VL 120
IS 2
BP 482
EP 503
DI 10.1097/ALN.0000000000000101
PG 22
WC Anesthesiology
SC Anesthesiology
GA AB1NU
UT WOS:000331559900027
PM 24322588
DA 2026-01-16
ER

PT J
AU Tang, WR
   Chen, WJ
   Yu, CT
   Chang, YC
   Chen, CM
   Wang, CH
   Yang, SH
AF Tang, Woung-Ru
   Chen, Wan-Jung
   Yu, Chih-Teng
   Chang, Yue-Cune
   Chen, Chuan-Mei
   Wang, Chiu-Hua
   Yang, Sien-Hung
TI Effects of acupressure on fatigue of lung cancer patients undergoing chemotherapy: An experimental pilot study
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Fatigue; Acupressure; Experimental study; Lung cancer
ID quality-of-life; sleep quality; acupoint stimulation; alternative medicine; palliative care; management; acupuncture; depression; symptoms; pain
AB Background: This study explored the effects of acupressure on fatigue of lung cancer patients undergoing chemotherapy. Patients and methods: For this experimental study, 57 subjects were randomly assigned to three groups: acupressure with essential oils (n=17), acupressure only (n=24), and sham acupressure (n=16). Acupoints were Hegu (LI4), Zusanli (ST36), and Sanyingjiao (SP6). All subjects received acupressure once every morning for 5 months, with each acupoint pressed for 1 min. Fatigue, functional status, anxiety, depression, and sleep quality were measured before initial chemotherapy (TO), on Day 1 of third chemotherapy (T1), and on Day 1 of sixth chemotherapy (T2). Outcome differences between groups were analyzed at T0, T1, and T2 by general estimating equations. Results: After controlling for baseline outcome values, age, and adherence to acupressure, subjects who received acupressure with essential oils and acupressure had significantly less fatigue in daily living activities and sleep better quality at T1 than subjects who received sham acupressure. Subjects who received acupressure with essential oils had significantly better sleep quality at T2 than the sham acupressure group. Subjects who received acupressure with or without essential oils had greater odds of better functional status at T1 than the sham group. Conclusion: It is plausible that acupressure with or without essential oils helps lung cancer patients undergoing chemotherapy reduce cancer-related fatigue and increase activity level. Further study is wanted to test this hypothesis. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Tang, Woung-Ru; Chen, Wan-Jung; Chen, Chuan-Mei; Wang, Chiu-Hua] Chang Gung Univ, Coll Med, Sch Nursing, Taoyuan, Taiwan.
   [Yu, Chih-Teng] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan.
   [Yu, Chih-Teng] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan.
   [Chang, Yue-Cune] Tamkang Univ, Dept Math, Taipei, Taiwan.
   [Yang, Sien-Hung] Chang Guns Mem Hosp, Dept Tradit Chinese Med, Taoyuan, Taiwan.
   [Yang, Sien-Hung] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Taoyuan, Taiwan.
C3 Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Tamkang University; Chang Gung University
RP Tang, WR (corresponding author), Chang Gung Univ, Coll Med, Sch Nursing, 259 Wen Hwa 1st Rd, Taoyuan, Taiwan.
EM wtang@mail.cgu.edu.tw
FU National Science Council in Taiwan [NMRPD180821]
CR Ahlberg K, 2003, LANCET, V362, P640, DOI 10.1016/S0140-6736(03)14186-4
   Andersson S, 1996, J CHIN MED, V7, P73
   Unknown -, 2012, CANCER FACTS AND FIGURES 2012, V0, P0
   Unknown -, 2008, REV ASI J TRADI MED, V0, P0
   Unknown -, 1999, FORMOS. J. MED, V0, P0
   Buccheri G, 1996, EUR J CANCER, V32A, P1135, DOI 10.1016/0959-8049(95)00664-8
   Butje A, 2008, J PSYCHOSOC NURS MEN, V46, P46, DOI 10.3928/02793695-20081001-12
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5
   Chen ML, 1999, J GERONTOL A-BIOL, V54, PM389, DOI 10.1093/gerona/54.8.M389
   Chen ML, 2000, J ADV NURS, V32, P944, DOI 10.1046/j.1365-2648.2000.01560.x
   Cho Yi-Ching, 2004, J NURS RES, V12, P51
   Chou TL, 2008, THESIS CHANG GUNG U, V0, P0
   COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155
   Cooley ME, 2000, J PAIN SYMPTOM MANAG, V19, P137, DOI 10.1016/S0885-3924(99)00150-5
   Dantzer R, 2012, NAT REV CLIN ONCOL, V9, P414, DOI 10.1038/nrclinonc.2012.88
   Department of Health Executive Yuan, 2011, 2010 MORT CAUS STAT, V0, P0
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   Essential Therapeutics, 2006, ESS THER, V0, P0
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Fitzmaurice GM, 2004, APPL LONGITUDINAL AN, V0, P0
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Goodwin L, 2012, PALLIATIVE MED, V26, P683, DOI 10.1177/0269216311412230
   Hu WY, 2003, J FORMOS MED ASSOC, V102, P97
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kohara Hiroyuki, 2004, J PALLIAT MED, V7, P791, DOI 10.1089/jpm.2004.7.791
   Lang T, 2007, AM J EMERG MED, V25, P887, DOI 10.1016/j.ajem.2007.01.016
   Lee YH, 2008, J CLIN NURS, V17, P876, DOI 10.1111/j.1365-2702.2007.02021.x
   Lin ZG, 2009, NEW COLOR ACUPUNCTUR, V0, P0
   Maa S H, 1997, J CARDIOPULM REHABIL, V17, P268, DOI 10.1097/00008483-199707000-00008
   Maa SH, 2007, J CLIN NURS, V16, P794, DOI 10.1111/j.1365-2702.2005.01515.x
   Manning H L, 2000, RESPIR CARE, V45, P1342
   Miaskowski Christine, 2004, J NATL CANCER INST MONOGR, V0, P17
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   MOSS IR, 1986, PEDIATR PULM, V2, P114, DOI 10.1002/ppul.1950020211
   Mystakidou K, 2007, J PSYCHOSOM RES, V62, P527, DOI 10.1016/j.jpsychores.2006.11.008
   National Comprehensive Cancer Network, 2010, NCCN GUID PAT, V0, P0
   Ng T, 2012, J PALLIAT MED, V15, P863, DOI 10.1089/jpm.2011.0417
   Osborn CE, 2001, COMPLEMENT THER MED, V9, P62, DOI 10.1054/ctim.2001.0433
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Shariati A, 2012, COMPLEMENT THER MED, V20, P417, DOI 10.1016/j.ctim.2012.08.001
   SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344
   TABONA MVZ, 1982, THORAX, V37, P834, DOI 10.1136/thx.37.11.834
   Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P417, DOI 10.1016/S0885-3924(02)00376-7
   Tang WR, 2010, J CLIN NURS, V19, P69, DOI 10.1111/j.1365-2702.2009.02959.x
   Tian JH, 2010, AM J CHINESE MED, V38, P15, DOI 10.1142/S0192415X10007646
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Tsay SL, 2004, AM J CHINESE MED, V32, P407, DOI 10.1142/S0192415X04002065
   Umezu T, 2001, PHARMACOL BIOCHEM BE, V69, P383, DOI 10.1016/S0091-3057(01)00543-3
   Wang GL, 2011, PSYCHO-ONCOLOGY, V20, P639, DOI 10.1002/pon.1952
   Wang RC, 2007, J PAIN SYMPTOM MANAG, V33, P32, DOI 10.1016/j.jpainsymman.2006.06.013
   Xu ZY, 2011, J CANCER RES CLIN, V137, P1117, DOI 10.1007/s00432-011-0975-3
   Yeh Chien-Ching, 2007, HU LI ZA ZHI, V54, P5
   Yip YB, 2004, COMPLEMENT THER MED, V12, P28, DOI 10.1016/j.ctim.2003.12.003
   Zick SM, 2011, EVID BASED COMPLEM A, V165, P1
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 63
TC 58
Z9 64
U1 2
U2 38
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD AUG 15
PY 2014
VL 22
IS 4
BP 581
EP 591
DI 10.1016/j.ctim.2014.05.006
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AO6MG
UT WOS:000341465600001
PM 25146059
DA 2026-01-16
ER

PT J
AU Bao, T
   Goloubeva, O
   Pelser, C
   Porter, N
   Primrose, J
   Hester, L
   Sadowska, M
   Lapidus, R
   Medeiros, M
   Lao, LX
   Dorsey, SG
   Badros, AZ
AF Bao, Ting
   Goloubeva, Olga
   Pelser, Colleen
   Porter, Neil
   Primrose, James
   Hester, Lisa
   Sadowska, Mariola
   Lapidus, Rena
   Medeiros, Michelle
   Lao, Lixing
   Dorsey, Susan G.
   Badros, Ashraf Z.
TI A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy in Patients With Multiple Myeloma
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; bortezomib; peripheral neuropathy; multiple myeloma
ID cytokine production; phase-iii; pain; neurotoxicity; score; reversibility; validation; asthma; growth; trial
AB Background. Peripheral neuropathy is the dose limiting toxicity of bortezomib in patients with multiple myeloma (MM). Objectives. To examine the safety, feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral neuropathy (BIPN) symptoms. Methods. Patients with MM experiencing persistent BIPN >= grade 2 despite adequate medical intervention and discontinuation of bortezomib received 10 acupuncture treatments for 10 weeks (2x/week for 2 weeks, 1x/week for 4 weeks, and then biweekly for 4 weeks). Responses were assessed by the Clinical Total Neuropathy Score (TNSc), Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire, and the Neuropathy Pain Scale (NPS). Repeated-measures analysis of variance was used to test for monotonic decline in scores on each of the measures. Serial serum levels of proinflammatory and neurotrophic cytokines were obtained at baseline and weeks 1, 2, 4, 8, and 14. Results. Twenty-seven patients with MM were enrolled in the trial. There were no adverse events associated with the acupuncture treatments. TNSc data were deemed invalid and therefore were not reported. At weeks 10 and 14, FACT/GOG-Ntx and NPS showed significant reduction suggesting decreased pain, and improved function (P values were <.0001 for both FACT/GOG-Ntx and NPS at weeks 10 and 14). However, nerve conduction studies did not significantly change between baseline assessment and end of study. There was no correlation in serum cytokines for responders versus none responders. Conclusions. Acupuncture is safe, feasible and produces subjective improvements in patients' symptoms. A follow-up randomized controlled trial is warranted.
C1 [Bao, Ting; Goloubeva, Olga; Pelser, Colleen; Porter, Neil; Primrose, James; Hester, Lisa; Sadowska, Mariola; Lapidus, Rena; Medeiros, Michelle; Lao, Lixing; Dorsey, Susan G.; Badros, Ashraf Z.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore
RP Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med & Breast Oncol Serv, 1429 First Ave, New York, NY 10021 USA.
EM baot@mskcc.org
FU [NCI K12 CA126849];  [R21 CA173263];  [NINR P30NR011396]
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Ahn Andrew C, 2007, ACUPUNCT MED, V25, P11
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Argyriou AA, 2008, BLOOD, V112, P1593, DOI 10.1182/blood-2008-04-149385
   Arnulf B, 2012, HAEMATOL-HEMATOL J, V97, P1925, DOI 10.3324/haematol.2012.067793
   Arrieta O, 2011, NEUROLOGY, V77, P987, DOI 10.1212/WNL.0b013e31822e045c
   Badros A, 2007, CANCER-AM CANCER SOC, V110, P1042, DOI 10.1002/cncr.22921
   Bao T, 2012, MED ACUPUNCT, V24, P181, DOI 10.1089/acu.2011.0868
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beijing College of Traditional Chinese Medicine, 1979, ESS CHIN AC, V0, P0
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Cata JP, 2007, J PAIN, V8, P296, DOI 10.1016/j.jpain.2006.09.014
   Cavaletti G, 2006, J PERIPHER NERV SYST, V11, P135, DOI 10.1111/j.1085-9489.2006.00078.x
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   Cavaletti G, 2010, LEUKEMIA LYMPHOMA, V51, P1178, DOI 10.3109/10428194.2010.483303
   Cornblath DR, 1999, NEUROLOGY, V53, P1660, DOI 10.1212/WNL.53.8.1660
   Fishbain DA, 2008, PAIN MED, V9, P149, DOI 10.1111/j.1526-4637.2007.00302.x
   Galantino MLA, 1999, J ALTERN COMPLEM MED, V5, P135, DOI 10.1089/acm.1999.5.135
   Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332
   Henry NL, 2011, CANCER-AM CANCER SOC, V117, P5469, DOI 10.1002/cncr.26230
   Hideshima T, 2001, CANCER RES, V61, P3071
   Jensen MP, 2006, CLIN J PAIN, V22, P97, DOI 10.1097/01.ajp.0000173018.64741.62
   Jeong HJ, 2003, AM J CHINESE MED, V31, P945, DOI 10.1142/S0192415X03001661
   Jeong HJ, 2002, IMMUNOPHARM IMMUNOT, V24, P265, DOI 10.1081/IPH-120003759
   Joos S, 2000, J ALTERN COMPLEM MED, V6, P519, DOI 10.1089/acm.2000.6.519
   Manni L, 2011, ARCH ITAL BIOL, V149, P247, DOI 10.4449/aib.v149i2.1365
   Petti Filomena Bangrazi, 2002, J TRADIT CHIN MED, V22, P104
   Qiu M L, 1993, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779
   Richardson PG, 2009, BRIT J HAEMATOL, V144, P895, DOI 10.1111/j.1365-2141.2008.07573.x
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Shi Q, 2013, J CLIN ONCOL S, V31, P0
   Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37
   Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467
   Wang XM, 2012, CYTOKINE, V59, P3, DOI 10.1016/j.cyto.2012.03.027
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wu HG, 1999, WORLD J GASTROENTERO, V5, P515
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 39
TC 45
Z9 52
U1 0
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2014
VL 13
IS 5
BP 396
EP 404
DI 10.1177/1534735414534729
PG 9
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA AN6QB
UT WOS:000340719500003
PM 24867959
DA 2026-01-16
ER

PT J
AU An, LX
   Chen, X
   Ren, XJ
   Wu, HF
AF An, Li-Xin
   Chen, Xue
   Ren, Xiu-Jun
   Wu, Hai-Feng
TI Electro-Acupuncture Decreases Postoperative Pain and Improves Recovery in Patients Undergoing a Supratentorial Craniotomy
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Electro-Acupuncture; Supratentorial Craniotomy; Postoperative Pain; Appetite; Dizziness
ID acupuncture analgesia; stimulation
AB We performed this study to examine the effect of electro-acupuncture (EA) on postoperative pain, postoperative nausea and vomiting (PONV) and recovery in patients after a supratentorial tumor resection. Eighty-eight patients requiring a supratentorial tumor resection were anesthetized with sevoflurane and randomly allocated to a no treatment group (Group C) or an EA group (Group A). After anesthesia induction, the patients in Group A received EA at LI4 and SJ5, at BL63 and LR3 and at ST36 and GB40 on the same side as the craniotomy. The stimulation was continued until the end of the operation. Patient-controlled intravenous analgesia (PCIA) was used for the postoperative analgesia. The postoperative pain scores, PONV, the degree of dizziness and appetite were recorded. In the first 6 hours after the operation, the mean total bolus, the effective times of PCIA bolus administrations and the VAS scores were much lower in the EA group (p < 0: 05). In the EA group, the incidence of PONV and degree of dizziness and feeling of fullness in the head within the first 24 hours after the operation was much lower than in the control group (p < 0: 05). In the EA group, more patients had a better appetite than did the patients in group C (51.2% vs. 27.5%) (p < 0: 05). The use of EA in neurosurgery patients improves the quality of postoperative analgesia, promotes appetite recovery and decreases some uncomfortable sensations, such as dizziness and feeling of fullness in the head.
C1 [An, Li-Xin] Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesia, Beijing 100050, Peoples R China.
   [Chen, Xue] Beijing Jishuitan Hosp, Dept Anesthesia, Beijing 100035, Peoples R China.
   [Ren, Xiu-Jun] Beijing Univ Tradit Chinese Med, Dept Acupuncture, Beijing 100029, Peoples R China.
   [Wu, Hai-Feng] Capital Med Univ, Dept Epidemiol & Biostat, Beijing 100069, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine; Capital Medical University
RP An, LX (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesia, 6 Tiantan Xili, Beijing 100050, Peoples R China.
EM anlixin8120@163.com
FU National Basic Research Program of China (973 Program) [2007CB512503]
CR An Li-xin, 2010, ZHONGGUO ZHEN JIU, V30, P669
   An Li-Xin, 2010, ZHEN CI YAN JIU, V35, P368
   Angster R, 2005, ANAESTHESIST, V54, P505, DOI 10.1007/s00101-005-0838-x
   Bilotta F, 2013, CURR OPIN ANAESTHESI, V0, P29
   Chernyak G, 2005, ANESTH ANALG, V100, P387, DOI 10.1213/01.ANE.0000142114.72117.E0
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Dong ZQ, 2013, AM J CHINESE MED, V41, P459, DOI 10.1142/S0192415X1350033X
   Grube T, 2009, SCHMERZ, V23, P370, DOI 10.1007/s00482-009-0798-1
   Han JS, 1997, ACUPUNCT RES, V26, P97
   Imaev A A, 2013, ZH VOPR NEIROKHIR IM N N BURDENKO, V77, P54
   Kumnerddee W, 2012, AM J CHINESE MED, V40, P1167, DOI 10.1142/S0192415X12500863
   Langenbach MR, 2012, COLORECTAL DIS, V14, PE486, DOI 10.1111/j.1463-1318.2012.02984.x
   Leung L, 2012, J ACUPUNCT MERIDIAN, V5, P261, DOI 10.1016/j.jams.2012.07.017
   Lin JG, 2009, AM J CHINESE MED, V37, P1
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Liodden I, 2013, CURR OPIN ANAESTHESI, V0, P21
   Lv JQ, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-153
   Pang WW, 2013, PAIN MED, V14, P1426, DOI 10.1111/pme.12166
   Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031
   Wang XQ, 2010, J NEUROSURG ANESTH, V22, P128, DOI 10.1097/ANA.0b013e3181c9fbde
   Yang CX, 2012, ACUPUNCTURE ELECTRO, V37, P125, DOI 10.3727/036012912X13831831256249
   Yang MX, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-311
   Yeh Mei-Ling, 2010, ACTA ANAESTHESIOL TAIWAN, V48, P80, DOI 10.1016/S1875-4597(10)60018-5
NR 24
TC 58
Z9 65
U1 0
U2 27
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2014
VL 42
IS 5
BP 1099
EP 1109
DI 10.1142/S0192415X14500682
PG 11
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA AQ1TA
UT WOS:000342562800004
PM 25169910
DA 2026-01-16
ER

PT J
AU Jiang, SH
   Tu, WZ
   Zou, EM
   Hu, J
   Wang, S
   Li, JR
   Wang, WS
   He, R
   Cheng, RD
   Liao, WJ
AF Jiang, Song-he
   Tu, Wen-zhan
   Zou, En-miao
   Hu, Jie
   Wang, Sai
   Li, Jiang-ru
   Wang, Wan-sheng
   He, Rong
   Cheng, Rui-dong
   Liao, Wei-jing
TI Neuroprotective Effects of Different Modalities of Acupuncture on Traumatic Spinal Cord Injury in Rats
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID functional recovery; electroacupuncture; stimulation; inflammation; inhibition; pain
AB Spinal cord injury (SCI) can induce a series of histological, biochemical, and functional changes. Acupuncture is commonly used for SCI patients. Using male rats of spinal cord injury with the New York University (NYU)Impactor, we investigated the response of electroacupuncture ( EA), manual acupuncture ( MA), and transcutaneous acupoint electrical stimulation (TAES)at Shuigou (DU26)and Fengfu (DU16) acupoints to understand the effects and mechanisms of acupuncture in neuroprotection and neuronal function recovery after SCI. Histological study showed a restored neural morphology and an increase in the quantity of neurons after EA, MA, and TAES administrations. Acupuncture's antioxidation effects were demonstrated by alleviation of the post-SCI superoxide dismutase (SOD) activity increase and malondialdehyde (MDA) level decrease. The anti-inflammation effect of acupuncture was shown as the reduced expression of inflammatory cytokines including interleukin-1 beta (IL-1 beta), interleukin-6 ( IL-6), and tumor necrosis factor-alpha (TNF-alpha) when SCI was treated. And the antiapoptosis role was approved by TUNEL staining. Our data confirmed that the role of acupuncture in neuroprotection and dorsal neuronal function recovery after rat SCI, especially, EA stimulating at Shuigou (DU26) and Fengfu (DU16) can greatly promote neuronal function recovery, which may result from antioxidation, anti-inflammation, and antiapoptosis effects of acupuncture.
C1 [Jiang, Song-he; Liao, Wei-jing] Wuhan Univ, Zhongnan Hosp, Dept Phys Med & Rehabil, Wuhan 430072, Hubei, Peoples R China.
   [Tu, Wen-zhan; Zou, En-miao; Hu, Jie; Wang, Sai; Wang, Wan-sheng; He, Rong] Wenzhou Med Univ, Dept Phys Med & Rehabil, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China.
   [Li, Jiang-ru] Zhejiang Hosp, Dept Rehabil Med, Hangzhou, Zhejiang, Peoples R China.
   [Cheng, Rui-dong] Zhejiang Prov Peoples Hosp, Dept Rehabil Med, Hangzhou, Zhejiang, Peoples R China.
C3 Wuhan University; Wenzhou Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital
RP Liao, WJ (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Phys Med & Rehabil, Donghu Rd, Wuhan 430072, Hubei, Peoples R China.
EM weijingliao@sina.com
FU Natural Science Foundation of Zhejiang province, China [Y12H270010]; Science and Technical Foundation of Wenzhou City, China [Y20110069]
CR Becker Daniel, 2012, HANDB CLIN NEUROL, V109, P445, DOI 10.1016/B978-0-444-52137-8.00028-0
   Celik EC, 2012, SPINAL CORD, V50, P585, DOI 10.1038/sc.2012.26
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   David S, 2012, INT REV NEUROBIOL, V106, P127, DOI 10.1016/B978-0-12-407178-0.00006-5
   David Samuel, 2012, HANDB CLIN NEUROL, V109, P485, DOI 10.1016/B978-0-444-52137-8.00030-9
   Ding Y, 2011, CELL TRANSPLANT, V20, P475, DOI 10.3727/096368910X528102
   Huang SF, 2011, NEUROSCI RES, V70, P294, DOI 10.1016/j.neures.2011.03.010
   Hui KKKS, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-2
   Jarosz Renata, 2012, TOP SPINAL CORD INJ REHABIL, V18, P315, DOI 10.1310/sci1804-315
   Jayaraman A, 2013, EUR J APPL PHYSIOL, V113, P191, DOI 10.1007/s00421-012-2429-2
   Jiang S-h, 2008, CLINICAL RESEARCH APPLICATION OF ACUPUNCTURE TUINA, V0, P0
   Jiang Y, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0066815
   Johansson J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0054357
   Khalatbary AR, 2012, IRAN RED CRESCENT ME, V14, P229
   Lee JY, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0073948
   Li WJ, 2012, NEUROCHEM INT, V61, P1397, DOI 10.1016/j.neuint.2012.10.002
   Li WJ, 2010, NEUROSCI RES, V67, P307, DOI 10.1016/j.neures.2010.04.012
   Li Y, 2010, CHIN J TRAUMATOL, V13, P356, DOI 10.3760/cma.j.issn.1008-1275.2010.06.007
   Litscher G, 2009, EVID-BASED COMPL ALT, V6, P153, DOI 10.1093/ecam/nem145
   Lu ZH, 2010, CHIN J INTEGR MED, V16, P229, DOI 10.1007/s11655-010-0229-6
   Markandaya M, 2012, CURRENT TREATMENT OP, V0, P0
   Mekhail M, 2012, PROG NEUROBIOL, V96, P322, DOI 10.1016/j.pneurobio.2012.01.008
   Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734
   Munce SEP, 2013, SYST REV-LONDON, V2, P0, DOI 10.1186/2046-4053-2-14
   Ng MML, 2003, J ALTERN COMPLEM MED, V9, P641, DOI 10.1089/107555303322524490
   Hoang NS, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-141
   Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x
   Smith PD, 2012, CIRCULATION, V126, PS110, DOI 10.1161/CIRCULATIONAHA.111.080275
   Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6
   Young W, 2002, PROG BRAIN RES, V137, P231
   Zhou F, 2011, J APPL PHYSIOL, V111, P1877, DOI 10.1152/japplphysiol.00313.2011
NR 32
TC 42
Z9 52
U1 1
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/431580
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AE8DV
UT WOS:000334230400001
PM 24803946
DA 2026-01-16
ER

PT J
AU Molassiotis, A
   Russell, W
   Hughes, J
   Breckons, M
   Lloyd-Williams, M
   Richardson, J
   Hulme, C
   Brearley, SG
   Campbell, M
   Garrow, A
   Ryder, WD
AF Molassiotis, Alexander
   Russell, Wanda
   Hughes, John
   Breckons, Matthew
   Lloyd-Williams, Mari
   Richardson, Janet
   Hulme, Claire
   Brearley, Sarah G.
   Campbell, Malcolm
   Garrow, Adam
   Ryder, W. David
TI The Effectiveness of Acupressure for the Control and Management of Chemotherapy-Related Acute and Delayed Nausea: A Randomized Controlled Trial
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Acupressure; nausea; vomiting; chemotherapy
ID acustimulation wrist bands; postchemotherapy nausea; cancer-chemotherapy; induced emesis; acupuncture; oncology; p6; stimulation; antiemetics; prophylaxis
AB Context. Both positive and negative results have been reported in the literature from the use of acupressure at the P6 point, providing evidence of highly suggestive but not conclusive results. Objectives. To clarify whether acupressure is effective in the management of chemotherapy-related nausea and vomiting. Methods. A randomized, three-group, sham-controlled trial was designed. Patients with cancer receiving chemotherapy were randomized to receive standardized antiemetics and acupressure wristbands, sham acupressure wristbands, or antiemetics alone. Primary outcome assessment (nausea) was carried out daily for seven days per chemotherapy cycle over four cycles. Secondary outcomes included vomiting, psychological distress, and quality of life. Results. Five hundred patients were randomized. Primary outcome analysis (nausea in Cycle 1) revealed no statistically significant differences between the three groups, although nausea levels in the proportion of patients using wristbands (both real and sham) were somewhat lower than those in the proportion of patients using antiemetics-only group. Adjusting for gender, age, and emetic risk of chemotherapy, the odds ratio of lower nausea experience was 1.18 and 1.42 for the acupressure and sham acupressure groups, respectively. A gender interaction effect was evident (P = 0.002). No significant differences were detected in relation to vomiting, anxiety, and quality-of-life measures. Conclusion. No clear recommendations can be made about the use of acupressure wristbands in the management of chemotherapy-related nausea and vomiting as results did not reach statistical significance. However, the study provided evidence of encouraging signals in relation to improved nausea experience and warrants further consideration in both practice and further clinical trials. (C) 2014 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Molassiotis, Alexander; Russell, Wanda; Campbell, Malcolm] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England.
   [Hughes, John; Lloyd-Williams, Mari] Univ Liverpool, Div Primary Care, Acad Palliat & Support Care Studies Grp, Liverpool L69 3BX, Merseyside, England.
   [Breckons, Matthew; Richardson, Janet] Univ Plymouth, Fac Hlth, Plymouth PL4 8AA, Devon, England.
   [Hulme, Claire] Univ Leeds, Leeds Inst Hlth Sci, Acad Unit Hlth Econ, Leeds, W Yorkshire, England.
   [Brearley, Sarah G.] Univ Lancaster, Fac Hlth & Med, Lancaster, England.
   [Garrow, Adam] Univ Salford, Sch Hlth Sci, Manchester, Lancs, England.
   [Ryder, W. David] Christie NHS Fdn Trust, Clin Trials Unit, Manchester, Lancs, England.
C3 University of Manchester; University of Liverpool; University of Plymouth; University of Leeds; Lancaster University; University of Salford; Christie NHS Foundation Trust
RP Molassiotis, A (corresponding author), Univ Manchester, Sch Nursing Midwifery & Social Work, Univ Pl, Manchester M13 9PL, Lancs, England.
EM alex.molassiotis@manchester.ac.uk
FU National Institute for Health Research (NIHR) Health Technology Assessment (HTA) program [07/31/02]
CR Aapro M, 2012, ANN ONCOL, V23, P1986, DOI 10.1093/annonc/mds021
   Alkaissi A, 1999, ACTA ANAESTH SCAND, V43, P270, DOI 10.1034/j.1399-6576.1999.430306.x
   ANDRYKOWSKI MA, 1992, PSYCHOSOM MED, V54, P48, DOI 10.1097/00006842-199201000-00007
   Unknown -, 1999, AM J HEALTH-SYST PH, V56, P729
   Bergkvist K, 2006, EUR J ONCOL NURS, V10, P21, DOI 10.1016/j.ejon.2005.03.007
   Dibble S L, 2000, ONCOL NURS FORUM, V27, P41
   Dibble SL, 2007, ONCOL NURS FORUM, V34, P815, DOI 10.1188/07.ONF.813-820
   DUBOIS A, 1992, EUR J CANCER, V28A, P450, DOI 10.1016/S0959-8049(05)80075-9
   DUNDEE JW, 1987, LANCET, V1, P1083
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   DUNDEE JW, 1990, J ROY SOC MED, V83, P360, DOI 10.1177/014107689008300608
   DUNDEE JW, 1991, J ROY SOC MED, V84, P210, DOI 10.1177/014107689108400409
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Fairclough DL, 1996, QUAL LIFE RES, V5, P321, DOI 10.1007/BF00433916
   Foubert Jan, 2005, EUR J ONCOL NURS, V9, P21, DOI 10.1016/j.ejon.2004.03.006
   Glaus A, 2004, SUPPORT CARE CANCER, V12, P708, DOI 10.1007/s00520-004-0662-x
   Griffin AM, 1996, ANN ONCOL, V7, P189
   Grunberg Steven M, 2004, J SUPPORT ONCOL, V2, P1
   Ihbe-Heffinger A, 2004, ANN ONCOL, V15, P526, DOI 10.1093/annonc/mdh110
   Kris MG, 2006, J CLIN ONCOL, V24, P2932, DOI 10.1200/JCO.2006.06.9591
   Lee EJ, 2011, J PAIN SYMPTOM MANAG, V42, P589, DOI 10.1016/j.jpainsymman.2011.01.007
   Liau CT, 2005, SUPPORT CARE CANCER, V13, P277, DOI 10.1007/s00520-005-0788-5
   Miller FG, 2009, PERSPECT BIOL MED, V52, P518, DOI 10.1353/pbm.0.0115
   Miller M, 2004, EUR J CANCER CARE, V13, P71, DOI 10.1111/j.1365-2354.2004.00446.x
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2002, SUPPORT CARE CANCER, V10, P139, DOI 10.1007/s00520-001-0321-4
   Molassiotis A, 2007, J PAIN SYMPTOM MANAG, V34, P148, DOI 10.1016/j.jpainsymman.2006.10.018
   MORROW GR, 1991, J PAIN SYMPTOM MANAG, V6, P215, DOI 10.1016/0885-3924(91)90011-R
   Olver I, 2011, SUPPORT CARE CANCER, V19, PS49, DOI 10.1007/s00520-010-1036-1
   Parsons NR, 2006, J ROY STAT SOC C-APP, V55, P507, DOI 10.1111/j.1467-9876.2006.00550.x
   Pearl ML, 1999, CANCER NURS, V22, P307, DOI 10.1097/00002820-199908000-00008
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Rhodes V A, 1999, ONCOL NURS FORUM, V26, P889
   Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078
   Roscoe JA, 2000, J PAIN SYMPTOM MANAG, V20, P113, DOI 10.1016/S0885-3924(00)00159-7
   Roscoe JA, 2005, J PAIN SYMPTOM MANAG, V29, P376, DOI 10.1016/j.jpainsymman.2004.07.007
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Roscoe JA, 2002, ALTERN THER HEALTH M, V8, P56
   Roscoe JA, 2010, J PAIN SYMPTOM MANAG, V40, P379, DOI 10.1016/j.jpainsymman.2009.12.024
   Shin YH, 2004, CANCER NURS, V27, P267, DOI 10.1097/00002820-200407000-00002
   Sinha A, 2011, INT J OBSTET ANESTH, V20, P110, DOI 10.1016/j.ijoa.2010.10.005
   Treish I, 2003, SUPPORT CARE CANCER, V11, P516, DOI 10.1007/s00520-003-0467-3
   Venables WN, 2002, MODERN APPL STAT S, VFourth, P0, DOI 10.1007/978-0-387-21706-2_1
   Wright Leonard D, 2005, AM J HOSP PALLIAT CARE, V22, P49, DOI 10.1177/104990910502200111
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 46
TC 33
Z9 39
U1 0
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JAN 15
PY 2014
VL 47
IS 1
BP 12
EP 25
DI 10.1016/j.jpainsymman.2013.03.007
PG 14
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 285YF
UT WOS:000329430300007
PM 23602325
DA 2026-01-16
ER

PT J
AU Cassileth, BR
AF Cassileth, Barrie R.
TI Psychiatric benefits of integrative therapies in patients with cancer
SO INTERNATIONAL REVIEW OF PSYCHIATRY
LA English
DT Article
ID quality-of-life; randomized controlled-trial; cognitive-behavioral therapy; brief hypnosis intervention; breast-cancer; stress reduction; physical-activity; massage therapy; palliative care; lung resection
AB Integrative oncology uses non-pharmacological adjuncts to mainstream care to manage physical, emotional, and psychological symptoms experienced by cancer survivors. Depression, anxiety, fatigue and pain are among the common, often burdensome symptoms that can occur in clusters, deplete patient morale, interfere with treatment plans, and hamper recovery. Patients already seek various modalities on their own to address a broad range of problems. Legitimate complementary therapies offered at major cancer institutions improve quality of life, speed recovery, and optimize patient support. They also augment the benefits of psychiatric interventions, due to their ability to increase self-awareness and improve physical and psychological conditioning. Further, these integrated therapies provide lifelong tools and develop skills that patients use well after treatment to develop self-care regimens. The active referral of patients to integrative therapies achieves three important objectives: complementary care is received from therapists experienced in working with cancer patients, visits become part of the medical record, allowing treatment teams to guide individuals in maximizing benefit, and patients are diverted from useless or harmful 'alternatives.' We review the reciprocal physical and psychiatric benefits of exercise, mind-body practices, massage, acupuncture, and music therapy for cancer survivors, and suggest how their use can augment mainstream psychiatric interventions.
C1 Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Cassileth, BR (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM Cassileth@mskcc.org
CR Ahmadi H, 2013, BJU INT, V111, P543, DOI 10.1111/j.1464-410X.2012.11774.x
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Allen JJB, 2006, J CLIN PSYCHIAT, V67, P1665, DOI 10.4088/JCP.v67n1101
   American Cancer Society, 2013, REIK, V0, P0
   Andersen SR, 2013, ACTA ONCOL, V52, P336, DOI 10.3109/0284186X.2012.745948
   Andreescu C, 2011, J CLIN PSYCHIAT, V72, P1129, DOI 10.4088/JCP.10m06105
   Unknown -, 2013, PALLIAT SUPPORT CARE, V0, P0
   Unknown -, 2024, LANCET ONCOL, V0, P0, DOI DOI 10.1016/S1470-2045
   Arbane G, 2011, LUNG CANCER, V71, P229, DOI 10.1016/j.lungcan.2010.04.025
   Balboni T, 2011, CANCER-AM CANCER SOC, V117, P5383, DOI 10.1002/cncr.26221
   Binkhorst L, 2013, BREAST CANCER RES TR, V139, P923, DOI 10.1007/s10549-013-2585-z
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Blair SN, 2012, SCAND J MED SCI SPOR, V22, PE24, DOI 10.1111/j.1600-0838.2012.01462.x
   Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a
   Blumenthal JA, 2012, J AM COLL CARDIOL, V60, P1053, DOI 10.1016/j.jacc.2012.04.040
   Bobbio A, 2008, EUR J CARDIO-THORAC, V33, P95, DOI 10.1016/j.ejcts.2007.10.003
   Borneman Tami, 2007, J NATL COMPR CANC NETW, V5, P1092
   Borneman T, 2010, J PAIN SYMPTOM MANAG, V39, P486, DOI 10.1016/j.jpainsymman.2009.08.007
   Botha D, 2013, CAN J ANESTH, V60, P208, DOI 10.1007/s12630-012-9830-5
   Bower JE, 2012, CANCER-AM CANCER SOC, V118, P3766, DOI 10.1002/cncr.26702
   Bradt J, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911
   Braun LA, 2012, J THORAC CARDIOV SUR, V144, P1453, DOI 10.1016/j.jtcvs.2012.04.027
   Breitbart W, 2012, J CLIN ONCOL, V30, P1304, DOI 10.1200/JCO.2011.36.2517
   Breitbart W, 2011, PSYCHO-ONCOLOGY, V20, P1, DOI 10.1002/pon.1872
   Brown JC, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0030955
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Campbell TS, 2012, J BEHAV MED, V35, P262, DOI 10.1007/s10865-011-9357-1
   Carli F, 2012, CAN J ANESTH, V59, P779, DOI 10.1007/s12630-012-9734-4
   Carlson LE, 2004, PSYCHONEUROENDOCRINO, V29, P448, DOI 10.1016/S0306-4530(03)00054-4
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Cassileth BR, 2012, ONCOLOGIST, V17, P590, DOI 10.1634/theoncologist.2012-0149
   CASSILETH BR, 1989, CANCER INVEST, V7, P361, DOI 10.3109/07357908909039864
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Cassileth BR, 2003, CANCER, V98, P2723, DOI 10.1002/cncr.11842
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1690, DOI 10.1002/cncr.27904
   Chiesa A, 2013, CLIN PSYCHOL REV, V33, P82, DOI 10.1016/j.cpr.2012.10.006
   Citrin DL, 2012, ONCOLOGIST, V17, P607, DOI 10.1634/theoncologist.2011-0468
   Coats V, 2013, CAN RESPIR J, V20, PE10, DOI 10.1155/2013/291059
   Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236
   Craft LL, 2012, CANCER EPIDEM BIOMAR, V21, P3, DOI 10.1158/1055-9965.EPI-11-0634
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.3.CO;2-Z
   de Raaf PJ, 2013, J CLIN ONCOL, V31, P716, DOI 10.1200/JCO.2012.44.4216
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   DeLoach Walworth Darcy, 2005, J PEDIATR NURS, V20, P276
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Deng GE, 2013, CHEST S5, V143, P0
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Desmarais JE, 2009, J CLIN PSYCHIAT, V70, P1688, DOI 10.4088/JCP.08r04856blu
   Dhruva A, 2012, J ALTERN COMPLEM MED, V18, P473, DOI 10.1089/acm.2011.0555
   Docherty SL, 2013, J ADOLESCENT HEALTH, V52, P170, DOI 10.1016/j.jadohealth.2012.05.010
   Doka KJ, 2013, UNDERSTANDING SPIRIT, V0, P0
   Duijts SFA, 2012, J CLIN ONCOL, V30, P4124, DOI 10.1200/JCO.2012.41.8525
   Dusetzina SB, 2013, BREAST CANCER RES TR, V137, P285, DOI 10.1007/s10549-012-2330-z
   Edwards A, 2010, PALLIATIVE MED, V24, P753, DOI 10.1177/0269216310375860
   Elkins G, 2008, J CLIN ONCOL, V26, P5022, DOI 10.1200/JCO.2008.16.6389
   Elkins GR, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-92
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Faber MJ, 2006, ARCH PHYS MED REHAB, V87, P885, DOI 10.1016/j.apmr.2006.04.005
   Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033
   Feiler Bruce, 2011, TIME, V177, P56
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Ford DW, 2013, CHEST S5, V143, P0
   Geeganage C, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000323.pub2
   GELLERT GA, 1993, J CLIN ONCOL, V11, P66, DOI 10.1200/JCO.1993.11.1.66
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Granger CL, 2013, INTEGR CANCER THER, V12, P213, DOI 10.1177/1534735412450461
   Gulde I, 2011, J PALLIAT CARE, V27, P296, DOI 10.1177/082585971102700406
   Gutgsell KJ, 2013, J PAIN SYMPTOM MANAG, V45, P822, DOI 10.1016/j.jpainsymman.2012.05.008
   Hadi S, 2008, CURR ONCOL, V15, P211
   Hameed KA, 2011, J PEDIAT HEMATOL ONC, V33, PS19, DOI 10.1097/MPH.0b013e3182121a45
   He JP, 1999, CLINICAL AND EXPERIMENTAL OBSTETRICS AND GYNECOLOGY, V26, P81
   Henderson VP, 2013, INTEGR CANCER THER, V12, P404, DOI 10.1177/1534735412473640
   Hilliard RE, 2005, EVID-BASED COMPL ALT, V2, P173, DOI 10.1093/ecam/neh076
   Hodgson NA, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/456897
   Hoffman BM, 2011, PSYCHOSOM MED, V73, P127, DOI 10.1097/PSY.0b013e31820433a5
   Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055-9965.EPI-07-0771
   Holland JC, 2010, J NATL COMPR CANC NE, V8, P448, DOI 10.6004/jnccn.2010.0034
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Hovind IL, 2013, J CLIN NURS, V22, P1044, DOI 10.1111/jocn.12167
   Howell D, 2013, CURR ONCOL, V20, PE233, DOI 10.3747/co.20.1302
   Hwang CL, 2012, SUPPORT CARE CANCER, V20, P3169, DOI 10.1007/s00520-012-1452-5
   Irwin ML, 2008, J CLIN ONCOL, V26, P3958, DOI 10.1200/JCO.2007.15.9822
   Jarden M, 2009, BONE MARROW TRANSPL, V43, P725, DOI 10.1038/bmt.2009.27
   Jin Y, 2005, JNCI-J NATL CANCER I, V97, P30, DOI 10.1093/jnci/dji005
   Jones LW, 2007, CANCER-AM CANCER SOC, V110, P590, DOI 10.1002/cncr.22830
   Jones L, 2013, J PAIN SYMPTOM MANAG, V46, P315, DOI 10.1016/j.jpainsymman.2012.08.017
   Jones P, 2013, PSYCHO-ONCOLOGY, V22, P2148, DOI 10.1002/pon.3251
   Kanakura Y, 2002, AM J CHINESE MED, V30, P37, DOI 10.1142/S0192415X02000041
   Kasymjanova G, 2013, CURR ONCOL, V20, P152, DOI 10.3747/co.20.1312
   Kim KH, 2011, DIS COLON RECTUM, V54, P1107, DOI 10.1097/DCR.0b013e318221a934
   Kondryn HJ, 2011, LANCET ONCOL, V12, P100, DOI 10.1016/S1470-2045(10)70069-3
   Ladas EJ, 2006, J PEDIAT HEMATOL ONC, V28, P601, DOI 10.1097/01.mph.0000212989.26317.52
   Lee MS, 2008, INT J CLIN PRACT, V62, P947, DOI 10.1111/j.1742-1241.2008.01729.x
   Lee TI, 2006, AM J CHINESE MED, V34, P37, DOI 10.1142/S0192415X06003618
   Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187
   Lin MR, 2006, PHYS THER, V86, P1189, DOI 10.2522/ptj.20040408
   López-Sendín N, 2012, J ALTERN COMPLEM MED, V18, P480, DOI 10.1089/acm.2011.0277
   Lu WD, 2012, CONTEMP CLIN TRIALS, V33, P700, DOI 10.1016/j.cct.2012.02.017
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   Mackereth Peter, 2012, BR J NURS, V21, P0
   Magill L, 2008, PSYCHIAT SERV, V59, P1216, DOI 10.1176/appi.ps.59.10.1216
   Marcus DA, 2013, AM J HOSP PALLIAT ME, V30, P216, DOI 10.1177/1049909112469275
   Matecki AL, 2009, ACUPUNCTURE SAFETY, V0, P0
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Memorial Sloan-Kettering Cancer Center, 2013, MED MASS CANC PAT 1, V0, P0
   Memorial Sloan-Kettering Cancer Center, 2013, INT MED HOM TOOLS, V0, P0
   Milani RV, 2011, AM J CARDIOL, V107, P64, DOI 10.1016/j.amjcard.2010.08.047
   Mishra SI, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007566.pub2
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2010, J CONSULT CLIN PSYCH, V78, P80, DOI 10.1037/a0017392
   Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582
   Mustian Karen M, 2012, ONCOL HEMATOL REV, V8, P81
   National Cancer Institute, 2013, OB CANC RISK FACT SH, V0, P0
   National Cancer Institute, 2013, CANC SURV RES SURV D, V0, P0
   National Center for Complementary and Alternative Medicine, 2013, EN MED OV, V0, P0
   National Comprehensive Cancer Network, 2013, NCCN GUID SUPP CAR V, V0, P0
   Navarro M, 2012, 9 INT C SOC INT ONC, V0, P0
   Oh B, 2010, ANN ONCOL, V21, P608, DOI 10.1093/annonc/mdp479
   Oh B, 2012, SUPPORT CARE CANCER, V20, P1235, DOI 10.1007/s00520-011-1209-6
   Oldervoll LM, 2011, ONCOLOGIST, V16, P1649, DOI 10.1634/theoncologist.2011-0133
   Paley CA, 2011, PHYSIOTHERAPY, V97, P256, DOI 10.1016/j.physio.2010.08.008
   Peppone LJ, 2013, J CLIN ONCOL, V31, P0
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Puterman E, 2011, PSYCHOSOM MED, V73, P604, DOI 10.1097/PSY.0b013e318229e1e0
   Ramondetta LM, 2013, SUPPORT CARE CANCER, V21, P2991, DOI 10.1007/s00520-013-1863-y
   Richmond J, 1996, JAMA-J AM MED ASSOC, V276, P313
   Riesenberg H, 2010, SUPPORT CARE CANCER, V18, P877, DOI 10.1007/s00520-009-0727-y
   Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112
   Schnur Julie B, 2008, CONTEMP HYPN, V25, P114, DOI 10.1002/ch.364
   Schnur JB, 2009, J CLIN PSYCHOL, V65, P443, DOI 10.1002/jclp.20559
   Schreiber KL, 2013, PAIN, V154, P660, DOI 10.1016/j.pain.2012.11.015
   Selman LE, 2012, EUR J CANCER CARE, V21, P87, DOI 10.1111/j.1365-2354.2011.01285.x
   Shapiro SL, 2003, J PSYCHOSOM RES, V54, P85, DOI 10.1016/S0022-3999(02)00546-9
   Sharp DM, 2010, EUR J CANCER, V46, P312, DOI 10.1016/j.ejca.2009.10.006
   Silver JK, 2013, AM J PHYS MED REHAB, V92, P715, DOI 10.1097/PHM.0b013e31829b4afe
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Society for Integrative Oncology, 2009, EV BAS CLIN PRACT GU, V0, P0
   Stafford L, 2013, SUPPORT CARE CANCER, V21, P3009, DOI 10.1007/s00520-013-1880-x
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Streeter CC, 2012, MED HYPOTHESES, V78, P571, DOI 10.1016/j.mehy.2012.01.021
   Tipples K, 2011, DRUG AGING, V28, P867, DOI 10.2165/11595820-000000000-00000
   Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466
   Tsang HWH, 2013, AGING MENT HEALTH, V17, P336, DOI 10.1080/13607863.2012.732035
   Tsay SL, 2008, CANCER NURS, V31, P109, DOI 10.1097/01.NCC.0000305694.74754.7b
   Tsivian M, 2012, UROLOGY, V79, P32, DOI 10.1016/j.urology.2011.09.037
   Vesey Siobhan, 2013, BR J COMMUNITY NURS, VSuppl, P0
   Virgo KS, 2013, J CLIN ONCOL, V31, P2322, DOI 10.1200/JCO.2012.45.6954
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang SM, 2008, ANESTH ANALG, V107, P811, DOI 10.1213/ane.0b013e3181804441
   Wang SM, 2007, J ALTERN COMPLEM MED, V13, P241, DOI 10.1089/acm.2006.6262
   Wang SM, 2005, ANESTH ANALG, V101, P666, DOI 10.1213/01.ANE.0000175212.17642.45
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wilkinson SM, 2007, J CLIN ONCOL, V25, P532, DOI 10.1200/JCO.2006.08.9987
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Würtzen H, 2013, EUR J CANCER, V49, P1365, DOI 10.1016/j.ejca.2012.10.030
   Wyatt G, 2007, ONCOL NURS FORUM, V34, P635, DOI 10.1188/07.ONF.635-642
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
NR 163
TC 10
Z9 14
U1 0
U2 46
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-0261
EI 1369-1627
J9 INT REV PSYCHIATR
JI Int. Rev. Psych.
PD FEB 15
PY 2014
VL 26
IS 1
BP 114
EP 127
DI 10.3109/09540261.2013.838153
PG 14
WC Psychiatry
SC Psychiatry
GA AB9QJ
UT WOS:000332130100010
PM 24716505
DA 2026-01-16
ER

PT J
AU Lin, M
   Li, X
   Liang, W
   Liu, J
   Guo, J
   Zheng, J
   Liu, X
AF Lin, Munan
   Li, Xihai
   Liang, Wenna
   Liu, Jianhua
   Guo, Jianhong
   Zheng, Jingxiong
   Liu, Xianxiang
TI Needle-knife therapy improves the clinical symptoms of knee osteoarthritis by
SO Experimental and therapeutic medicine
LA English
DT Journal Article
DE acupuncture; knee joint; needle-knife therapy; osteoarthritis
AB Knee osteoarthritis (KOA) is a degenerative joint disease that occurs mainly in  the elderly population. However, there are currently no effective treatments for  treating this condition. In this study, the efficacy of needle-knife therapy, a  technique of traditional Chinese medicine that has been widely used to treat KOA  was investigated. Patients (n=170) with KOA were randomly divided for  needle-knife therapy (treatment group) and acupuncture therapy (control group).  Outcome evaluation included stiffness, pain, physiological function, overall  changes, total symptom score, clinical curative effects and the concentrations of  interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) in the synovial  fluid. The trial was completed in 151 patients (233 knees) from a total of 170  patients (264 knees); the treatment group comprised 76 patients (117 knees) who  completed the trial and 9 patients (14 knees) who were removed from the study,  and the control group comprised 75 patients (116 knees) who completed the trial  and 10 patients (17 knees) who were removed from the study. The symptom scores of  KOA in stages I-IV were reduced significantly in the treatment group and those of  stages I-III were decreased significantly in the control group. The effective  rate of the KOA therapy in the patients of stages III and IV in the treatment  group was significantly higher than that in the control group. After treatment,  the decrements of IL-1β, IL-6 and TNF-α in the treatment group were greater than  those in the control group. These results showed that the use of needle-knife  therapy to treat KOA effectively improved the clinical symptoms by inhibiting the  expression of inflammatory cytokines.
C1 Department of Traditional Chinese Medicine, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian 350025, P.R. China.
   Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
   Research Base of Traditional Chinese Medicine Syndrome, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China.
   Department of Traditional Chinese Medicine, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian 350025, P.R. China.
   Department of Traditional Chinese Medicine, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian 350025, P.R. China.
   Department of Traditional Chinese Medicine, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian 350025, P.R. China.
   Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China.
NR 0
TC 0
SN 1792-101
EI 1792-098
J9 Exp Ther Med
PD MAR 29
PY 2014
VL 7
IS 4
BP 835
EP 842
DI 10.3892/etm.2014.1516
PG 7
UT PubMed:24669238
PM 24669238
DA 2014-03-29
ER

PT J
AU Frankel, E
   Garland, S
   Meghani, SH
   Vapiwala, N
   Mao, JJ
AF Frankel, Eitan
   Garland, Sheila
   Meghani, Salimah H
   Vapiwala, Neha
   Mao, Jun J
TI Patients' Perspectives on Integrating Acupuncture into the Radiation Oncology
SO European journal of integrative medicine
LA English
DT Journal Article
DE Acupuncture; CAM; health disparity; knowledge; pain; radiotherapy
AB INTRODUCTION: Acupuncture has potential as a supportive care service for cancer  symptom management. However, little is known about patients' willingness to use  acupuncture in the context of conventional cancer care. METHODOLOGY: We conducted  a cross-sectional survey study among patients with cancer during their last week  of fractionated/external beam radiotherapy (RT). The main outcome variable was  self-reported likelihood of using acupuncture during RT. Knowledge about  acupuncture and pain severity was measured along with socio-demographic and  clinical variables. Multivariate logistic regression was performed to identify  factors associated with willingness to use acupuncture. RESULTS: Among the 305  participants, 79 (26.4%) were likely to use acupuncture during RT if such  services were offered at a reasonable price, 143 (46.9%) had no knowledge of  acupuncture, and 206 (67.6%) reported having pain. In multivariate analyses,  non-Whites (adjusted odds ratio [AOR] 1.94, 95% Confidence Interval [CI]  1.06-3.56), and those with pain (AOR 2.52, CI 1.25-5.10) were more interested in  using acupuncture. In addition, patients with preexisting knowledge about  acupuncture were also more likely to use acupuncture than those without this  knowledge (AOR 2.23, CI 1.28-3.88). CONCLUSIONS: Patients of non-White race,  those with pain or those with prior knowledge about acupuncture were more willing  to utilize acupuncture during RT. Since half of the patients had no knowledge  about acupuncture, interventions to improve patients' knowledge are needed to  facilitate the successful integration of acupuncture into cancer care.
C1 Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
   Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
   Abramson Cancer Center,Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
   Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
   University of Pennsylvania School of Nursing,Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
   Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
   Department of Radiation Oncology, PerelmanSchool of Medicine at the University of Pennsylvania, Philadelphia, PA.
   Department of Family Medicine and Community Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 
   Abramson Cancer Center,Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA ;Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicineat the University of Pennsylvania, Philadelphia, PA.
NR 0
TC 0
SN 1876-383
EI 1876-382
J9 Eur J Integr Med
PD NOV 12
PY 2014
VL 6
IS 5
BP 532
EP 537
DI 10.1016/j.eujim.2014.06.007
PG 5
UT PubMed:25386224
PM 25386224
DA 2014-11-12
ER

PT J
AU Garcia, MK
   McQuade, J
   Lee, R
   Haddad, R
   Spano, M
   Cohen, L
AF Garcia, M Kay
   McQuade, Jennifer
   Lee, Richard
   Haddad, Robin
   Spano, Michael
   Cohen, Lorenzo
TI Acupuncture for symptom management in cancer care: an update.
SO Current oncology reports
LA English
DT Journal Article
AB In a previous systematic review of the worldwide literature of randomized  controlled trials (RCTs) involving needle insertion into acupuncture points for  symptom management in cancer patients, we identified only one high-quality RCT  that was deemed to have a low risk of bias. Medline, Embase, CINAHL, Cochrane  (all databases), Scopus, and PubMed were searched from inception through December  2011 with no language limits applied. A total of 41 RCTs met all inclusion  criteria and were rated. In the current review, we examined 18 trials published  since our last report. The purpose of this update was to emphasize important  recent findings and discuss how concerns such as blinding, separating  non-specific placebo effects from specific needling effects, determining biologic  mechanisms and dosing parameters, evaluating determinants of response such as  expectation, controlling for sources of bias, and the lack of standardization in  treatment and study methods may affect the interpretation of study results.
C1 Department of General Oncology, Integrative Medicine Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0462, Houston, TX,77030, USA, kaygarcia@mdanderson.org.
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD OCT 19
PY 2014
VL 16
IS 12
BP 418
EP 418
DI 10.1007/s11912-014-0418-9
PG 0
WC Acupuncture Therapy; Antineoplastic Agents; administration & dosage; Arthralgia; chemically induced; Evidence-Based Medicine; Fatigue; etiology; Hot Flashes; etiology; Humans; Nausea; etiology; Neoplasms; complications; Randomized Controlled Trials as Topic; Treatment Outcome; Xerostomia; chemically induced
UT PubMed:25325937
PM 25325937
DA 2014-10-19
ER

PT J
AU Baccetti, S
   Da Frè, M
   Becorpi, A
   Faedda, M
   Guerrera, A
   Monechi, MV
   Munizzi, RM
   Parazzini, F
AF Baccetti, Sonia
   Da Fre, Monica
   Becorpi, Angelamaria
   Faedda, Marina
   Guerrera, Antonella
   Monechi, M. Valeria
   Munizzi, Rosa Maria
   Parazzini, Fabio
TI Acupuncture and Traditional Chinese Medicine for Hot Flushes in Menopause: A Randomized Trial
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID postmenopausal women; vasomotor symptoms; breast-cancer; flashes; placebo; perimenopausal; estrogen; safety
AB Objective: To evaluate the effect of acupuncture on hot flushes and other menopause-related symptoms used in an integrated system, including such therapeutic techniques as diet therapy and Tuina self-massage. Design: Randomized trial. Setting: Outpatient center. Participants: One hundred women in spontaneous menopause with at least three episodes of hot flushes daily were randomly allocated to two treatment groups (50 per group): Women in group A were given diet, self-massage training, and treatment with acupuncture, and women in group B (the control group) were given the same diet and self-massage training, but treatment with acupuncture started 6 weeks after they were enrolled into the study. Intervention: Acupuncture treatments were scheduled twice weekly for 6 consecutive weeks. Outcome measures: Mean change in frequency and/or intensity in menopause-related symptoms were estimated by questionnaire after treatment at week 4. Results: Treatment with acupuncture significantly reduced the occurrence of hot flushes and sudden sweating (p<.001). Other symptoms (sleep disorders, tightness in the chest, irritability, bone pain, feeling depressed) significantly improved. Conclusions: Acupuncture in an integrated system that includes therapeutic techniques such as diet therapy and Tuina self-massage can be used to treat hot flushes and selected symptoms in postmenopausal women.
C1 [Baccetti, Sonia; Faedda, Marina; Guerrera, Antonella; Monechi, M. Valeria; Munizzi, Rosa Maria] Referring Ctr Complementary Med, San Donnino, Campi Bisenzio, Italy.
   [Da Fre, Monica] Reg Hlth Agcy Tuscany, Epidemiol Unit, Florence, Italy.
   [Becorpi, Angelamaria] AOU Careggi, Italian Soc Gynaecol Elderly Age, Dept Obstet & Gynaecol, Florence, Italy.
   [Parazzini, Fabio] Univ Milan, Fdn IRCCS Policlin, Dept Obstet & Gynecol, I-20122 Milan, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Parazzini, F (corresponding author), Univ Milan, Fdn IRCCS Policlin, Dept Obstet & Gynecol, Via Commenda 12, I-20122 Milan, Italy.
EM fabio.parazzini@unimi.it
CR Alraek T, 2009, J ALTERN COMPLEM MED, V15, P153, DOI 10.1089/acm.2008.0310
   Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   Avis NE, 2008, MENOPAUSE, V15, P1070, DOI 10.1097/gme.0b013e31816d5b03
   Bologna M, 1999, DIETETICA MED SCI TR, V0, P0
   Borud EK, 2009, MENOPAUSE, V16, P484, DOI 10.1097/gme.0b013e31818c02ad
   Cabyoglu MT, 2006, INT J NEUROSCI, V116, P115, DOI 10.1080/00207450500341472
   Cai Jingfeng, 1995, DIETETICA CINESE, V0, P0
   Cho SH, 2009, MENOPAUSE, V16, P1065, DOI 10.1097/gme.0b013e3181a48abd
   Cohen Susan M, 2003, HOLIST NURS PRACT, V17, P295
   De Aloysio D, 2001, MENOPAUSE, V8, P290
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100
   Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605
   Kim DI, 2011, ACUPUNCT MED, V29, P249, DOI 10.1136/aim.2011.004085
   Kim KH, 2010, MENOPAUSE, V17, P269, DOI 10.1097/gme.0b013e3181bfac3b
   Lee MS, 2009, CLIMACTERIC, V12, P16, DOI 10.1080/13697130802566980
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Lund Irene, 2009, CHIN MED, V4, P1, DOI 10.1186/1749-8546-4-1
   Maciocia G, 2002, OSTETRICIA GINECOLOG, V0, P0
   Mollard Brusini Y, 2004, DIETETICA CINESE 2 T, V0, P0
   Muccioli M, 2001, DIETETICA TRADIZIONA, VI, P0
   Muccioli M, 2001, DIETETICA TRADIZIONA, VII, P0
   Painovich JM, 2012, MENOPAUSE, V19, P54, DOI 10.1097/gme.0b013e31821f9171
   Shen X, 2006, J TRADIT CHIN MED, V25, P3
   Sherman Sherry, 2005, AM J MED, V118 Suppl 12B, P166, DOI 10.1016/j.amjmed.2005.12.004
   Sotte L, 2011, DIETETICA CINESE TRA, V0, P0
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Uchida S, 2008, EVID-BASED COMPL ALT, V5, P145, DOI 10.1093/ecam/nem051
   Venzke L, 2010, COMPLEMENT THER MED, V18, P59, DOI 10.1016/j.ctim.2010.02.002
   Vickers AJ, 2002, EVAL HEALTH PROF, V25, P421, DOI 10.1177/0163278702238055
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   White AR, 2003, J FAM PLAN REPROD H, V29, P233, DOI 10.1783/147118903101197863
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Zaborowska E, 2007, CLIMACTERIC, V10, P38, DOI 10.1080/13697130601165059
NR 38
TC 17
Z9 17
U1 0
U2 41
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD JUL 15
PY 2014
VL 20
IS 7
BP 550
EP 557
DI 10.1089/acm.2012.0499
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AL5VO
UT WOS:000339201600005
PM 24827469
DA 2026-01-16
ER

PT J
AU Yu, JN
   Guo, CQ
   Hu, B
   Liu, NG
   Sun, HM
   Xu, H
   Wu, HX
   Guo, Y
   Liang, CX
   Chen, ZX
   Li, XH
AF Yu, Jia Ni
   Guo, Chang Qing
   Hu, Bo
   Liu, Nai Gang
   Sun, Hong Mei
   Xu, Hong
   Wu, Hai Xia
   Guo, Yan
   Liang, Chu Xi
   Chen, Zhan Xia
   Li, Xiao Hong
TI Effects of acupuncture knife on inflammatory factors and pain in third lumbar
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB The aim of this paper was to explore the long-term effects and pain relief  mechanism of acupuncture knife on third lumbar vertebrae (L3) transverse process  syndrome. Forty SD rats were randomized into control, model, electroacupuncture  (EA), and acupuncture knife (AK) group. Except control rats, other rats were  subjected to an operation to emulate L3 transverse process syndrome. Fourteen  days after the operation, EA and AK rats were given electroacupuncture and  acupuncture knife treatments, respectively. Fifty-six days after the operation,  enzyme-linked immunosorbent assay was used to measure substance P (SP),  5-hydroxytryptamine (5-HT), interleukin-1β (IL-1β), interleukin-10 (IL-10), tumor  necrosis factor-α (TNF-α), and transforming growth factor-β (TGF-β) in peripheral  blood. The tail flick test was used to observe pain threshold. We found that rats  with the simulation operation had significantly higher levels of SP, 5-HT, IL-1,  IL-10, TNF-α, and TGF-β, while the AK rats had lower levels. In addition, the  pain threshold of AK rats was similar to that of control rats. AK pretreatment  could alleviate pain through modulating inflammatory response.
C1 School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   Acupuncture & Moxibustion and Physiotherapy Department, Beijing Shuili Hospital, No. 19 Yu Yuan Tan South Road, Haidian District, Beijing 100036, China.
   Acupuncture and Moxibustion Department, China-Japan Friendship Hospital, No. 2 The Ying Hua Yuan East Street, Chaoyang District, Beijing 100029, China.
   School of Basic Medical Sciences, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Basic Medical Sciences, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Basic Medical Sciences, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
   School of Acupuncture and Moxibustion, Beijing University of Chinese Medicine, No. 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD DEC 30
PY 2014
VL 2014
IS 
BP 892406
EP 892406
DI 10.1155/2014/892406
PG 0
UT PubMed:25544854
PM 25544854
DA 2014-12-30
ER

PT J
AU An, LX
   Chen, X
   Ren, XJ
   Wu, HF
AF An, Li-Xin
   Chen, Xue
   Ren, Xiu-Jun
   Wu, Hai-Feng
TI Electro-acupuncture decreases postoperative pain and improves recovery in
SO The American journal of Chinese medicine
LA English
DT Journal Article
DE Appetite; Dizziness; Electro-Acupuncture; Postoperative Pain; Supratentorial Craniotomy
AB We performed this study to examine the effect of electro-acupuncture (EA) on  postoperative pain, postoperative nausea and vomiting (PONV) and recovery in  patients after a supratentorial tumor resection. Eighty-eight patients requiring  a supratentorial tumor resection were anesthetized with sevoflurane and randomly  allocated to a no treatment group (Group C) or an EA group (Group A). After  anesthesia induction, the patients in Group A received EA at LI4 and SJ5, at BL63  and LR3 and at ST36 and GB40 on the same side as the craniotomy. The stimulation  was continued until the end of the operation. Patient-controlled intravenous  analgesia (PCIA) was used for the postoperative analgesia. The postoperative pain  scores, PONV, the degree of dizziness and appetite were recorded. In the first 6  hours after the operation, the mean total bolus, the effective times of PCIA  bolus administrations and the VAS scores were much lower in the EA group (p <  0.05). In the EA group, the incidence of PONV and degree of dizziness and feeling  of fullness in the head within the first 24 hours after the operation was much  lower than in the control group (p < 0.05). In the EA group, more patients had a  better appetite than did the patients in group C (51.2% vs. 27.5%) (p < 0.05).  The use of EA in neurosurgery patients improves the quality of postoperative  analgesia, promotes appetite recovery and decreases some uncomfortable  sensations, such as dizziness and feeling of fullness in the head.
C1 Department of Anesthesia, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD AUG 30
PY 2014
VL 42
IS 5
BP 1099
EP 109
DI 10.1142/S0192415X14500682
PG -990
WC Adolescent; Adult; Analgesia, Patient-Controlled; statistics & numerical data; Craniotomy; Dizziness; prevention & control; Electroacupuncture; methods; Female; Humans; Male; Middle Aged; Pain, Postoperative; therapy; Postoperative Complications; prevention & control; Postoperative Nausea and Vomiting; prevention & control; Supratentorial Neoplasms; surgery; Young Adult
UT PubMed:25169910
PM 25169910
DA 2014-08-30
ER

PT J
AU Mao, JJ
   Xie, SX
   Farrar, JT
   Stricker, CT
   Bowman, MA
   Bruner, D
   DeMichele, A
AF Mao, Jun J.
   Xie, Sharon X.
   Farrar, John T.
   Stricker, Carrie T.
   Bowman, Marjorie A.
   Bruner, Deborah
   DeMichele, Angela
TI A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Acupuncture; Breast neoplasm; Clinical trial; Aromatase inhibitors; Adverse effects; Musculoskeletal; Joint pain
ID acupuncture; symptoms; discontinuation; management
AB Background: Arthralgia is a common and debilitating side-effect experienced by breast cancer patients receiving aromatase inhibitors (AIs) and often results in premature drug discontinuation. Methods: We conducted a randomised controlled trial of electro-acupuncture (EA) as compared to waitlist control (WLC) and sham acupuncture (SA) in postmenopausal women with breast cancer who self-reported arthralgia attributable to AIs. Acupuncturists performed 10 EA/SA treatments over 8 weeks using a manualised protocol with 2 Hz electro-stimulation delivered by a TENS unit. Acupuncturists administered SA using Streitberger (non-penetrating) needles at non-traditional acupuncture points without electro-stimulation. The primary end-point was pain severity by Brief Pain Inventory (BPI) between EA and WLC at Week 8; durability of response at Week 12 and comparison of EA to SA were secondary aims. Findings: Of the 67 randomly assigned patients, mean reduction in pain severity was greater in the EA group than in the WLC group at Week 8 (-2.2 versus -0.2, p = 0.0004) and at Week 12 (-2.4 versus -0.2, p < 0.0001). Pain-related interference measured by BPI also improved in the EA group compared to the WLC group at both Week 8 (-2.0 versus 0.2, p = 0.0006) and Week 12 (-2.1 versus -0.1, p = 0.0034). SA produced a magnitude of change in pain severity and pain-related interference at Week 8 (-2.3, -1.5 respectively) and Week 12 (-1.7, -1.3 respectively) similar to that of EA. Participants in both EA and SA groups reported few minor adverse events. Interpretations: Compared to usual care, EA produced clinically important and durable improvement in arthralgia related to AIs in breast cancer patients, and SA had a similar effect. Both EA and SA were safe. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mao, Jun J.] Univ Penn, Dept Family Med & Community Hlth, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Xie, Sharon X.; Farrar, John T.; DeMichele, Angela] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Xie, Sharon X.; Farrar, John T.; DeMichele, Angela] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Farrar, John T.; Stricker, Carrie T.; DeMichele, Angela] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Bowman, Marjorie A.] Wright State Univ, Sch Med, Dayton, OH 45435 USA.
   [Bruner, Deborah] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University System of Ohio; Wright State University Dayton; Emory University
RP Mao, JJ (corresponding author), Univ Penn, Dept Family Med & Community Hlth, 3400 Spruce St 2 Gates, Philadelphia, PA 19104 USA.
EM jun.mao@uphs.upenn.edu
FU National Institutes of Health/National Center for Complementary and Alternative Medicine (NCCAM) [R21 AT004695]; NCCAM [K23 AT004112]
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Burstein HJ, 2007, J CLIN ONCOL, V25, P0, DOI 10.1200/JCO.2007.11.9529
   Chen L, 2010, PAIN MED, V11, P530, DOI 10.1111/j.1526-4637.2010.00815.x
   Cheng Xin-Nong, 1987, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Felson DT, 2005, ARTHRITIS RHEUM-US, V52, P2594, DOI 10.1002/art.21364
   Fitzmaurice GM, 2004, APPL LONGITUDINAL AN, V0, P0
   Gummesson C, 2006, BMC MUSCULOSKEL DIS, V7, P0, DOI 10.1186/1471-2474-7-44
   Hammerschlag R, 2006, J ALTERN COMPLEM MED, V12, P943, DOI 10.1089/acm.2006.12.943
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2013, PHARMACOEPIDEM DR S, V22, P256, DOI 10.1002/pds.3365
   Mao JJ, 2011, BREAST CANCER RES, V13, P0, DOI 10.1186/bcr2813
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x
   Sloan JA, 2002, MAYO CLIN PROC, V77, P479, DOI 10.4065/77.5.479
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Vickers AJ, 2012, ARCH. INTERN. MED, V0, P0
   Vincent C, 1990, COMPLEMENTARY MEDICAL RESEARCH, V4, P8
NR 31
TC 107
Z9 125
U1 0
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JAN 15
PY 2014
VL 50
IS 2
BP 267
EP 276
DI 10.1016/j.ejca.2013.09.022
PG 10
WC Oncology
SC Oncology
GA 293PV
UT WOS:000329986500003
PM 24210070
DA 2026-01-16
ER

PT J
AU Garcia, MK
   McQuade, J
   Lee, R
   Haddad, R
   Spano, M
   Cohen, L
AF Garcia, M. Kay
   McQuade, Jennifer
   Lee, Richard
   Haddad, Robin
   Spano, Michael
   Cohen, Lorenzo
TI Acupuncture for Symptom Management in Cancer Care: an Update
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article
DE Acupuncture; Cancer; Integrative medicine; Complementary medicine; Symptom management; Pain; Fatigue; Peripheral neuropathy; Lymphedema; Hot flashes
ID randomized controlled-trial; induced peripheral neuropathy; radiation-induced xerostomia; breast-cancer; musculoskeletal symptoms; vasomotor symptoms; feasibility trial; double-blind; hot flashes; dual-center
AB In a previous systematic review of the worldwide literature of randomized controlled trials (RCTs) involving needle insertion into acupuncture points for symptom management in cancer patients, we identified only one high-quality RCT that was deemed to have a low risk of bias. Medline, Embase, CINAHL, Cochrane (all databases), Scopus, and PubMed were searched from inception through December 2011 with no language limits applied. A total of 41 RCTs met all inclusion criteria and were rated. In the current review, we examined 18 trials published since our last report. The purpose of this update was to emphasize important recent findings and discuss how concerns such as blinding, separating non-specific placebo effects from specific needling effects, determining biologic mechanisms and dosing parameters, evaluating determinants of response such as expectation, controlling for sources of bias, and the lack of standardization in treatment and study methods may affect the interpretation of study results.
C1 [Garcia, M. Kay; McQuade, Jennifer; Lee, Richard; Haddad, Robin; Spano, Michael; Cohen, Lorenzo] Univ Texas MD Anderson Canc Ctr, Integrat Med Program, Dept Gen Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Garcia, MK (corresponding author), Univ Texas MD Anderson Canc Ctr, Integrat Med Program, Dept Gen Oncol, 1515 Holcombe Blvd,Unit 0462, Houston, TX 77030 USA.
EM kaygarcia@mdanderson.org; jmcquade@mdanderson.org; rtlee@mdanderson.org; rhaddad@mdanderson.org; mrspano@mdanderson.org; lcohen@mdanderson.org
CR Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Braga FDF, 2011, BRAZ ORAL RES, V25, P180
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2009, EUR UROL, V55, P156, DOI 10.1016/j.eururo.2008.02.002
   Frisk JW, 2014, SUPPORT CARE CANCER, V22, P1409, DOI 10.1007/s00520-014-2126-2
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Guo J, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/163850
   Henry NL, 2010, CANCER-AM CANCER SOC, V116, P4360, DOI 10.1002/cncr.25385
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Huo ZJ, 2013, CHIN J INTEGR MED, V19, P187, DOI 10.1007/s11655-012-1240-6
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lu LM, 2013, EXPERT REV ANTICANC, V13, P489, DOI 10.1586/era.13.27
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Vickers AJ, 2012, ARCH. INTERN. MED, V0, P0
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
NR 41
TC 26
Z9 28
U1 1
U2 45
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD DEC 15
PY 2014
VL 16
IS 12
BP 
EP 
DI 10.1007/s11912-014-0418-9
PG 9
WC Oncology
SC Oncology
GA AU0RX
UT WOS:000345332900006
PM 25325937
DA 2026-01-16
ER

PT J
AU Bao, YJ
   Kong, XY
   Yang, LP
   Liu, R
   Shi, Z
   Li, WD
   Hua, BJ
   Hou, W
AF Bao, Yanju
   Kong, Xiangying
   Yang, Liping
   Liu, Rui
   Shi, Zhan
   Li, Weidong
   Hua, Baojin
   Hou, Wei
TI Complementary and Alternative Medicine for Cancer Pain: An Overview of Systematic Reviews
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID quality-of-life; breast-cancer; methodological quality; measurement tool; prostate-cancer; massage; reflexology; acupuncture; therapy; efficacy
AB Background and Objective. Now with more and more published systematic reviews of Complementary and Alternative Medicine (CAM) on adult cancer pain, it is necessary to use the methods of overview of systematic review to summarize available evidence, appraise the evidence level, and give suggestions to future research and practice. Methods. A comprehensive search (the Cochrane Library, PubMed, Embase, and ISIWeb of Knowledge) was conducted to identify all systematic reviews or meta-analyses of CAM on adult cancer pain. And the evidence levels were evaluated using GRADE approach. Results. 27 systematic reviews were included. Based on available evidence, we could find that psychoeducational interventions, music interventions, acupuncture plus drug therapy, Chinese herbal medicine plus cancer therapy, compound kushen injection, reflexology, lycopene, TENS, qigong, cupping, cannabis, Reiki, homeopathy (Traumeel), and creative arts therapies might have beneficial effects on adult cancer pain. No benefits were found for acupuncture (versus drug therapy or shame acupuncture), and the results were inconsistent for massage therapy, transcutaneous electric nerve stimulation (TENS), and Viscum album L plus cancer treatment. However, the evidence levels for these interventions were low or moderate due to high risk of bias and/or small sample size of primary studies. Conclusion. CAM may be beneficial for alleviating cancer pain, but the evidence levels were found to be low or moderate. Future large and rigor randomized controlled studies are needed to confirm the benefits of CAM on adult cancer pain.
C1 [Bao, Yanju; Liu, Rui; Shi, Zhan; Li, Weidong; Hua, Baojin; Hou, Wei] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, Beijing 100053, Peoples R China.
   [Kong, Xiangying] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
   [Yang, Liping] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Nephrol, Beijing 100053, Peoples R China.
C3 Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences
RP Hua, BJ (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, Beixiange 5, Beijing 100053, Peoples R China.
EM huabaojin1@163.com; houweipu@163.com
FU National Natural Science Foundation of China [81273718, 81302961]
CR Adams Mariama, 2007, INT SEMIN SURG ONCOL, V4, P10, DOI 10.1186/1477-7800-4-10
   Unknown -, 2011, EVIDENCE BASED COMPL, V0, P0
   Unknown -, 2004, COCHRANE DB SYST REV, V0, P0
   Unknown -, 2004, COCHRANE DATABASE SY, V0, P0
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Bennett MI, 2009, PAIN, V143, P192, DOI 10.1016/j.pain.2009.01.016
   Beurskens CHG, 2007, BMC CANCER, V7, P0, DOI 10.1186/1471-2407-7-166
   Bradt J, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911
   Carson JW, 2009, SUPPORT CARE CANCER, V17, P1301, DOI 10.1007/s00520-009-0587-5
   Cassileth Barrie, 2007, CURR PAIN HEADACHE REP, V11, P265, DOI 10.1007/s11916-007-0202-8
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chrystal Kathryn, 2003, N Z MED J, V116, P0
   Clark CE, 2010, PRIM CARE RESP J, V19, P307, DOI 10.4104/pcrj.2010.00041
   Corner Jessica, 1995, INT J PALLIAT NURS, V1, P67, DOI 10.12968/ijpn.1995.1.2.67
   Devine E C, 1995, ONCOL NURS FORUM, V22, P1369
   Devine Elizabeth C, 2003, ONCOL NURS FORUM, V30, P75, DOI 10.1188/03.ONF.75-89
   Downey L, 2009, J PALLIAT CARE, V25, P100, DOI 10.1177/082585970902500204
   Ernst E, 2011, MATURITAS, V68, P116, DOI 10.1016/j.maturitas.2010.10.011
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Ernst E, 2005, PHARM J, V275, P55
   Ernst E, 2009, MED J AUSTRALIA, V191, P263, DOI 10.5694/j.1326-5377.2009.tb02780.x
   Falkensteiner Maria, 2011, ISRN NURS, V2011, P929868, DOI 10.5402/2011/929868
   Fernández-Lao C, 2012, J MANIP PHYSIOL THER, V35, P94, DOI 10.1016/j.jmpt.2011.09.011
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Grealish L, 2000, CANCER NURS, V23, P237, DOI 10.1097/00002820-200006000-00012
   Greer JA, 2012, J CLIN ONCOL, V30, P394, DOI 10.1200/JCO.2011.35.7996
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Haseen F, 2009, PROSTATE CANCER P D, V12, P325, DOI 10.1038/pcan.2009.38
   Hernandez-Reif M, 2005, INT J NEUROSCI, V115, P495, DOI 10.1080/00207450590523080
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Induru RR, 2011, CLEV CLIN J MED, V78, P449, DOI 10.3949/ccjm.78a.10054
   Johannsen M, 2013, BREAST CANCER RES TR, V138, P675, DOI 10.1007/s10549-013-2503-4
   Kienle GS, 2010, INTEGR CANCER THER, V9, P142, DOI 10.1177/1534735410369673
   Kim JI, 2010, INTEGR CANCER THER, V9, P326, DOI 10.1177/1534735410387423
   Kung Jason, 2010, OPEN DENT J, V4, P84, DOI 10.2174/1874210601004020084
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee MS, 2009, J PAIN, V10, P1121, DOI 10.1016/j.jpain.2009.03.009
   Liberati A, 2009, BRITISHMEDICAL J, V339, P0
   Linde Klaus, 2001, INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, V30, P526, DOI 10.1093/ije/30.3.526
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Marie N, 2013, SUPPORT CARE CANCER, V21, P3529, DOI 10.1007/s00520-013-1995-0
   Martin-Sánchez E, 2009, PAIN MED, V10, P1353, DOI 10.1111/j.1526-4637.2009.00703.x
   Milazzo S, 2006, EUR J CANCER, V42, P282, DOI 10.1016/j.ejca.2005.09.025
   Molassiotis Alexander, 2005, COMPLEMENT THER CLIN PRACT, V11, P105, DOI 10.1016/j.ctcp.2004.12.005
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Ponholzer A, 2003, EUR UROL, V43, P604, DOI 10.1016/S0302-2838(03)00155-6
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Puetz TW, 2013, JAMA INTERN MED, V173, P960, DOI 10.1001/jamainternmed.2013.836
   Risberg T, 1997, EUR J CANCER, V33, P575, DOI 10.1016/S0959-8049(96)00504-7
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916-012-0275-x
   Shea BJ, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-10
   Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009
   Shea BJ, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0001350
   Shuai P, 2012, STAT MED, V31, P606, DOI 10.1002/sim.4034
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   VanderVaart S, 2009, J ALTERN COMPLEM MED, V15, P1157, DOI 10.1089/acm.2009.0036
   Wang Shi-Jun, 2013, CHIN J INTEGR MED, V0, P0
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   Wilkie D J, 2000, HOSP J, V15, P31
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Xu L, 2007, INTEGR CANCER THER, V6, P208, DOI 10.1177/1534735407305705
   Zhang JM, 2012, SUPPORT CARE CANCER, V20, P3043, DOI 10.1007/s00520-012-1606-5
NR 71
TC 67
Z9 92
U1 0
U2 108
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUN 15
PY 2014
VL 2014
IS 
BP 
EP 
DI 10.1155/2014/170396
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA AG1EX
UT WOS:000335159000001
PM 24817897
DA 2026-01-16
ER

PT J
AU Kim, KM
   Kang, EY
   Lee, SH
   Jung, AY
   Nam, DH
   Cheon, JH
AF Kim, Kyoung Min
   Kang, Eun Young
   Lee, Sung Hoon
   Jung, A Young
   Nam, Doo Hyoun
   Cheon, Ji Hwan
TI Therapeutic approach of wrist ganglion using electroacupuncture: two case
SO Annals of rehabilitation medicine
LA English
DT Journal Article
DE Electroacupuncture; Ganglion cysts
AB A ganglion cyst is a relatively common benign tumor on the wrist. Conservative  and surgical approaches have been used for its treatment. Various conservative  treatment methods have been suggested such as reassurance, aspiration, sclerosant  injection, and direct compression. But, there is no acceptable treatment of  choice yet because each suggested method has a relatively high recurrence rate.  We want to report two cases in which the size of the wrist ganglion was decreased  by using electroacupuncture. One patient presented with a chronic ganglion for  six years and the other patient presented with a recently occurred acute  ganglion. We applied electroacupuncture for 20 minutes once a week for eight  weeks to both of them. Afterwards, the size of the wrist ganglion diminished in  the follow-up sonography and the accompanying pain was also relieved. Herein we  report both cases along with a review of the relevant literature.
C1 Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
   Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
   Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
   Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
   Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
   Department of Rehabilitation Medicine, Kwangju Christian Hospital, Gwangju, Korea.
NR 0
TC 0
SN 2234-065
EI 2234-064
J9 Ann Rehabil Med
PD JUL 16
PY 2014
VL 38
IS 3
BP 415
EP 20
DI 10.5535/arm.2014.38.3.415
PG -395
UT PubMed:25024969
PM 25024969
DA 2014-07-16
ER

PT J
AU Lu, DP
   Lu, GP
AF Lu, Dominic P
   Lu, Gabriel P
TI An Historical Review and Perspective on the Impact of Acupuncture on U.S.
SO Medical acupuncture
LA English
DT Review
DE Acupuncture; Health Care; Impact; Perspective
AB BACKGROUND: It took almost 300 years for Europe and 400 years for the United  States to finally appreciate the therapeutic value of acupuncture. Findings from  basic medical research that acupuncture stimulation causes release of endorphins,  serotonin, enkephalins, and γ-amino-butyric acid (GABA; a major inhibitory  neurotransmitter of the brain), norepinephrine, and dopamine helped to explain  the acupuncture effect on a biomedical and pharmacological basis that was  acceptable to the Western medical establishment. CONTEXT: In the United States,  there is significantly increased familiarity with acupuncture and U.S. patients  have sought acupuncture treatment to relieve stress-related syndromes, to enhance  the immune system, to reduce insomnia, to improve athletic performance, and to  address Alzheimer's disease, as well as for cardiac and poststroke therapy. This  article briefly reviews the history of acupuncture in the United States and  discusses the potential of this modality in the the future. DISCUSSION:  Acupuncture can be combined with conventional Western medicine for pain  management in patient with cancer to reduce dosages of narcotic medications,  side-effects, adverse reactions, and the possibility of narcotic addiction.  Because of acupuncture's increased popularity, acupuncture training schools have  been set up in the United States, and some insurance companies cover acupuncture  therapy. CONCLUSIONS: By studying both Eastern and Western medicine and using  them in a complementary fashion, we open ourselves to many discoveries for the  benefit of humanity.
C1 Department of Oral Medicine, University Pennsylvania , Philadelphia, PA.
   Department of Clinical Anesthesiology, Albert Einstein College of Medicine , Bronx, NY.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD APR 25
PY 2014
VL 25
IS 5
BP 311
EP 316
DI 10.1089/acu.2012.0921
PG 5
UT PubMed:24761180
PM 24761180
DA 2014-04-25
ER

PT J
AU Yeh, CH
   Chien, LC
   Chiang, YC
   Ren, D
   Suen, LK
AF Yeh, Chao Hsing
   Chien, Lung-Chang
   Chiang, Yi Chien
   Ren, Dianxu
   Suen, Lorna Kwai-Ping
TI Auricular point acupressure as an adjunct analgesic treatment for cancer
SO Pain management nursing : official journal of the American Society of Pain
LA English
DT Journal Article
AB This study aimed (1) to examine the feasibility of an auricular point acupressure  (APA) research protocol in terms of recruitment and for the assessment and  management of pain and (2) to examine the potential APA analgesic effects for  cancer patients. This study was a repeated-measures one-group design.  Participants were recruited from the cancer center follow-up clinic affiliated  with a large university hospital in the northeastern United States. Participants  included 50 patients aged 55-87 years with a diagnosis of cancer. Participants  received 7 days of APA treatment for their pain. After appropriate acupoints were  identified, vaccaria seeds were carefully taped onto each selected auricular  point on each ear. The study recruitment and retention rates were 92% and 91%,  respectively. Importantly, the study found preliminary evidence for the analgesic  effects of APA for cancer pain management. For example, by the end of the 7-day  study, APA reduced pain intensity more than 55% for "worst pain" and about 57%  for "average pain" and "pain intensity." Moreover, the use of pain medication was  reduced during the APA treatment (e.g., 78% of patients [n = 39] took less pain  medication than before the treatment). APA appears to be highly acceptable to  patients with cancer-related pain. However, without a placebo control, we cannot  draw conclusive evidence for the analgesic effect of APA for cancer patients. A  sham group must be added to future studies to differentiate the true effects of  APA from the possible psychological effects of the APA treatment.
C1 School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
   Division of Biostatistics, University of Texas School of Public Health at San Antonio Regional Campus, San Antonio, Texas
   Research to Advance Community HealthCenter, University of Texas Health Science Center at San Antonio Regional Campus,San Antonio, Texas.
   Department of Nursing, Chang Gung University of Science and Technology, Tao-Yuen, Taiwan. 
   School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania.
   School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
EM ycchiang@gw.cgust.edu.tw
NR 0
TC 0
SN 1532-863
EI 
J9 Pain Manag Nurs
PD DEC 3
PY 2014
VL 16
IS 3
BP 285
EP 93
DI 10.1016/j.pmn.2014.08.005
PG -192
WC Acupressure; Acupuncture Analgesia; methods; Acupuncture Points; Aged; Aged, 80 and over; Analgesics; therapeutic use; Cancer Pain; prevention & control; Combined Modality Therapy; Feasibility Studies; Female; Humans; Male; Middle Aged; Pain Measurement; Patient Satisfaction
UT PubMed:25439120
PM 25439120
DA 2014-12-03
ER

PT J
AU de la Calle, JL
   De Andres, J
   Pérez, M
   López, V
AF de la Calle, Jose-Luis
   De Andres, Jose
   Perez, Maria
   Lopez, Vanessa
TI Add-On Treatment with Pregabalin for Patients with Uncontrolled Neuropathic Pain Who Have Been Referred to Pain Clinics
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article
ID diabetic peripheral neuropathy; usual care; hospital anxiety; cost-utility; questionnaire; validation; management; individuals; combination; community
AB Objective The aim of this study was to investigate the impact of pregabalin on pain, other symptoms, and patient-reported outcomes for patients with uncontrolled pain who have been referred to pain clinics. Patients and Methods Adult patients with uncontrolled pain who had a score of >= 4 in the DN4 questionnaire were evaluated at baseline, month 3, and month 6. Evaluations included pain levels using a visual analog (VAS) scale as well as anxiety, depression, sleep, disability, and treatment satisfaction employing validated tools. Results Our sample comprised 413 patients who met the selection criteria, had not received pregabalin previously, and were prescribed pregabalin at the study initiation, mainly (97 %) as add-on therapy. Overall, patients had a statistically significant reduction in VAS pain score of 41 points (54 % reduction, p < 0.001), varying from 64 % reduction (oncological pain) to 31 % reduction (central neuropathic pain). Effect sizes for anxiety, depression, sleep, and treatment satisfaction improvement were moderate to large depending on the dimension and clinical entity. Conclusion Our results suggest that in patients with uncontrolled neuropathic pain of various origins who were treated at pain clinics, the addition of pregabalin to a wider pharmacological treatment regimen was associated with a clinically relevant improvement of pain and psychological well-being and a reduction in the impact of neuropathic pain on daily activities. Add-on treatment with pregabalin was well tolerated.
C1 [de la Calle, Jose-Luis] Hop Ramon y Cajal, Pain Unit, Madrid, Spain.
   [De Andres, Jose] Univ Valencia, Gen Hosp, Sch Med, Anesthesia Crit Care & Multidisciplinary Pain Man, Valencia, Spain.
   [Perez, Maria; Lopez, Vanessa] Pfizer Espana, Med Unit, Madrid 28108, Spain.
C3 University of Valencia; Pfizer; Pfizer Spain
RP Pérez, M (corresponding author), Pfizer Espana, Med Unit, Avda Europa,20 B,Parque Empresarial La Moraleja, Madrid 28108, Spain.
EM maria.perez2@pfizer.com
FU Pfizer, S.L.U.
CR Achar A, 2010, INDIAN J DERMATOL VE, V76, P63, DOI 10.4103/0378-6323.58686
   Bouhassira D, 2005, PAIN, V114, P29, DOI 10.1016/j.pain.2004.12.010
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   Cardenas DD, 2013, NEUROLOGY, V80, P533, DOI 10.1212/WNL.0b013e318281546b
   Carter G T, 2001, PHYS MED REHABIL CLIN N AM, V12, P447
   de Andrés J, 2014, PAIN RES TREAT, V2014, P0, DOI 10.1155/2014/518716
   de Salas-Cansado M, 2012, PRIM CARE DIABETES, V6, P303, DOI 10.1016/j.pcd.2012.03.001
   de Salas-Cansado M, 2012, PAIN MED, V13, P699, DOI 10.1111/j.1526-4637.2012.01375.x
   Dworkin RH, 2010, MAYO CLIN PROC, V85, PS3, DOI 10.4065/mcp.2009.0649
   Flórez-García M, 2011, PAIN PRACT, V11, P369, DOI 10.1111/j.1533-2500.2010.00430.x
   Gordon Jason, 2012, J MED ECON, V15, P207, DOI 10.3111/13696998.2011.632797
   Gore M, 2006, J PAIN, V7, P892, DOI 10.1016/j.jpain.2006.04.013
   Harden N, 2003, J PAIN SYMPTOM MANAG, V25, PS12, DOI 10.1016/S0885-3924(03)00065-4
   Hays RD, 1992, MEASURING FUNCTIONIN, V0, P235
   Herrero MJ, 2003, GEN HOSP PSYCHIAT, V25, P277, DOI 10.1016/S0163-8343(03)00043-4
   KAZIS LE, 1989, MED CARE, V27, PS178, DOI 10.1097/00005650-198903001-00015
   Lampl C, 2010, J NEUROL, V257, P1265, DOI 10.1007/s00415-010-5504-9
   Luciano JV, 2010, J AFFECT DISORDERS, V121, P52, DOI 10.1016/j.jad.2009.05.008
   McDermott AM, 2006, EUR J PAIN, V10, P127, DOI 10.1016/j.ejpain.2005.01.014
   Morera-Domínguez C, 2010, CLIN DRUG INVEST, V30, P517, DOI 10.2165/11536280-000000000-00000
   National Institute for Health and Clinical Excellence, 2010, NEURP PAIN PHARM MAN, V0, P0
   Navarro A, 2012, PAIN PRACT, V12, P382, DOI 10.1111/j.1533-2500.2011.00515.x
   Perez C, 2011, CLIN MED REV THER, V11, P325
   Pérez C, 2009, CLIN DRUG INVEST, V29, P441, DOI 10.2165/00044011-200929070-00002
   Perez C, 2007, HEALTH QUAL LIFE OUT, V5, P0, DOI 10.1186/1477-7525-5-66
   Plested M, 2010, BMC NEUROL, V10, P0, DOI 10.1186/1471-2377-10-116
   Prettyjohns Matthew, 2012, J MED ECON, V15, P1097, DOI 10.3111/13696998.2012.704458
   Rehm S, 2010, CURR MED RES OPIN, V26, P1607, DOI 10.1185/03007995.2010.483675
   Rejas J, 2007, EUR J PAIN, V11, P329, DOI 10.1016/j.ejpain.2006.05.002
   Rejas J, 2011, BMC MED RES METHODOL, V11, P0, DOI 10.1186/1471-2288-11-142
   Romanò CL, 2009, J ORTHOP TRAUMATOL, V10, P185, DOI 10.1007/s10195-009-0077-z
   Ruiz MA, 2008, VALUE HEALTH, V11, P913, DOI 10.1111/j.1524-4733.2008.00323.x
   Saldaña MT, 2012, CLIN DRUG INVEST, V32, P401, DOI 10.2165/11599400-000000000-00000
   Smith BH, 2012, BMC NEUROL, V12, P0, DOI 10.1186/1471-2377-12-29
   Stacey BR, 2008, PAIN MED, V9, P1202, DOI 10.1111/j.1526-4637.2008.00423.x
   Taylor Rod S, 2006, PAIN PRACT, V6, P22, DOI 10.1111/j.1533-2500.2006.00054.x
   Tolle Thomas, 2006, PAIN PRACT, V6, P153, DOI 10.1111/j.1533-2500.2006.00079.x
   Torrance N, 2013, PAIN, V154, P690, DOI 10.1016/j.pain.2012.12.022
   Vázquez-Barquero JL, 2000, ACTAS ESP PSIQUIATRI, V28, P77
   Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0
   World Health Organization, 2004, WHO DIS ASS SCHED 2, V0, P0
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zin CS, 2010, J PAIN, V11, P462, DOI 10.1016/j.jpain.2009.09.003
NR 43
TC 6
Z9 6
U1 0
U2 5
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-2563
EI 1179-1918
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PD DEC 15
PY 2014
VL 34
IS 12
BP 833
EP 844
DI 10.1007/s40261-014-0239-5
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AU1NR
UT WOS:000345388000001
PM 25421816
DA 2026-01-16
ER

PT J
AU Cassileth, BR
AF Cassileth, Barrie R
TI Psychiatric benefits of integrative therapies in patients with cancer.
SO International review of psychiatry (Abingdon, England)
LA English
DT Review
AB Integrative oncology uses non-pharmacological adjuncts to mainstream care to  manage physical, emotional, and psychological symptoms experienced by cancer  survivors. Depression, anxiety, fatigue and pain are among the common, often  burdensome symptoms that can occur in clusters, deplete patient morale, interfere  with treatment plans, and hamper recovery. Patients already seek various  modalities on their own to address a broad range of problems. Legitimate  complementary therapies offered at major cancer institutions improve quality of  life, speed recovery, and optimize patient support. They also augment the  benefits of psychiatric interventions, due to their ability to increase  self-awareness and improve physical and psychological conditioning. Further,  these integrated therapies provide lifelong tools and develop skills that  patients use well after treatment to develop self-care regimens. The active  referral of patients to integrative therapies achieves three important  objectives: complementary care is received from therapists experienced in working  with cancer patients, visits become part of the medical record, allowing  treatment teams to guide individuals in maximizing benefit, and patients are  diverted from useless or harmful 'alternatives.' We review the reciprocal  physical and psychiatric benefits of exercise, mind-body practices, massage,  acupuncture, and music therapy for cancer survivors, and suggest how their use  can augment mainstream psychiatric interventions.
C1 Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center , New York , USA.
NR 0
TC 0
SN 1369-162
EI 
J9 Int Rev Psychiatry
PD APR 11
PY 2014
VL 26
IS 1
BP 114
EP 27
DI 10.3109/09540261.2013.838153
PG -87
WC Complementary Therapies; methods; Humans; Mental Disorders; etiology; Neoplasms; psychology; Survivors; psychology
UT PubMed:24716505
PM 24716505
DA 2014-04-11
ER

PT J
AU Silva, JG
   Santana, CG
   Inocêncio, KR
   Orsini, M
   Machado, S
   Bergmann, A
AF Silva, Julio Guilherme
   Santana, Camila Goncalves
   Inocencio, Kelly Rosane
   Orsini, Marco
   Machado, Sergio
   Bergmann, Anke
TI Electrocortical Analysis of Patients with Intercostobrachial Pain Treated with TENS after Breast Cancer Surgery
SO JOURNAL OF PHYSICAL THERAPY SCIENCE
LA English
DT Article
DE Transcutaneous electric nerve stimulation; Mastectomy; Electroencephalography
ID electrical nerve-stimulation; high-frequency; eeg alpha; attention; cortex; power
AB [Purpose] Among the physical therapeutic procedures to decrease pain, there is transcutaneous electrical neural stimulation (TENS). There is no consensus about its efficacy for oncological patients, especially for post-mastectomy pain and eletrocortical changes in somatosensory areas. The aim of this study was to analyze acute electrocortical changes after TENS treatment of patients with intercostobrachial post mastectomy pain. [Subjects] Eighteen patients were divided into acupuncture (A) and burst (B) group. [Methods] In this pre and post-intervention study each group was measured for EEG analysis in absulte power in alpha band (8-14 Hz). Outcomes variables were the alpha waveband in the sensorymotor cortex and pain pre-and-post TENS intervention. Data were analyzed using ANOVA to compare times (rest, 10 and 15 min), group and electrodes. Pain was analyzed using percentual pain evaluation (PPE) in both groups. [Results] Outcomes indicate main effects of time and electrodes because of slow (8-10 Hz) and fast alpha (10-12 Hz) wavebands decreased. PPE reduced 88.4% in A and 66.3% in G. [Conclusion] TENS promoted electrical modification in the parietal region and a decrease in pain. Future studies should investigate other wave must be proposed for other bands and use different methods of EEG analysis to elucidate the actual mechanisms behind the efficacy of TENS treatment.
C1 [Silva, Julio Guilherme; Orsini, Marco] Fed Univ Rio de Janeiro UFRJ, Dept Phys Therapy, Rio De Janeiro, Brazil.
   [Silva, Julio Guilherme; Santana, Camila Goncalves; Bergmann, Anke] Augusto Motta Univ Ctr UNISUAM, Rehabil Sci Masters Program, BR-21041021 Rio De Janeiro, Brazil.
   [Machado, Sergio] Fed Univ Rio de Janeiro UFRJ, Pan & Respirat Lab, Inst Psychiat, Rio De Janeiro, Brazil.
   [Machado, Sergio] Cent Univ, Quiropraxia Program, Santiago, Chile.
C3 Universidade Federal do Rio de Janeiro; Centro Universitario Augusto Motta (UNISUAM); Universidade Federal do Rio de Janeiro; Universidad Central de Chile
RP Silva, JG (corresponding author), Fed Univ Rio de Janeiro UFRJ, Dept Phys Therapy, Rio De Janeiro, Brazil.
EM jgl-silva@yahoo.com.br
CR Bevilacqua JLB, 2012, ANN SURG ONCOL, V19, P2580, DOI 10.1245/s10434-012-2290-x
   Cameroon M, 2008, AGENTES FISICOS REAB, V0, P0
   Domingues CA, 2008, ARQ NEURO-PSIQUIAT, V66, P336, DOI 10.1590/S0004-282X2008000300010
   Dong WK, 1995, FRONTIER PAIN RES, V0, P183
   Downian R, 2008, CLIN NEUROPHYSIOL, V119, P1201, DOI 10.1016/j.clinph.2008.01.019
   Foxe JJ, 1998, NEUROREPORT, V9, P3929, DOI 10.1097/00001756-199812010-00030
   Frot M, 2001, PAIN, V94, P65, DOI 10.1016/S0304-3959(01)00342-6
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Jung BF, 2003, PAIN, V104, P1, DOI 10.1016/S0304-3959(03)00241-0
   Klimesch W, 1998, NEUROSCI LETT, V244, P73, DOI 10.1016/S0304-3940(98)00122-0
   Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3
   Léonard G, 2011, J PAIN, V12, P213, DOI 10.1016/j.jpain.2010.07.003
   Leonard G, 2010, PAIN, V151, P215, DOI 10.1016/j.pain.2010.07.012
   Liebano RE, 2011, PAIN, V152, P335, DOI 10.1016/j.pain.2010.10.040
   Ministerio de Agricultura Alimentacion y Medio Ambiente, 2012, ENC SUP REND CULT ES, V0, P1
   NEIDERMEYER E, 1999, ELECTROENCEPHALOGRAP, V0, P0
   Fabro EAN, 2012, BREAST, V21, P321, DOI 10.1016/j.breast.2012.01.019
   Pena R, 2008, REVISTA BRASILEIRA DE CANCEROLOGIA, V54, P193, DOI 10.32635/2176-9745.RBC.2008V54N2.1750
   Rakel B, 2003, J PAIN, V4, P455, DOI 10.1067/S1526-5900(03)00780-6
   Robb K, 2009, J PAIN SYMPTOM MANAG, V37, P746, DOI 10.1016/j.jpainsymman.2008.03.022
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Sampaio LR, 2005, REV BRAS CANCEROL, V51, P339, DOI 10.32635/2176-9745.RBC.2005v51n4.1940
   Sauseng P, 2005, EUR J NEUROSCI, V22, P2917, DOI 10.1111/j.1460-9568.2005.04482.x
   Silva JG, 2006, ARQ NEURO-PSIQUIAT, V64, P473, DOI 10.1590/S0004-282X2006000300023
   Sluka KA, 2005, J NEUROCHEM, V95, P1794, DOI 10.1111/j.1471-4159.2005.03511.x
   Thatcher RW, 2005, CLIN EEG NEUROSCI, V36, P116, DOI 10.1177/155005940503600211
   Thut G, 2006, J NEUROSCI, V26, P9494, DOI 10.1523/JNEUROSCI.0875-06.2006
   Tiezzi DG, 2009, REV BRAS GINECOL OBS, V31, P213, DOI 10.1590/S0100-72032009000500001
   Worden MS, 2000, J NEUROSCI, V20, P0
NR 29
TC 22
Z9 27
U1 0
U2 13
PU SOC PHYSICAL THERAPY SCIENCE
PI TOKYO
PA C/O PUBLICATION CENTER, 1-24-12 SUGAMO, TOSHIMA-KU, TOKYO, 170-0002, JAPAN
SN 0915-5287
EI 2187-5626
J9 J PHYS THER SCI
JI J. Phys. Ther. Sci.
PD MAR 15
PY 2014
VL 26
IS 3
BP 349
EP 353
DI 10.1589/jpts.26.349
PG 5
WC Rehabilitation
SC Rehabilitation
GA AM1QA
UT WOS:000339621300006
PM 24707082
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Tan, T
   Li, SQ
   Meghani, SH
   Glanz, K
   Bruner, D
AF Mao, Jun J.
   Tan, Tiffany
   Li, Susan Q.
   Meghani, Salimah H.
   Glanz, Karen
   Bruner, Deborah
TI Attitudes and barriers towards participation in an acupuncture trial among breast cancer patients: a survey study
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Acupuncture; Breast neoplasm; Clinical trial; Aromatase inhibitors/*adverse effects; Musculoskeletal; Joint pain; Attitudes; Barriers
ID alternative medicine use; randomized clinical-trials; complementary/alternative medicine; expectancy scale; survivors; women; willingness; oncology; impact; race
AB Background: As breast cancer patients increasingly use complementary and alternative medicine (CAM), clinical trials are needed to guide appropriate clinical use. We sought to identify socio-demographic, clinical and psychological factors related to willingness to participate (WTP) and to determine barriers to participation in an acupuncture clinical trial among breast cancer patients. Methods: We conducted a cross-sectional survey study among post-menopausal women with stage I-III breast cancer on aromatase inhibitors at an urban academic cancer center. Results: Of the 300 participants (92% response rate), 148 (49.8%) reported WTP in an acupuncture clinical trial. Higher education (p = 0.001), increased acupuncture expectancy (p < 0.001), and previous radiation therapy (p = 0.004) were significantly associated with WTP. Travel difficulty (p = 0.002), concern with experimentation (p = 0.013), and lack of interest in acupuncture (p < 0.001) were significant barriers to WTP. Barriers differed significantly by socio-demographic factors with white people more likely to endorse travel difficulty (p = 0.018) and non-white people more likely to report concern with experimentation (p = 0.024). Older patients and those with lower education were more likely to report concern with experimentation and lack of interest in acupuncture (p < 0.05). Conclusions: Although nearly half of the respondents reported WTP, significant barriers to participation exist and differ among subgroups. Research addressing these barriers is needed to ensure effective accrual and improve the representation of individuals from diverse backgrounds.
C1 [Mao, Jun J.; Tan, Tiffany; Li, Susan Q.] Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Glanz, Karen] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   [Mao, Jun J.; Glanz, Karen] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Tan, Tiffany; Meghani, Salimah H.; Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
   [Bruner, Deborah] Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania
RP Mao, JJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Family Med & Community Hlth, 3400 Spruce St,2 Gates Bldg, Philadelphia, PA 19104 USA.
EM jun.mao@uphs.upenn.edu
FU American Cancer Society [IRF-78-002-30]; University of Pennsylvania Center for Undergraduate Research and Fellowships; National Institute of Health/National Center for Complementary and Alternative Medicine [R21 AT004695, K23004112]
CR Agrawal M, 2006, J CLIN ONCOL, V24, P4479, DOI 10.1200/JCO.2006.06.0269
   Baggstrom MQ, 2011, J THORAC ONCOL, V6, P98, DOI 10.1097/JTO.0b013e3181fb50d8
   Baker F, 2005, CANCER, V104, P2565, DOI 10.1002/cncr.21488
   Boon Heather S, 2007, BMC WOMENS HEALTH, V7, P4, DOI 10.1186/1472-6874-7-4
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Cheng SK, 2011, CLIN CANCER RES, V17, P1947, DOI 10.1158/1078-0432.CCR-10-1730
   Cheng SK, 2010, CLIN CANCER RES, V16, P5557, DOI 10.1158/1078-0432.CCR-10-0133
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Comis RL, 2003, J CLIN ONCOL, V21, P830, DOI 10.1200/JCO.2003.02.105
   Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x
   Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458
   Ellis Peter M, 1999, HEALTH EXPECT, V2, P33, DOI 10.1046/j.1369-6513.1999.00028.x
   Ellis PM, 2001, J CLIN ONCOL, V19, P3554, DOI 10.1200/JCO.2001.19.15.3554
   Ellis PM, 2000, ANN ONCOL, V11, P939, DOI 10.1023/A:1008342222205
   Gross CP, 2005, CANCER, V103, P483, DOI 10.1002/cncr.20792
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   Jacobson JS, 2000, J CLIN ONCOL, V18, P668, DOI 10.1200/JCO.2000.18.3.668
   Jones LW, 2006, LANCET ONCOL, V7, P1017, DOI 10.1016/S1470-2045(06)70976-7
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Lamberti MJ, 2009, STATE CLIN TRIALS IN, V0, P0
   Lara PN Jr, 2005, J CLIN ONCOL, V23, P9282, DOI 10.1200/JCO.2005.02.6245
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Levine Alison Spatz, 2012, INT J YOGA THERAP, V0, P95
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Matthews AK, 2007, J ALTERN COMPLEM MED, V13, P555, DOI 10.1089/acm.2007.03-9040
   Mills EJ, 2006, LANCET ONCOL, V7, P141, DOI 10.1016/S1470-2045(06)70576-9
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720
   Nahleh Zeina, 2003, PALLIAT SUPPORT CARE, V1, P267
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Phillips KM, 2013, PSYCHO-ONCOLOGY, V22, P936, DOI 10.1002/pon.3066
   Richardson MA, 1998, ANN BEHAV MED, V20, P190, DOI 10.1007/BF02884960
   Schneider J, 2003, J ALTERN COMPLEM MED, V9, P389, DOI 10.1089/107555303765551615
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Trauth J M, 2000, J HEALTH SOC POLICY, V12, P23
   Upchurch DM, 2005, WOMEN HEALTH ISS, V15, P5, DOI 10.1016/j.whi.2004.08.010
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Wyatt G, 2010, NURS RES, V59, P58, DOI 10.1097/NNR.0b013e3181c3bd26
NR 43
TC 24
Z9 27
U1 0
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
EI 
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JAN 8
PY 2014
VL 14
IS 
BP 
EP 
DI 10.1186/1472-6882-14-7
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 294OX
UT WOS:000330057300002
PM 24400734
DA 2026-01-16
ER

PT J
AU Golianu, B
   Yeh, AM
   Brooks, M
AF Golianu, Brenda
   Yeh, Ann Ming
   Brooks, Meredith
TI Acupuncture for Pediatric Pain.
SO Children (Basel, Switzerland)
LA English
DT Review
DE acupressure; acupuncture; integrative medicine; laser acupuncture; pain; pediatric; review
AB Chronic pain is a growing problem in children, with prevalence as high as 30.8%.  Acupuncture has been found to be useful in many chronic pain conditions, and may  be of clinical value in a multidisciplinary treatment program. The basic  principles of acupuncture are reviewed, as well as studies exploring basic  mechanisms of acupuncture and clinical efficacy. Conditions commonly treated in  the pediatric pain clinic, including headache, abdominal pain, fibromyalgia,  juvenile arthritis, complex regional pain syndrome, cancer pain, as well as  perioperative pain studies are reviewed and discussed. Areas in need of further  research are identified, and procedural aspects of acupuncture practice and  safety studies are reviewed. Acupuncture can be an effective adjuvant in the care  of pediatric patients with painful conditions, both in a chronic and an acute  setting. Further studies, including randomized controlled trials, as well as  trials of comparative effectiveness are needed.
C1 Department of Anesthesiology and Pain Medicine, Pediatric Anesthesiology, Stanford University, 300 Pasteur Dr. Stanford, CA 94304, USA.bgolianu@stanford.edu.
   Pediatric Gastroenterology, Stanford University, 750 Welch Road, Suite 116, Palo Alto CA 94304, USA. annming@stanford.edu.
   Department of Anesthesiology and Pain Medicine, Pediatric Anesthesiology, Stanford University, 300 Pasteur Dr. Stanford, CA 94304, USA.mrbrooks@stanford.edu.
NR 0
TC 0
SN 2227-906
EI 2227-906
J9 Children (Basel)
PD JAN 1
PY 2014
VL 1
IS 2
BP 134
EP 48
DI 10.3390/children1020134
PG -86
UT PubMed:27417472
PM 27417472
DA 2014-01-01
ER

